<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Chlorpromazine versus atypical antipsychotic drugs for schizophrenia - Saha, KB - 2016 | Cochrane Library</title> <meta content="Chlorpromazine versus atypical antipsychotic drugs for schizophrenia - Saha, KB - 2016 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010631.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Chlorpromazine versus atypical antipsychotic drugs for schizophrenia - Saha, KB - 2016 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010631.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD010631.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Chlorpromazine versus atypical antipsychotic drugs for schizophrenia" name="citation_title"/> <meta content="Kumar B Saha" name="citation_author"/> <meta content="Leeds and York Partnerships NHS Foundation Trust" name="citation_author_institution"/> <meta content="Li Bo" name="citation_author"/> <meta content="Xiyuan Hospital" name="citation_author_institution"/> <meta content="dr.libo@vip.163.com" name="citation_author_email"/> <meta content="Sai Zhao" name="citation_author"/> <meta content="Systematic Review Solutions Ltd" name="citation_author_institution"/> <meta content="Jun Xia" name="citation_author"/> <meta content="The University of Nottingham" name="citation_author_institution"/> <meta content="Stephanie Sampson" name="citation_author"/> <meta content="The University of Nottingham" name="citation_author_institution"/> <meta content="Rashid U Zaman" name="citation_author"/> <meta content="Oxford Policy Management" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="4" name="citation_issue"/> <meta content="10.1002/14651858.CD010631.pub2" name="citation_doi"/> <meta content="2016" name="citation_date"/> <meta content="2016/04/05" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010631.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010631.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010631.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antipsychotic Agents [*therapeutic use]; Benzodiazepines [therapeutic use]; Chlorpromazine [*therapeutic use]; Olanzapine; Quetiapine Fumarate [therapeutic use]; Randomized Controlled Trials as Topic; Risperidone [therapeutic use]; Schizophrenia [*drug therapy]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010631.pub2&amp;doi=10.1002/14651858.CD010631.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010631.pub2&amp;doi=10.1002/14651858.CD010631.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010631.pub2&amp;doi=10.1002/14651858.CD010631.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010631.pub2&amp;doi=10.1002/14651858.CD010631.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010631.pub2&amp;doi=10.1002/14651858.CD010631.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010631.pub2&amp;doi=10.1002/14651858.CD010631.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010631.pub2&amp;doi=10.1002/14651858.CD010631.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010631.pub2&amp;doi=10.1002/14651858.CD010631.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010631.pub2&amp;doi=10.1002/14651858.CD010631.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010631.pub2&amp;doi=10.1002/14651858.CD010631.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010631.pub2&amp;doi=10.1002/14651858.CD010631.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010631.pub2&amp;doi=10.1002/14651858.CD010631.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010631.pub2&amp;doi=10.1002/14651858.CD010631.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010631.pub2&amp;doi=10.1002/14651858.CD010631.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010631.pub2&amp;doi=10.1002/14651858.CD010631.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010631.pub2&amp;doi=10.1002/14651858.CD010631.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010631.pub2&amp;doi=10.1002/14651858.CD010631.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010631.pub2&amp;doi=10.1002/14651858.CD010631.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010631.pub2&amp;doi=10.1002/14651858.CD010631.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010631.pub2&amp;doi=10.1002/14651858.CD010631.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010631.pub2&amp;doi=10.1002/14651858.CD010631.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010631.pub2&amp;doi=10.1002/14651858.CD010631.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010631.pub2&amp;doi=10.1002/14651858.CD010631.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="7LavyS58";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD010631\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD010631\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010631\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010631\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","hr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD010631.pub2",title:"Chlorpromazine versus atypical antipsychotic drugs for schizophrenia",firstPublishedDate:"Apr 5, 2016 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Schizophrenia Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=7LavyS58&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010631.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010631.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD010631.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD010631.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010631.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD010631.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD010631.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD010631.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD010631.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD010631.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3441 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD010631.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010631.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010631.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010631.pub2/full#CD010631-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010631.pub2/full#CD010631-sec-0520"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010631.pub2/full#CD010631-sec-0015"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010631.pub2/full#CD010631-sec-0016"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010631.pub2/full#CD010631-sec-0021"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010631.pub2/full#CD010631-sec-0022"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010631.pub2/full#CD010631-sec-0107"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010631.pub2/full#CD010631-sec-0492"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010631.pub2/appendices#CD010631-sec-0530"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/table_n/CD010631StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/table_n/CD010631StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010631.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010631.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010631.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010631.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010631.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD010631.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2016 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Chlorpromazine versus atypical antipsychotic drugs for schizophrenia</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010631.pub2/information#CD010631-cr-0002">Kumar B Saha</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010631.pub2/information#CD010631-cr-0003"><i class="icon corresponding-author fa fa-envelope"></i>Li Bo</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010631.pub2/information#CD010631-cr-0004">Sai Zhao</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010631.pub2/information#CD010631-cr-0005">Jun Xia</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010631.pub2/information#CD010631-cr-0006">Stephanie Sampson</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010631.pub2/information#CD010631-cr-0007">Rashid U Zaman</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/information/en#CD010631-sec-0539">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 05 April 2016 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD010631.pub2">https://doi.org/10.1002/14651858.CD010631.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD010631-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010631-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010631-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010631-abs-0007">فارسی</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD010631-abs-0001" lang="en"> <section id="CD010631-sec-0001"> <h3 class="title" id="CD010631-sec-0001">Background</h3> <p>Chlorpromazine is an aliphatic phenothiazine, which is one of the widely‐used typical antipsychotic drugs. Chlorpromazine is reliable for its efficacy and one of the most tested first generation antipsychotic drugs. It has been used as a ‘gold standard’ to compare the efficacy of older and newer antipsychotic drugs. Expensive new generation drugs are heavily marketed worldwide as a better treatment for schizophrenia, but this may not be the case and an unnecessary drain on very limited resources. </p> </section> <section id="CD010631-sec-0002"> <h3 class="title" id="CD010631-sec-0002">Objectives</h3> <p>To compare the effects of chlorpromazine with atypical or second generation antipsychotic drugs, for the treatment of people with schizophrenia. </p> </section> <section id="CD010631-sec-0003"> <h3 class="title" id="CD010631-sec-0003">Search methods</h3> <p>We searched the Cochrane Schizophrenia Group's Trials Register up to 23 September 2013. </p> </section> <section id="CD010631-sec-0004"> <h3 class="title" id="CD010631-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) that compared chlorpromazine with any other atypical antipsychotic drugs for treating people with schizophrenia. Adults (as defined in each trial) diagnosed with schizophrenia, including schizophreniform, schizoaffective and delusional disorders were included in this review. </p> </section> <section id="CD010631-sec-0005"> <h3 class="title" id="CD010631-sec-0005">Data collection and analysis</h3> <p>At least two review authors independently screened the articles identified in the literature search against the inclusion criteria and extracted data from included trials. For homogeneous dichotomous data, we calculated the risk ratio (RR) and the 95% confidence intervals (CIs). For continuous data, we determined the mean difference (MD) values and 95% CIs. We assessed the risk of bias in included studies and rated the quality of the evidence using the GRADE approach. </p> </section> <section id="CD010631-sec-0006"> <h3 class="title" id="CD010631-sec-0006">Main results</h3> <p>This review includes 71 studies comparing chlorpromazine to olanzapine, risperidone or quetiapine. None of the included trials reported any data on economic costs. </p> <p><b>1. Chlorpromazine versus olanzapine</b> </p> <p>In the short term, there appeared to be a significantly greater clinical response (as defined in each study) in people receiving olanzapine (3 RCTs, N = 204; RR 2.34, 95% CI 1.37 to 3.99, <i>low quality evidence</i> ). There was no difference between drugs for relapse (1 RCT, N = 70; RR 1.5, 95% CI 0.46 to 4.86, <i>very low quality evidence</i> ), nor in average endpoint score using the Brief Psychiatric Rating Scale (BPRS) for mental state (4 RCTs, N = 245; MD 3.21, 95% CI −0.62 to 7.05,<i>very low quality evidence</i> ). There were significantly more extrapyramidal symptoms experienced amongst people receiving chlorpromazine (2 RCTs, N = 298; RR 34.47, 95% CI 4.79 to 248.30,<i>very low quality evidence</i> ). Quality of life ratings using the general quality of life interview (GQOLI) ‐ physical health subscale were more favourable with people receiving olanzapine (1 RCT, N = 61; MD −10.10, 95% CI −13.93 to −6.27, <i>very low quality evidence</i> ). There was no difference between groups for people leaving the studies early (3 RCTs, N = 139; RR 1.69, 95% CI 0.45 to 6.40, <i>very low quality evidence</i>). </p> <p><b>2. Chlorpromazine versus risperidone</b> </p> <p>In the short term, there appeared to be no difference in clinical response (as defined in each study) between chlorpromazine or risperidone (7 RCTs, N = 475; RR 0.84, 95% CI 0.53 to 1.34, <i>low quality of evidence</i> ), nor in average endpoint score using the BPRS for mental state 4 RCTs, N = 247; MD 0.90, 95% CI −3.49 to 5.28, <i>very low quality evidence</i> ), or any observed extrapyramidal adverse effects (3 RCTs, N = 235; RR 1.7, 95% CI 0.85 to 3.40,<i>very low quality evidence</i> ). Quality of life ratings using the QOL scale were significantly more favourable with people receiving risperidone (1 RCT, N = 100; MD −14.2, 95% CI −20.50 to −7.90, <i>very low quality evidence</i> ). There was no difference between groups for people leaving the studies early (one RCT, N = 41; RR 0.21, 95% CI 0.01 to 4.11, <i>very low quality evidence</i>). </p> <p><b>3. Chlorpromazine versus quetiapine</b> </p> <p>In the short term, there appeared to be no difference in clinical response (as defined in each study) between chlorpromazine or quetiapine (28 RCTs, N = 3241; RR 0.93, 95% CI 0.81 to 1.06, <i>moderate quality evidence</i> ) nor in average endpoint score using the BPRS for mental state (6 RCTs, N = 548; MD −0.18, 95% CI −1.23 to 0.88<i>, very low quality evidence</i> ). Quality of life ratings using the GQOL1‐74 scale were significantly more favourable with people receiving quetiapine (1 RCT, N = 59; MD −6.49, 95% CI −11.30 to −1.68, <i>very low quality evidence</i> ). Significantly more people receiving chlorpromazine experienced extrapyramidal adverse effects (8 RCTs, N = 644; RR 8.03, 95% CI 4.78 to 13.51, <i>low quality of evidence</i> ). There was no difference between groups for people leaving the studies early in the short term (12 RCTs, N = 1223; RR 1.04, 95% CI 0.77 to 1.41,<i>moderate quality evidence</i>). </p> </section> <section id="CD010631-sec-0007"> <h3 class="title" id="CD010631-sec-0007">Authors' conclusions</h3> <p>Most included trials included inpatients from hospitals in China. Therefore the results of this Cochrane review are more applicable to the Chinese population. Mostincluded trials were short term studies, therefore we cannot comment on the medium and long term use of chlorpromazine compared to atypical antipsychotics. Low qualityy evidence suggests chlorpromazine causes more extrapyramidal adverse effects. However, all studiesused varying dose ranges, and higher doses would be expected to be associated with more adverse events. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD010631-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010631-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010631-abs-0006">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010631-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD010631-abs-0005">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD010631-abs-0004">Русский</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD010631-abs-0003" lang="en"> <h3>Chlorpromazine compared with newer atypical antipsychotics</h3> <p>People with schizophrenia often hear voices or see things (hallucinations) and have strange beliefs (delusions). The main treatment for people with these symptoms of schizophrenia is antipsychotic drugs. Chlorpromazine was one of the first drugs discovered to be effective for treating people with schizophrenia. It remains one of the most commonly used and inexpensive treatments. However, being an older drug (typical or first generation) it also has serious side effects, including blurred vision, a dry mouth, tremors or uncontrollable shaking, depression, muscle stiffness and restlessness. </p> <p>In this Cochrane review we examined the effects of chlorpromazine for treating people with schizophrenia compared with newer antipsychotic drugs. </p> <p>We searched the literature for randomised controlled trials up to 23 September 2013, and included 71 trials. The included studies compared chlorpromazine with three newer antipsychotics: risperidone, quetiapine or olanzapine. Most included trials were short term studies and undertaken in China. Based on low quality evidence, we found that chlorpromazine is not much different to risperidone or quetiapine but is associated with more side effects. More favourable results were found for olanzapine with those receiving olanzapine experiencing fewer side effects and greater improvements in global state and quality of life than those receiving chlorpromazine, but again this is based on low quality evidence. Larger, longer, better conducted and reported trials should focus on important outcomes such as quality of life, levels of satisfaction with treatment or care, relapse, costs and hospital discharge or admission. Also, more international studies are needed. Outpatient treatment was under‐represented in the included studies, and future research should also include work with this group of people. </p> <p>Due to the limitations of evidence in this Cochrane review, it is difficult to draw firm conclusions. Chlorpormazine is available widely, is comparable with the newer antipsychotics and is relatively cheap so despite its propensity to cause side effects, is likely to remain one of the benchmark antipsychotics. </p> <p>The plain language summary has been written by a consumer. Ben Gray: Senior Peer Researcher, McPin Foundation. <a href="http://mcpin.org/" target="_blank">http://mcpin.org/</a>. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD010631-sec-0520" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD010631-sec-0520"></div> <h3 class="title" id="CD010631-sec-0521">Implications for practice</h3> <section id="CD010631-sec-0521"> <section id="CD010631-sec-0522"> <h5 class="title">1. For people with schizophrenia</h5> <p>Based on weak evidence, chlorpromazine is not much different to risperidone or quetiapine and slightly less effective than olanzapine for levels of clinical response. Chlorpromazine was associated with more extrapyramidal adverse effects, particularly akathisia and tremor compared to risperidone and quetiapine. Risperidone has a lower adverse event profile than any of the other atypical comparators. Generally, chlorpromazine was associated with more, and varied adverse effects. There is a lack of evidence relating to patient‐oriented outcomes, including satisfaction with treatment or care and well‐reported QoL outcomes. </p> </section> <section id="CD010631-sec-0523"> <h5 class="title">2. For clinicians</h5> <p>It is surprising how few studies outside of China have investigated the effects of chlorpromazine versus other atypical antipsychotics on people with schizophrenia. Most data relate only to short‐term studies; therefore it is impossible to comment on the medium and long‐term use of chlorpromazine in the research setting. Chlorpromazine was generally associated with more adverse events. However all studies made use of varying dose ranges; and the use of higher doses would be expected to be associated with greater adverse events. As included studies did not provide mean doses, we could not perform a sensitivity analysis to assess such differences in the results. </p> </section> <section id="CD010631-sec-0524"> <h5 class="title">3. For managers or policy makers</h5> <p>Included studies reported no data relating to service utilisation, functioning in the community or cost features. Chlorpromazine is a cheap drug compared to new 'atypical' antipsychotics. Therefore, investing some money in research on this drug could be cost saving in the long run. </p> </section> </section> <h3 class="title" id="CD010631-sec-0525">Implications for research</h3> <section id="CD010631-sec-0525"> <section id="CD010631-sec-0526"> <h5 class="title">1. General</h5> <p>Future studies in this area need to be well reported, long term (&gt; one year) and adhere to the Consolidated Standards of Reporting Trials (CONSORT) statement (<a href="http://www.consort-statement.org/" target="_blank">CONSORT</a>; <a href="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007445.pub2/full#CD007445-bbs2-0037" target="_blank">Moher 2001</a>). This states that all research needs to be clearly and transparently reported, and be accompanied by a flow diagram to simply display the study progress and process. </p> </section> <section id="CD010631-sec-0527"> <h5 class="title">2. Specific</h5> <p>The trials that met the inclusion criteria of this Cochrane review were all undertaken in China, predominantly in an inpatient surrounding, and focused only on short‐term outcomes (average of eight weeks). Further research should be international in scope and fairly representative of other healthcare systems. Outpatient treatment was under‐represented in the included studies, and future research should work with this population. More participant focused outcomes (e.g. functioning in social, occupational, family life, satisfaction with care, etc.) and economic considerations could be addressed. </p> </section> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD010631-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD010631-sec-0015"></div> <div class="table" id="CD010631-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">CHLORPROMAZINE versus OLANZAPINE for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Chlorpromazine versus olanzapine for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with schizophrenia<br/> <b>Settings:</b> inpatient and outpatient<br/> <b>Intervention:</b> chlorpromazine<br/> <b>Comparison:</b> olanzapine </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Olanzapine</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Chlorpromazine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>No significant clinical response: short term (up to 6 months)</b> <br/> Follow‐up: 6 to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low<sup>1</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 2.34</b> <br/> (1.37 to 3.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>204<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>700 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1000 per 1000</b> <br/> (959 to 1000) </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>190 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>445 per 1000</b> <br/> (260 to 758) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Relapse: long term (over 12 months)</b> <br/> Follow‐up: mean 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.5</b> <br/> (0.46 to 4.86) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>70<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>114 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>171 per 1000</b> <br/> (53 to 555) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>114 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>171 per 1000</b> <br/> (52 to 554) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: short term (up to 6 months)</b> <br/> BRPS average endpoint score (high = poor)<br/> Follow‐up: 6 to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state: short term (up to 6 months) in the intervention groups was<br/> <b>3.21 higher</b> <br/> (0.62 lower to 7.05 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>245<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,5,6,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months)</b> <br/> Follow‐up: mean 8 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 34.47</b> <br/> (4.79 to 248.3) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>298<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>10 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>345 per 1000</b> <br/> (48 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1000 per 1000</b> <br/> (479 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>250 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1000 per 1000</b> <br/> (1000 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life: short term (up to 6 months)</b> <br/> GQOLI‐physical health subscale score (high = good)<br/> Follow‐up: mean 8 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean quality of life: short term (up to 6 months) in the intervention groups was<br/> <b>10.10 lower</b> <br/> (13.93 to 6.27 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,7,9,10</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Leaving the study early due to any reason: short term (up to 6 months)</b> <br/> Follow‐up: mean 6 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population<sup>11</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.69</b> <br/> (0.45 to 6.4) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>139<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>3,12,13</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>159 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>268 per 1000</b> <br/> (71 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate<sup>11</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>229 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>387 per 1000</b> <br/> (103 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Control risk: the control risks are representative of the control group risks of the study population.<br/> <sup>2</sup>Risk of bias: rated serious ‐ most included studies had unclear risk of bias in terms of allocation and blinding, hence selection and detection bias are likely to be present. Two studies also had high risk of reporting bias.<br/> <sup>3</sup>Publication bias: strongly suspected ‐ we identified only small trial(s) from China for this outcome. Publication bias is highly suspected.<br/> <sup>4</sup>Imprecision: serious ‐ only one small trial with unclear risk of selection and detection bias contributed data to this outcome. The result was imprecise with few event and a wide CI.<br/> <sup>5</sup>Inconsistency: serious ‐ unexplained heterogeneity present, suggesting different magnitude of effect.<br/> <sup>6</sup>Indirectness: serious ‐ binary outcome assessing mental state is unavailable. We, therefore, employed BPRS score as an alternative indicator.<br/> <sup>7</sup>Imprecision: serious ‐ a relatively wide CI around the point of estimate of effect. Sample size is smaller than the optimal information size.<br/> <sup>8</sup>Imprecision: serious ‐ although significant difference was observed between groups, the CI was wide (95% CI 4.97 to 248.3).<br/> <sup>9</sup>Indirectness: serious ‐ binary outcome for quality of life is unavailable. We, thus, used outcome from QOL‐ physical health subscale as an alternative indicator.<br/> <sup>10</sup>Imprecision: serious ‐ although significant difference was observed between group, the total sample size is smaller than the optimal information size.<br/> <sup>11</sup>Control risk: the control risks in the study population are very close to the moderate risk observed here. Thus we adopted it to represent the control risk.<br/> <sup>12</sup>Risk of bias: serious ‐ most included studies that contributed data to this outcome had high risk of bias with the selection, detection and reporting of the result.<br/> <sup>13</sup>Imprecision: serious ‐ estimate of effect was not significant and the total sample size is smaller than the desired optimal information size. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010631-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">CHLORPROMAZINE versus RISPERIDONE for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Chlorpromazine versus risperidone for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with schizophrenia<br/> <b>Settings:</b> inpatient and outpatient<br/> <b>Intervention:</b> chlorpromazine<br/> <b>Comparison:</b> risperidone </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Risperidone</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Chlorpromazine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>No significant clinical response ‐ short term (up to 6 months)</b> <br/> Follow‐up: median 8 to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low<sup>1</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 0.84</b> <br/> (0.53 to 1.34) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>475<br/> (7 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>‐</p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>60 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>50 per 1000</b> <br/> (32 to 80) </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>114 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>96 per 1000</b> <br/> (60 to 153) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>240 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>202 per 1000</b> <br/> (127 to 322) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: short term (up to 6 months)</b> <br/> BPRS endpoint scale score (high = poor)<br/> Follow‐up: 6 to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state: short term (up to 6 months) in the intervention groups was<br/> <b>0.9 higher</b> <br/> (3.49 lower to 5.28 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>247<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,4,5,6,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months)</b> <br/> Follow‐up: 8 to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low<sup>1</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.7</b> <br/> (0.85 to 3.4) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>235<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,6,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>130 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>221 per 1000</b> <br/> (111 to 442) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>240 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>408 per 1000</b> <br/> (204 to 816) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life: short term (up to 6 months)</b> <br/> QOL endpoint scale score (high = good)<br/> Follow‐up: mean 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean quality of life: short term (up to 6 months) in the intervention groups was<br/> <b>14.2 lower</b> <br/> (20.5 to 7.9 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>7,8,9,10</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Leaving the study early due to adverse effects ‐ short term (up to 6 months)</b> <br/> Follow‐up: mean 8 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.21</b> <br/> (0.01 to 4.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>41<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>7,10</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>95 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>20 per 1000</b> <br/> (1 to 391) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>95 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>20 per 1000</b> <br/> (1 to 390) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Control risk: the control risks are representative of those observed in the study population.<br/> <sup>2</sup>Risk of bias: serious ‐ most of the included studies had unclear risk of bias in terms of allocation and blinding, hence selection and detection bias are likely to be present. Some of the studies also had high risk of reporting bias.<br/> <sup>3</sup>Publication bias: strongly suspected ‐ only Chinese studies with relatively small sample size were identified. Publication bias is highly likely.<br/> <sup>4</sup>Inconsistency: serious ‐ unexplained heterogeneity present, suggesting different magnitude of effect.<br/> <sup>5</sup>Indirectness: serious ‐ binary outcome assessing mental state is unavailable. We, therefore, employed BPRS score as an alternative indicator.<br/> <sup>6</sup>Imprecision: serious ‐ although the CI around the estimate of effect relatively tight, the result was not significant and sample size was smaller than the optimal information size.<br/> <sup>7</sup>Publication bias: strongly suspected ‐ only one study with unclear risk of selection and detection bias available for this outcome.<br/> <sup>8</sup>Indirectness: serious ‐ binary outcome for quality of life was not available. Therefore, we adopted QOL score as an indicator.<br/> <sup>9</sup>Imprecision: serious ‐ estimate of effect was significant with tight CI, but the study sample size is smaller than the optimal information size.<br/> <sup>10</sup>Imprecision: serious ‐ estimate of effect was not significant and with relatively wide CI. Sample size was smaller than the optimal information size. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010631-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">CHLORPROMAZINE versus QUETIAPINE for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Chlorpromazine versus quetiapine for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with schizophrenia<br/> <b>Settings:</b> inpatient and outpatient<br/> <b>Intervention:</b> chlorpromazine<br/> <b>Comparison:</b> quetiapine </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Quetiapine</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Chlorpromazine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>No significant clinical response: short term (up to 6 months)</b> <br/> Follow‐up: 4 to 16 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 0.93</b> <br/> (0.81 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>3241<br/> (28 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>‐</p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>70 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>65 per 1000</b> <br/> (57 to 74) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b><sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>128 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>119 per 1000</b> <br/> (104 to 136) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>High</b><sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>360 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>335 per 1000</b> <br/> (292 to 382) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: short term (up to 6 months)</b> <br/> BPRS endpoint scale score (high = poor)<br/> Follow‐up: 6 to 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state: short term (up to 6 months) in the intervention groups was<br/> <b>0.18 lower</b> <br/> (1.23 lower to 0.88 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>548<br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life: short term (up to 6 months)</b> <br/> GQOL1‐74 endpoint scale score (high = good)<br/> Follow‐up: mean 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean quality of life: short term (up to 6 months) in the intervention groups was<br/> <b>6.49 lower</b> <br/> (11.3 to 1.68 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>6,7,8,9</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months)</b> <br/> Follow‐up: 6 to 8 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 8.03</b> <br/> (4.78 to 13.51) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>644<br/> (8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>36 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>293 per 1000</b> <br/> (174 to 493) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>High</b> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>80 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>642 per 1000</b> <br/> (382 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Leaving the study early due to any reason short term (up to 6 months)</b> <br/> Follow‐up: 6 to 16 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.04</b> <br/> (0.77 to 1.41) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1223<br/> (12 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>93 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>97 per 1000</b> <br/> (72 to 131) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>High</b><sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>280 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>291 per 1000</b> <br/> (216 to 395) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Control risk: are representative of those observed in the study population.<br/> <sup>2</sup>Risk of bias: serious ‐ most of the included studies had unclear risk of bias in terms of allocation and blinding, hence selection and detection bias are likely to be present. Some of the studies also had high risk of reporting bias.<br/> <sup>3</sup>Indirectness: serious ‐ binary outcome on mental state is not available. Thus we employed BPRS rating as an indicator.<br/> <sup>4</sup>Imprecision: serious ‐ although the estimate of effect was not significant, the CI was relatively tight around the point of estimate. The sample size is also relatively large and exceed the calculated optimal information size.<br/> <sup>5</sup>Publication bias: strongly suspected ‐ only Chinese trials with small sample size were identified for this outcome.<br/> <sup>6</sup>Risk of bias: serious ‐ the only study contributed data to this outcome had unclear risk of selection and detection bias. It also had attrition data that we excluded from the final analysis.<br/> <sup>7</sup>Indirectness: serious ‐ there was no binary measurement available on quality of life. Therefore, we used GQOLI‐74 as an alternative indicator.<br/> <sup>8</sup>Imprecision: serious ‐ sample size was smaller than the optimal information size.<br/> <sup>9</sup>Publication bias: strongly suspected ‐ we only identified a Chinese trial with a small sample size with positive findings for this outcome. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD010631-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD010631-sec-0016"></div> <section id="CD010631-sec-0017"> <h3 class="title" id="CD010631-sec-0017">Description of the condition</h3> <p>Schizophrenia is a severe form of mental health disorder. It has a high lifetime prevalence rate, affecting (4 per 1000 people (<a href="./references#CD010631-bbs2-0179" title="SahaS , ChantD , WelhamJ , McGrathJ . A systematic review of the prevalence of schizophrenia. PLoS Medicine2005;2(5):e141. [DOI: 10.1371/journal.pmed.0020141] ">Saha 2005</a>), but low incident rate because of the chronic nature of the illness. The median incident rate of schizophrenia is 15.2 per 100,000 people (<a href="./references#CD010631-bbs2-0168" title="McGrathJ , SahaS , ChantD , WelhamJ . Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiologic Reviews2008;30:67‐76. [DOI: 10.1093/epirev/mxn001] ">McGrath 2008</a>). </p> <p>The International Classification of Diseases (ICD) classifies the illness into categories F20 to F29 as ‘schizophrenia, schizotypal and delusional disorder’ (<a href="./references#CD010631-bbs2-0151" title="World Health Organization. F‐20. The ICD‐10 Classification of Mental and Behavioural Disorders. Geneva: Divison of Mental Health, WHO, 1992:86‐109. ">ICD‐10 1992</a>), particularly ‘schizophrenia’ in F20. The ICD‐10 states that "schizophrenic disorders are characterized in general by fundamental and characteristic distortions of thinking and perception, and affects that are inappropriate or blunted". The Diagnostic and Statistical Manual of the American Psychiatric Association has also used the term ‘schizophrenia’ (<a href="./references#CD010631-bbs2-0137" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. Washington DC: American Psychiatric Association, 2000. ">DSM‐IV‐TR 2000</a>). </p> <p>The prognosis of schizophrenia is quite variable, and in the past psychiatrists were not very optimistic about its treatment (<a href="./references#CD010631-bbs2-0157" title="KraeplinE . Dementia Praecox and Paraphrenia. Edinburgh: E&amp;S Livingstone, 1919. ">Kraeplin 1919</a>). However, recent studies show that the outcome of schizophrenia treatment is better than previously thought. The use of phenothiazines may have contributed to this as well as other factors, such as improving community services (<a href="./references#CD010631-bbs2-0124" title="BlandRC , ParkerJH , OrnH . Prognosis in schizophrenia. Prognostic predictors and outcome. Archives of General Psychiatry1978;35(1):72‐7. [DOI: 10.1001/archpsyc.1978.01770250074007] ">Bland 1978</a>). </p> </section> <section id="CD010631-sec-0018"> <h3 class="title" id="CD010631-sec-0018">Description of the intervention</h3> <p>Psychiatrists have prescribed typical antipsychotic drugs since the 1950s, when the first antipsychotic medication, chlorpromazine, was synthesized. Chlorpromazine was first used as an antihistaminic agent to treat allergies. Later, surgeons used it as a pre‐surgical medication to sedate people before surgical procedures (<a href="./references#CD010631-bbs2-0158" title="LaboritH , HuguenardP . Artificial hibernation by physical and pharmacodynamic means [L'hibernation artificielle par moyens pharmacodynamiques et physiques]. Presse Médicale1951;59:1329. ">Laborit 1951</a>). In 1952, Paul Charpentier, from Laboratories Rhône‐Poulenc in France, and Delay and Deniker's team described the antipsychotic properties of chlorpromazine (<a href="./references#CD010631-bbs2-0133" title="DelayJ , DenikerP . The treatment of psychosis in a derivative of the neuroleptic hibernotherapie method [Le traitement des psychoses par une méthode neuroleptique dérivée de l'hibernothérapie]. In: OssaPC editor(s). CR Congrès des Médicins Aliénistes et Neurologistes de France et des Pays de Langue Française. Paris: Masson, 1952:479. ">Delay 1952</a>). Chlorpromazine is considered a pivotal discovery in the field of psychosis treatment, with other antipsychotics often measured in 'chlorpromazine equivalents' (<a href="./references#CD010631-bbs2-0186" title="TurnerT . Chlorpromazine: unlocking psychosis. BMJ (Clinical research ed.)2007;334 Suppl 1:s7. [PUBMED: 17204765] ">Turner 2007</a>; <a href="./references#CD010631-bbs2-0192" title="YorstonG , PinneyA . Chlorpromazine equivalents and percentage of British National Formulary maximum recommended dose in patients receiving high‐dose antipsychotics. Psychiatric Bulletin2000;24(4):130‐2. ">Yorston 2000</a>). </p> <p>There are now many antipsychotic drugs available. They are broadly divided into two groups: ‘typical antipsychotic drugs’ and ‘atypical antipsychotic drugs’. Typical antipsychotic drugs are also known as ‘first generation’, ‘conventional’ or ‘classical’ antipsychotic drugs, e.g. chlorpromazine and haloperidol. Atypical antipsychotic drugs are also known as ‘second generation’ or ‘newer antipsychotic drugs’, e.g. clozapine, risperidone, quetiapine and olanzapine. Typical antipsychotic drugs have a good reputation regarding their efficacy in treating the 'positive' symptoms of schizophrenia (e.g. delusions and hallucinations) (<a href="./references#CD010631-bbs2-0167" title="MathewsM , MuzinaDJ . Atypical antipsychotics: new drugs, new challenges. Cleveland Clinic Journal of Medicine2007;74(8):597‐606. ">Mathews 2007</a>). They are also well known for their adverse effects, such as movement disorders (extrapyramidal symptoms (EPS) or extrapyramidal side effects (EPSE)), sedation, metabolic syndromes and sometimes potentially fatal conditions, such as neuroleptic malignant syndrome (<a href="./references#CD010631-bbs2-0122" title="AranaGW . An overview of side effects caused by typical antipsychotics. Journal of Clinical Psychiatry2000;61(Suppl 8):5‐11. ">Arana 2000</a>). The second generation antipsychotic drugs arrived on the market, claiming notable differences. They had a reputed low side‐effect profile and, according to pharmaceutical companies, higher efficacy (<a href="./references#CD010631-bbs2-0153" title="JanssenPA , NiemegeersCJ , AwoutersF , SchellekensKH , MegensAA , MeertTF . Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin‐S2 and dopamine‐D2 antagonistic properties. Journal of Pharmacology and Experimental Therapeutics1988;244(2):685‐93. ">Janssen 1988</a>). However, research funded independently of pharmaceutical companies has suggested that there may be little difference between the older and newer drugs (<a href="./references#CD010631-bbs2-0115" title="AdamsCE , AwadG , RathboneJ , ThornleyB . Chlorpromazine versus placebo for schizophrenia. Cochrane Database of Systematic Reviews2014, Issue 1. [DOI: 10.1002/14651858.CD000284.pub3] ">Adams 2014</a>). This has subsequently fuelled debate as to whether new atypical antipsychotics are more effective than older established first‐generation antipsychotics, and whether questioning the efficacy of the two classifications of drugs creates an improper generalisation of antipsychotics that do not form a homogenous class (<a href="./references#CD010631-bbs2-0163" title="LeuchtS , CorvesC , ArbterD , EngelRR , LiC , DavisJM . Second‐generation versus first‐generation antipsychotic drugs for schizophrenia: a meta‐analysis. Lancet2009;373(9657):31‐41. ">Leucht 2009</a>). Against this backdrop, chlorpromazine remains a benchmark drug in the treatment of schizophrenia. Although imperfect, it is relatively inexpensive and remains one of the most common drugs used for treating people with schizophrenia worldwide (<a href="./references#CD010631-bbs2-0113" title="AdamsCE , RathboneJ , ThornleyB , ClarkeM , BorrillJ , WahlbeckK , et al. Chlorpromazine for schizophrenia: a Cochrane systematic review of 50 years of randomised controlled trials. BMC Medicine2005;3:15. [DOI: 10.1186/1741‐7015‐3‐15] ">Adams 2005</a>). </p> </section> <section id="CD010631-sec-0019"> <h3 class="title" id="CD010631-sec-0019">How the intervention might work</h3> <p>Chlorpromazine is an aliphatic phenothiazine, which is one of the widely‐used typical antipsychotic drugs. Chlorpromazine is reliable for its efficacy and one of the most tested first generation antipsychotic drugs. It has been used as a ‘gold standard’ to compare the efficacy of older and newer antipsychotic drugs. It blocks alpha 1, 5HT2A, D2 and D1 receptors in the brain, and thus it works as an antipsychotic. It also has effect on muscarinic, serotonin and H1 receptors. By blocking D2 receptor it can also cause extrapyramidal side effects. Other adverse effects include dry mouth, blurred vision, restlessness, sedation, neuroleptic malignant syndrome (<a href="./references#CD010631-bbs2-0136" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. Washington DC: American Psychiatric Association, 1994. ">DSM‐IV 1994</a>) etc. On the other hand, atypical antipsychotic drugs by definition may cause decreased or no extrapyramidal side effects (<a href="./references#CD010631-bbs2-0156" title="KinonB J , LiebermanJA . Mechanisms of action of atypical antipsychotic drugs: a critical analysis. Psychopharmacology1996;124(1‐2):2‐34. [DOI: 10.1007/BF02245602] ">Kinon 1996</a>). Different atypical antipsychotic drugs act in different ways; for example, clozapine blocks D2 and 5HT2 receptors (<a href="./references#CD010631-bbs2-0169" title="MeltzerHY . Clinical studies on the mechanism of action of clozapine: the dopamine‐serotonin hypothesis of schizophrenia. Psychopharmacology1989;99 Suppl:S18‐27. [DOI: 10.1007/BF00442554] ">Meltzer 1989</a>). Both clozapine and quetiapine blocks more 5HT2 receptors than D2 receptors. olanzapine blocks 5HT2A, 5HT6, D1, D2, D3 and muscarinic receptors (<a href="./references#CD010631-bbs2-0193" title="ZhangW , BymasterFPP . The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors. Psychopharmacology1999;141(3):267‐78. [DOI: 10.1007/s002130050834] ">Zhang 1999</a>). </p> </section> <section id="CD010631-sec-0020"> <h3 class="title" id="CD010631-sec-0020">Why it is important to do this review</h3> <p>This is one of a family of related Cochrane reviews on this important compound (<a href="#CD010631-tbl-0004">Table 1</a>). </p> <div class="table" id="CD010631-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Related Cochrane Reviews</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reference</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010631-bbs2-0115" title="AdamsCE , AwadG , RathboneJ , ThornleyB . Chlorpromazine versus placebo for schizophrenia. Cochrane Database of Systematic Reviews2014, Issue 1. [DOI: 10.1002/14651858.CD000284.pub3] ">Adams 2014</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine versus haloperidol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010631-bbs2-0162" title="LeuchtC , KitzmantelM , ChuaL , KaneJ , LeuchtS . Haloperidol versus chlorpromazine for schizophrenia. Cochrane Database of Systematic Reviews2008, Issue 1. [DOI: 10.1002/14651858.CD004278.pub2] ">Leucht 2008</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine doses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010631-bbs2-0164" title="LiuX , DeHaanS . Chlorpromazine dose for people with schizophrenia. Cochrane Database of Systematic Reviews2009, Issue 2. [DOI: 10.1002/14651858.CD007778] ">Liu 2009</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine cessation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010631-bbs2-0117" title="AlmerieMQ , AlkhateebH , EssaliA , MatarHE , RezkE . Cessation of medication for people with schizophrenia already stable on chlorpromazine. Cochrane Database of Systematic Reviews2007, Issue 1. [DOI: 10.1002/14651858.CD006329] ">Almerie 2007</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine for acute aggression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010631-bbs2-0116" title="AhmedU , JonesH , AdamsCE . Chlorpromazine for psychosis induced aggression or agitation. Cochrane Database of Systematic Reviews2010, Issue 4. [DOI: 10.1002/14651858.CD007445.pub2] ">Ahmed 2010</a> </p> </td> </tr> </tbody> </table> </div> <p>Chlorpromazine is one of two oral antipsychotic drugs on the World Health Organization's Essential Drug list (<a href="./references#CD010631-bbs2-0188" title="World Health Organization. WHO model list of essential medicines. 17th Edition. Geneva: World Health Organization, March 2011. ">WHO 2011</a>). It is globally accessible and has been known for its effectiveness in schizophrenia treatment since the 1950s (<a href="./references#CD010631-bbs2-0115" title="AdamsCE , AwadG , RathboneJ , ThornleyB . Chlorpromazine versus placebo for schizophrenia. Cochrane Database of Systematic Reviews2014, Issue 1. [DOI: 10.1002/14651858.CD000284.pub3] ">Adams 2014</a>), and it is also the most commonly used and inexpensive treatment for schizophrenia (<a href="./references#CD010631-bbs2-0173" title="OdejideAO , BanTA . Psychotropic drug prescription pattern in a developing country (Nigeria). The need for an essential psychotherapeutic drug list. International Pharmacopsychiatry1982;17(3):163‐9. ">Odejide 1982</a>). Expensive new generation drugs are heavily marketed worldwide as a better treatment for schizophrenia. However, this may not be the case and may be an unnecessary drain on very limited resources (<a href="./references#CD010631-bbs2-0114" title="AdamsCE , TharyanP , CoutinhoES , StroupTS . The schizophrenia drug‐treatment paradox: pharmacological treatment based on best possible evidence may be hardest to practise in high‐income countries. British Journal of Psychiatry2006;189:391‐2. [PUBMED: 17077426] ">Adams 2006</a>). Also, comparisons with new generation drugs, which are coming off‐patent and are therefore more accessible, are important to assist informed and independent choice of treatment for people with schizophrenia. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD010631-sec-0021" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD010631-sec-0021"></div> <p>To compare the effects of chlorpromazine with atypical or second generation antipsychotic drugs, for treatment of people with schizophrenia (see<a href="#CD010631-sec-0543">Differences between protocol and review</a>). </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD010631-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD010631-sec-0022"></div> <section id="CD010631-sec-0023"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD010631-sec-0024"> <h4 class="title">Types of studies</h4> <p>We included all relevant randomised controlled trials (RCTs). If a trial was described as double‐blind but implied randomisation, we included such trials in a sensitivity analysis (see <a href="#CD010631-sec-0101">Sensitivity analysis</a>). If their inclusion did not result in a substantive difference, we kept these trials in the analyses. If their inclusion resulted in statistically significant differences, we did not add the data from these lower quality studies to the results of the better trials, but presented such data within a subcategory. We excluded quasi‐RCTs (e.g. allocating by alternate days of the week). Where people were given additional treatments within the chlorpromazine and atypical antipsychotic groups, we only included data if the adjunct treatment was evenly distributed between groups and only the chlorpromazine and atypical antipsychotic groups were randomised. </p> </section> <section id="CD010631-sec-0025"> <h4 class="title">Types of participants</h4> <p>Adults (as defined in each trial) diagnosed with schizophrenia, including schizophreniform, schizoaffective and delusional disorders (any means of diagnosis, including operational criteria (<a href="./references#CD010631-bbs2-0136" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. Washington DC: American Psychiatric Association, 1994. ">DSM‐IV 1994</a>; <a href="./references#CD010631-bbs2-0151" title="World Health Organization. F‐20. The ICD‐10 Classification of Mental and Behavioural Disorders. Geneva: Divison of Mental Health, WHO, 1992:86‐109. ">ICD‐10 1992</a>) or clinical opinion). </p> <p>We are interested in making sure that information is as relevant to the current care of people with schizophrenia as possible so if the information was reported we clearly highlighted in the <a href="./references#CD010631-sec-0545" title="">Characteristics of included studies</a> and <a href="#CD010631-sec-0108">Description of studies</a>, the current clinical state (acute, early post ‐ acute, partial remission, remission) as well as the stage (prodromal, first episode, early illness, persistent) and as to whether the studies primarily focused on people with particular problems (for example, negative symptoms, treatment‐resistant illnesses). </p> </section> <section id="CD010631-sec-0026"> <h4 class="title">Types of interventions</h4> <section id="CD010631-sec-0027"> <h5 class="title">1. Chlorpromazine</h5> <p>Any dose and any route of administration.</p> </section> <section id="CD010631-sec-0028"> <h5 class="title">2. Any atypical antipsychotic</h5> <p>Atypical antipsychotic drugs including: amisulpride, aripiprazole, asenapine (<a href="./references#CD010631-bbs2-0181" title="SmithTLL , CarterCW . Asenapine: a novel atypical antipsychotic agent for schizophrenia and bipolar I disorder. Journal of Pharmacy Technology2010;26:352‐61. ">Smith 2010</a>), clozapine, clothiapine or clotiapine (<a href="./references#CD010631-bbs2-0185" title="TorenP , SamuelE , WeizmanR , GolombA , EldarS , LaorN . Emergence of transient compulsive symptoms during treatment with clothiapine. Journal of the American Academy of Child &amp; Adolescent Psychiatry1995;34(11):1469‐72. [DOI: 10.1097/00004583‐199511000‐00013] ">Toren 1995</a>), iloperidone (<a href="./references#CD010631-bbs2-0127" title="CacciaS , PasinaL , NobiliA . New atypical antipsychotic drugs for schizophrenia: iloperidone. Drug Design, Development and Therapy2010;4:33–48. ">Caccia 2010</a>), lurasidone (<a href="./references#CD010631-bbs2-0176" title="RisboodV , LeeJR , Roche‐DesiletsJ , FullerMA . Lurasidone: an atypical antipsychotic for schizophrenia. Annals of Pharmacotherapy2012;46(7‐8):1033‐46. ">Risbood 2012</a>), mosapramine (<a href="./references#CD010631-bbs2-0184" title="TakahashiN , TeraoT , OgaT , OkadaM . Comparison of risperidone and mosapramine addition to neuroleptic treatment in chronic schizophrenia. Neuropsychobiology1999;39(2):81‐5. ">Takahashi 1999</a>), olanzapine, paliperidone, perospirone (<a href="./references#CD010631-bbs2-0123" title="BianQ , KatoT , MonjiA , HashiokaS , MizoguchiY , HorikawaH , et al. The effect of atypical antipsychotic drugs, perospirone, ziprasidone and quetiapine on microglial activation induced by interferon‐gamma. Progress in Neuro‐Psychopharmacology and Biological Psychiatry2008;32(1):42‐8. ">Bian 2008</a>), quetiapine, remoxipride (<a href="./references#CD010631-bbs2-0172" title="NadalR . Pharmacology of the atypical antipsychotic remoxipride, a dopamine D2 receptor antagonist. CNS Drug Reviews2001;7(3):265‐82. ">Nadal 2001</a>), risperidone, sertindole (<a href="./references#CD010631-bbs2-0130" title="CincottaSL , RodeferJS . Emerging role of sertindole in the management of schizophrenia. Neuropsychiatric Disease and Treatment2010;7:429‐41. ">Cincotta 2010</a>), sulpiride (<a href="./references#CD010631-bbs2-0178" title="RzewuskaM . Sulpiride: the best known atypical, safe neuroleptic drug. Review of literature. Psychiatria Polska1998;32(5):655‐66. [PUBMED: 9921002] ">Rzewuska 1988</a>), ziprasidone and zotepine (list non‐exhaustive). </p> <p>Any dose and any route of administration.</p> </section> </section> <section id="CD010631-sec-0029"> <h4 class="title">Types of outcome measures</h4> <p>If possible, we divided outcomes into short term (up to six months), medium term (seven to 12 months) and long term (over one year). </p> <section id="CD010631-sec-0030"> <h5 class="title">Primary outcomes</h5> <section id="CD010631-sec-0031"> <h6 class="title">1. Clinical response</h6> <p>Clinically significant improvement as defined by each included trial.</p> </section> <section id="CD010631-sec-0032"> <h6 class="title">2. Relapse</h6> <p>As defined by each trial.</p> </section> </section> <section id="CD010631-sec-0033"> <h5 class="title">Secondary outcomes</h5> <section id="CD010631-sec-0034"> <h6 class="title">1. Death: natural death or suicide</h6> </section> <section id="CD010631-sec-0035"> <h6 class="title">2. Global state</h6> <p>2.1 Any change in global state.<br/> 2.2 Deterioration.<br/> 2.3 Need for additional antipsychotic drugs.<br/> 2.4 Need for additional benzodiazepines.<br/> 2.5 Poor compliance. </p> </section> <section id="CD010631-sec-0036"> <h6 class="title">3. Mental state</h6> <section id="CD010631-sec-0037"> <p><b>3.1 General symptoms</b></p> <p>3.1.1 Any change in general symptoms.<br/> 3.1.2 Average endpoint general symptom score.<br/> 3.1.3 Average change in general symptom score. </p> </section> <section id="CD010631-sec-0038"> <p><b>3.2 Specific symptoms (positive and negative symptoms of schizophrenia, depression and mania/hypomania)</b></p> <p>3.2.1 Any change of specific symptoms.<br/> 3.2.2 Average endpoint specific symptom score.<br/> 3.2.3 Average change specific symptom score. </p> </section> </section> <section id="CD010631-sec-0039"> <h6 class="title">4. Service involvement</h6> <p>4.1 Duration of hospital stay.<br/> 4.2 Re‐hospitalisation.<br/> 4.3 Engagement with community services.<br/> 4.4 Engagement with inpatient/outpatient services. </p> </section> <section id="CD010631-sec-0040"> <h6 class="title">5. Functioning</h6> <section id="CD010631-sec-0041"> <p><b>5.1 General functioning</b></p> <p>5.1.1 Any change in general functioning.<br/> 5.1.2 Average endpoint score in general functioning.<br/> 5.1.3 Average change score in general functioning. </p> </section> <section id="CD010631-sec-0042"> <p><b>5.2 Social functioning</b></p> <p>5.1.1 Any change in social functioning.<br/> 5.1.2 Average endpoint score in social functioning.<br/> 5.1.3 Average change score in social functioning </p> </section> <section id="CD010631-sec-0043"> <p><b>5.3 Employment status</b></p> <p>5.1.1 Any change in employment status.<br/> 5.1.2 Average endpoint score in employment functioning.<br/> 5.1.3 Average change score in employment functioning. </p> </section> </section> <section id="CD010631-sec-0044"> <h6 class="title">6. Behaviour</h6> <p>6.1 General behaviour.<br/> 6.2 Any improvement in behaviour, as defined in each trial.<br/> 6.3 Specific behaviour (e.g. agitation, aggression, violent incidents).<br/> 6.4 Average endpoint in behaviour scores.<br/> 6.5 Average change in behaviour scores. </p> </section> <section id="CD010631-sec-0045"> <h6 class="title">7. Adverse effects</h6> <p>7.1 Anticholinergic.<br/> 7.2 Cardiovascular.<br/> 7.3 Central nervous system.<br/> 7.4 Gastrointestinal.<br/> 7.5 Endocrine (e.g. amenorrhoea, galactorrhoea, hyperlipidaemia, hyperglycaemia, hyperinsulinemia).<br/> 7.6 Haematology (e.g. haemogram, leukopenia, agranulocytosis/neutropenia).<br/> 7.7 Hepatitic (e.g. abnormal transaminase, abnormal liver function).<br/> 7.8 Metabolic.<br/> 7.9 Movement disorders.<br/> 7.10 Various other. </p> </section> <section id="CD010631-sec-0046"> <h6 class="title">8. Satisfaction</h6> <p>8.1 Patient satisfaction.<br/> 8.2 Carer satisfaction.<br/> 8.3 Professional satisfaction (managers/doctors/nurses). </p> </section> <section id="CD010631-sec-0047"> <h6 class="title">9. Economic outcomes</h6> <p>9.1 Direct costs, as defined in each study.<br/> 9.2 Indirect costs, as defined in each study.<br/> 9.3 Cost‐effectiveness, as defined in each study. </p> </section> <section id="CD010631-sec-0048"> <h6 class="title">10. Quality of life</h6> <p>10.1 Average endpoint score in quality of life.<br/> 10.2 Average change score in quality of life.<br/> 10.3 Any improvement in quality of life. </p> </section> <section id="CD010631-sec-0049"> <h6 class="title">11. Leaving the study early</h6> </section> <section id="CD010631-sec-0050"> <h6 class="title">'Summary of findings' tables</h6> <p>We used the GRADE approach to interpret findings (<a href="./references#CD010631-bbs2-0180" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Chichester: The Cochrane Collaboration, 2008:359‐83. ">Schünemann 2008</a>) and used GRADE profiler (<a href="http://www.tech.cochrane.org/gradepro" target="_blank">GRADEPRO</a>) to import data from RevMan 5 (<a href="http://www.tech.cochrane.org/revman" target="_blank">Teview Manager</a>) to create 'Summary of findings' tables. These tables provide outcome ‐ specific information concerning the overall quality of evidence from each included study in the comparison, the magnitude of effect of the interventions examined, and the sum of available data on all outcomes we rated as important to patient care and decision making. We aimed to select the following main outcomes for inclusion in the 'Summary of findings' tables: </p> <p> <ul id="CD010631-list-0001"> <li> <p>Clinical response: clinically significant improvement (as defined by each of the studies) by medium term. </p> </li> <li> <p>Relapse (as defined by each of the studies) by medium term.</p> </li> <li> <p>Mental state: average endpoint score (Brief Psychiatric Rating Scale (BPRS)) by medium term. </p> </li> <li> <p>Adverse effects: extrapyramidal side effects: reported by the number participants by medium term. </p> </li> <li> <p>Quality of life: improvement as defined by each of the study by medium term.</p> </li> <li> <p>Participants leaving the study early by medium term.</p> </li> <li> <p>Economic outcomes: cost effectiveness (as defined in each study) by long term.</p> </li> </ul> </p> </section> </section> </section> </section> <section id="CD010631-sec-0051"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD010631-sec-0052"> <h4 class="title">Electronic searches</h4> <section id="CD010631-sec-0053"> <h5 class="title">1. Cochrane Schizophrenia Group Trials Register</h5> <p>We searched the Cochrane Schizophrenia Group's Trials Register up to 23 September 2013 using the phrase: </p> <p>[((*chlorpromazine* AND (*amisulprid* or *aripiprazol* or *clozapin* or *olanzapin* or *quetiapin* or *risperidon* or *sertindol* or *ziprasidon* or *zotepin*or *sulpiride* or *remoxipride* or *paliperidone* or *perospirone* or asenapine or clothiapine or clotiapine or iloperidone or lurasidone or mosapramine or ((Atypical or (Second NEXT generation)) and antipsychotic*))) in title, abstract or index terms of REFERENCE or interventions of STUDY)] </p> <p>The Cochrane Schizophrenia Group's Trials Register is compiled by systematic searches of major databases, handsearches and conference proceedings (see <a href="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/SCHIZ/frame.html" target="_blank">Group Module</a>). </p> <p>The seatch strategy was changed after protocol publication and we added new search terms to the strategy. The search strategy in protocol step is in Appendix 1. </p> </section> </section> <section id="CD010631-sec-0054"> <h4 class="title">Searching other resources</h4> <section id="CD010631-sec-0055"> <h5 class="title">1. Reference searching</h5> <p>We inspected references of all included trials for further relevant studies published in any language. </p> </section> <section id="CD010631-sec-0056"> <h5 class="title">2. Personal contact</h5> <p>If necessary we contacted the first author, relevant pharmaceutical companies, and drug approval agencies of trials for additional information. </p> </section> </section> </section> <section id="CD010631-sec-0057"> <h3 class="title" id="CD010631-sec-0057">Data collection and analysis</h3> <section id="CD010631-sec-0058"> <h4 class="title">Selection of studies</h4> <p>Two review authors (BL and SZ) independently inspected citations from the searches and identified relevant abstracts. JX independently re‐inspected a random 20% sample to ensure reliability. Where disputes arose, the full report was acquired for more detailed scrutiny. BL obtained and inspected full reports of the abstracts meeting the review criteria and JX re‐inspected a random 20% of these reports in order to ensure reliable selection. Where it was not possible to resolve disagreement by discussion, we attempted to contact the authors of the study for clarification. </p> </section> <section id="CD010631-sec-0059"> <h4 class="title">Data extraction and management</h4> <section id="CD010631-sec-0060"> <h5 class="title">1. Extraction</h5> <p>Two review authors (BL and SZ) extracted data from all included trials. To ensure reliability of data extraction, JX independently extracted data from a random sample of these studies, comprising 10% of the total. We discussed and documented any disagreements. Another review author (SS) helped to clarify any remaining issues and we documented these final decisions. If possible, we extracted data presented only in graphs and figures, but only included this data if two review authors independently had the same result. If necessary, we attempted to contact the trial authors through an open‐ended request in order to obtain missing information or for clarification whenever necessary. </p> </section> <section id="CD010631-sec-0061"> <h5 class="title">2. Management</h5> <section id="CD010631-sec-0062"> <h6 class="title">2.1 Forms</h6> <p>We extracted data onto standard, pre‐designed simple forms.</p> </section> <section id="CD010631-sec-0063"> <h6 class="title">2.2 Scale‐derived data</h6> <p>We included continuous data from rating scales only if:</p> <p> <ul id="CD010631-list-0002"> <li> <p>The psychometric properties of the measuring instrument had been described in a peer‐reviewed journal (<a href="./references#CD010631-bbs2-0166" title="MarshallM , LockwoodA , BradleyC , AdamsC , JoyC , FentonM . Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry2000;176:249‐52. ">Marshall 2000</a>); and </p> </li> <li> <p>The measuring instrument had not been written or modified by one of the trialists for that particular trial. </p> </li> </ul> </p> <p>Ideally, the measuring instrument should either be i. a self‐report or ii. completed by an independent rater or relative (not the therapist). We realise that this is not often reported clearly. We noted in the '<a href="#CD010631-sec-0108">Description of studies</a>' if this was the case or not. </p> </section> <section id="CD010631-sec-0064"> <h6 class="title">2.3 Endpoint versus change data</h6> <p>There are advantages to both endpoint and change data. Change data can remove a component of between person variability from the analysis. However, calculation of change requires two assessments (baseline and endpoint), which can be difficult in unstable and difficult to measure conditions, such as schizophrenia. We decided to primarily use endpoint data, and only use change data if the former were unavailable. We combined endpoint and change data in the analysis as we preferred to use MD rather than standardised mean difference (SMD) values throughout (<a href="./references#CD010631-bbs2-0146" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> </section> <section id="CD010631-sec-0065"> <h6 class="title">2.4 Skewed data</h6> <p>Continuous data on clinical and social outcomes are often not normally distributed. To avoid the pitfall of applying parametric tests to non‐parametric data we applied the following standards to all data before inclusion: </p> <section id="CD010631-sec-0066"> <p><b>For change data:</b></p> <p>We entered change data, as when continuous data are presented on a scale that includes a possibility of negative values (such as change data), it is difficult to tell whether data are skewed or not. We presented and entered change data into statistical analyses. </p> </section> <section id="CD010631-sec-0067"> <p><b>For endpoint data:</b></p> <p>a) When a scale started from the finite number 0, we subtracted the lowest possible value from the mean, and divided this by the SD. If this value was &lt; 1, it strongly suggested a skew, and we excluded the study. If this ratio was higher than 1 but below 2, there was suggestion of skew. We entered the study and tested whether its inclusion or exclusion would change the results substantially. Finally, if the ratio was &gt; 2, we included the study because skew was less likely (<a href="./references#CD010631-bbs2-0118" title="AltmanDG , BlandJM . Detecting skewness from summary information. BMJ1996;313(7066):1200. ">Altman 1996</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z1506231229092750134863197782982%26format=REVMAN#REF-Higgins-2011" target="_blank">Higgins 2011</a>). </p> <p>b) If a scale started from a positive value (such as the Positive and Negative Syndrome Scale (PANSS), which can have values from 30 to 210) (<a href="./references#CD010631-bbs2-0154" title="KaySR , OplerLA , FiszbeinA . Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi‐Health Systems, 1986. ">Kay 1986</a>), we modified the calculation described above to take into account the scale starting point. In such cases skew was present if 2 SD &gt; (S ‐ S<sub>min</sub>), where S is the mean score and S<sub>min</sub> is the minimum score. </p> <p>(Please note, irrespective of the above rules, we entered endpoint data from studies of at least 200 participants in the analysis because skewed data pose less of a problem in large studies). </p> </section> </section> <section id="CD010631-sec-0068"> <h6 class="title">2.5 Common measure</h6> <p>To facilitate comparison between trials, we intended to convert variables that can be reported in different metrics, such as days in hospital (mean days per year, per week or per month) to a common metric (e.g. mean days per month). However, we did not identify such data. </p> </section> <section id="CD010631-sec-0069"> <h6 class="title">2.6 Conversion of continuous to binary</h6> <p>Where possible, we made efforts to convert outcome measures to dichotomous data. This can be done by identifying cut‐off points on rating scales and dividing participants accordingly into 'clinically improved' or 'not clinically improved'. It is generally assumed that if there is a 50% reduction in a scale derived score, such as the BPRS (<a href="./references#CD010631-bbs2-0174" title="OverallJE , GorhamDR . The brief psychiatric rating scale. Psychological Reports1962;10:799‐812. ">Overall 1962</a>) or the PANSS (<a href="./references#CD010631-bbs2-0154" title="KaySR , OplerLA , FiszbeinA . Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi‐Health Systems, 1986. ">Kay 1986</a>), this could be considered a clinically significant response (<a href="./references#CD010631-bbs2-0159" title="LeuchtS , KaneJM , KisslingW , HamannJ , EtschelE , EngelR . Clinical implications of Brief Psychiatric Rating Scale scores. British Journal of Psychiatry2005;187:366‐71. [PUBMED: 16199797] ">Leucht 2005a</a>; <a href="./references#CD010631-bbs2-0160" title="LeuchtS , KaneJM , KisslingW , HamannJ , EtschelE , EngelRR . What does the PANSS mean?. Schizophrenia Research2005;79(2‐3):231‐8. [PUBMED: 15982856] ">Leucht 2005b</a>). </p> </section> <section id="CD010631-sec-0070"> <h6 class="title">2.7 Direction of graphs</h6> <p>Where possible, we entered data in such a way that the area to the left of the line of no effect indicates a favourable outcome for chlorpromazine. Where keeping to this made it impossible to avoid outcome titles with clumsy double‐negatives (e.g. 'not un‐improved') we reported data where the left of the line indicates an unfavourable outcome. We have noted this in the relevant graphs. </p> </section> </section> </section> <section id="CD010631-sec-0071"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (BL and SZ) independently assessed the risk of bias of included trials by using criteria described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010631-bbs2-0146" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). This set of criteria is based on evidence of association between overestimate of effect and high risk of bias of the article, such as sequence generation, allocation concealment, blinding, incomplete outcome data and selective reporting. </p> <p>If the two review authors disagreed, we made the final rating by consensus, with the involvement of another review author from the team. Where inadequate details of randomisation and other characteristics of trials were provided, we contacted trial authors for further information. We reported non‐concurrence in quality assessment, but if disputes arose as to which category a trial was to be allocated, again, we resolved this by discussion. </p> <p>We described the results of the 'Risk of bias' assessments in both the review text and in the 'Summary of findings' tables. </p> </section> <section id="CD010631-sec-0072"> <h4 class="title">Measures of treatment effect</h4> <section id="CD010631-sec-0073"> <h5 class="title">1. Binary data−</h5> <p>For binary outcomes we calculated a standard estimation of the risk ratio (RR) and its 95% confidence interval (CI). It has been shown that RR is more intuitive (<a href="./references#CD010631-bbs2-0126" title="BoisselJP , CucheratM , LiW , ChatellierG , GueyffierF , BuyseM , et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Apercu sur la problematique des indices d'efficacite therapeutique, 3: comparaison des indices et utilisation. Groupe d'etude des indices d'efficacite]. Therapie1999;54(4):405‐11. [PUBMED: 10667106] ">Boissel 1999</a>) than odds ratios (ORs) and that ORs tend to be interpreted as RRs by clinicians (<a href="./references#CD010631-bbs2-0131" title="DeeksJ . Issues in the selection for meta‐analyses of binary data. Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25‐28; Cape Town. Cape Town: The Cochrane Collaboration, 2000. ">Deeks 2000</a>). The number needed to treat for an additional beneficial outcome (NNTB)/number needed to treat for an additional harmful outcome (NNTH) statistic with its CIs is intuitively attractive to clinicians but is problematic both in its accurate calculation in meta analyses and interpretation (<a href="./references#CD010631-bbs2-0150" title="HuttonJL . Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials. British Journal of Haematology2009;146(1):27‐30. ">Hutton 2009</a>). For binary data presented in the 'Summary of findings' table(s), where possible, we calculated illustrative comparative risks. </p> </section> <section id="CD010631-sec-0074"> <h5 class="title">2. Continuous data</h5> <p>For continuous outcomes, we estimated the MD between groups. We preferred not to calculate effect size measures (SMD). However, if scales of considerable similarity were used, we assumed there was a small difference in measurement, calculated effect size and transformed the effect back to the units of one or more of the specific instruments. </p> </section> </section> <section id="CD010631-sec-0075"> <h4 class="title">Unit of analysis issues</h4> <section id="CD010631-sec-0076"> <h5 class="title">1. Cluster trials</h5> <p>Studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice) but analysis and pooling of clustered data poses problems. Firstly, study authors often fail to account for intra‐class correlation in clustered studies, leading to a 'unit of analysis' error (<a href="./references#CD010631-bbs2-0134" title="DivineGW , BrownJT , FrazierLM . The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine1992;7(6):623‐9. ">Divine 1992</a>) whereby P values are spuriously low, CIs unduly narrow and statistical significance overestimated. This causes type I errors (<a href="./references#CD010631-bbs2-0125" title="BlandJM , KerrySM . Statistics notes. Trials randomised in clusters. BMJ1997;315(7108):600. ">Bland 1997</a>; <a href="./references#CD010631-bbs2-0142" title="GullifordMC , UkoumunneOC , ChinnS . Components of variance and intraclass correlations for the design of community‐based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology1999;149(9):876‐83. ">Gulliford 1999</a>). </p> <p>We did not identify any cluster‐randomised studies. However, if we identify such studies in future updates of this Cochrane review where clustering is not accounted for in primary studies, we will present data in a table, with an asterisk (*) to indicate the presence of a probable unit of analysis error. In updates of this review we will try to contact first authors of such studies to obtain intra‐class correlation coefficients (ICCs) for their clustered data and to adjust for this by using accepted methods (<a href="./references#CD010631-bbs2-0142" title="GullifordMC , UkoumunneOC , ChinnS . Components of variance and intraclass correlations for the design of community‐based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology1999;149(9):876‐83. ">Gulliford 1999</a>). </p> <p>Where clustering was incorporated into the analysis of primary studies, we presented these data as if from a non‐cluster randomised study, but adjusted for the clustering effect. </p> <p>We received statistical advice that binary data presented in a report should be divided by a 'design effect'. This is calculated using the mean number of participants per cluster (m) and the ICC [Design effect = 1 + (m − 1)*ICC] (<a href="./references#CD010631-bbs2-0135" title="DonnerA , KlarN . Issues in the meta‐analysis of cluster randomized trials. Statistics in Medicine2002;21(19):2971‐80. ">Donner 2002</a>). If the ICC was not reported, we assumed it was 0.1 (<a href="./references#CD010631-bbs2-0187" title="UkoumunneOC , GullifordMC , ChinnS , SterneJAC , BurneyPGJ . Methods for evaluating area‐wide and organisation‐based intervention in health and health care: a systematic review. Health Technology Assessment1999;3(5):iii‐92. ">Ukoumunne 1999</a>). </p> <p>Where cluster studies had been appropriately analysed taking into account ICCs and relevant data documented in the report, synthesis with other studies was possible using the generic inverse variance technique. </p> </section> <section id="CD010631-sec-0077"> <h5 class="title">2. Cross‐over trials</h5> <p>A major concern of cross‐over trials is the carry‐over effect. It occurs if an effect (e.g. pharmacological, physiological or psychological) of the treatment in the first phase is carried over to the second phase. As a consequence on entry to the second phase, the participants can differ systematically from their initial state despite a wash‐out phase. For the same reason cross‐over trials are not appropriate if the condition of interest is unstable (<a href="./references#CD010631-bbs2-0139" title="ElbourneD , AltmanDG , HigginsJPT , CurtinaF , WorthingtondHV , VaileA . Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology2002;31(1):140‐9. ">Elbourne 2002</a>). As both effects are very likely in severe mental illness, we planned to only use data from the first phase of cross‐over studies. However, we did not identify any cross‐over trials for inclusion in this review. </p> </section> <section id="CD010631-sec-0078"> <h5 class="title">3. Studies with multiple treatment groups</h5> <p>Where a study involves more than two treatment arms, if relevant, we presented the additional treatment arms in comparisons. If data were binary, we simply added these and combined within the two‐by‐two table. If data were continuous, we had planned to combine data following the formula in Section 7.7.3.8 (Combining groups) of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010631-bbs2-0147" title="HigginsJPT , DeeksJJ . Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org2011. ">Higgins 2011a</a>). Where the additional treatment arms were irrelevant, we did not reproduce these data. </p> </section> </section> <section id="CD010631-sec-0079"> <h4 class="title">Dealing with missing data</h4> <section id="CD010631-sec-0080"> <h5 class="title">1. Overall loss of credibility</h5> <p>At some degree of loss of follow‐up, data must lose credibility (<a href="./references#CD010631-bbs2-0191" title="XiaJ , AdamsCE , BhagatN , BhagatV , BhoopathiP , El‐SayehH , et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin2009;33(7):254‐7. ">Xia 2009</a>). We chose that, for any particular outcome, should more than 50% of data be unaccounted for, we would not reproduce these data or use them within analyses. If more than 50% of those in one arm of a study were lost but the total loss was less than 50%, we addressed this within the 'Summary of findings' table(s) by downgrading the quality of the evidence. We also downgraded the quality of the evidence within the 'Summary of findings' table(s) where loss was 25% to 50% in total. </p> </section> <section id="CD010631-sec-0081"> <h5 class="title">2. Binary</h5> <p>In the case where attrition for a binary outcome was between 0% and 50% and where these data were not clearly described, we presented these data on a 'once‐randomised‐always‐analyse' basis (an intention‐to‐treat (ITT) analysis). We assumed all those leaving the study early to have the same rates of negative outcome as those who completed, with the exception of the outcome of death and adverse effects. For these outcomes, we used the rate of those who stayed in the study in that particular arm of the trial for those who did not. We undertook a sensitivity analysis to test how prone the primary outcomes were to change when 'completer' data only were compared to the ITT analysis using the above assumptions. </p> </section> <section id="CD010631-sec-0082"> <h5 class="title">3. Continuous</h5> <section id="CD010631-sec-0083"> <h6 class="title">3.1 Attrition</h6> <p>In cases where attrition for a continuous outcome was between 0% and 50% and completer‐only data was reported, we reproduced these. </p> </section> <section id="CD010631-sec-0084"> <h6 class="title">3.2 Standard deviations</h6> <p>If SD values were not reported, we first tried to obtain the missing values from the trial authors. If unavailable, where there were missing measures of variance for continuous data, but an exact standard error (SE) and CIs available for group means, and either 'P' value or 't' value available for differences in mean, we calculated them according to the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010631-bbs2-0146" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>): when only the standard error (SE) is reported, SDs are calculated by the formula SD = SE * square root (n). Chapters 7.7.3 and 16.1.3 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010631-bbs2-0147" title="HigginsJPT , DeeksJJ . Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org2011. ">Higgins 2011a</a>; <a href="./references#CD010631-bbs2-0148" title="HigginsJPT , DeeksJJ , AltmanDG , on behalf of the Cochrane Statistical Methods Group. Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org2011. ">Higgins 2011b</a>) present detailed formulae for estimating SDs from P values, t or F values, CIs, ranges or other statistics. If these formula did not apply, we calculated the SDs according to a validated imputation method, which is based on the SDs of the other included studies (<a href="./references#CD010631-bbs2-0141" title="FurukawaTA , BarbuiC , CiprianiA , BrambillaP , WatanabeN . Imputing missing standard deviations in meta‐analyses can provide accurate results. Journal of Clinical Epidemiology2006;59(1):7‐10. ">Furukawa 2006</a>). Although some of these imputation strategies can introduce error, the alternative would be to exclude a given study's outcome and thus to lose information. We did not impute any continuous data in this review. </p> </section> <section id="CD010631-sec-0085"> <h6 class="title">3.3 Last observation carried forward</h6> <p>We anticipated that in some studies would employ the method of last observation carried forward (LOCF) within the study report. As with all methods of imputation to deal with missing data, LOCF introduces uncertainty about the reliability of the results (<a href="./references#CD010631-bbs2-0161" title="LeuchtS , EngelRR , BäumlJ , DavisJM . Is the superior efficacy of new generation antipsychotic drugs an artifact of LOCF?. Schizophrenia Bulletin2007;33(1):183‐91. [PUBMED: 16905632] ">Leucht 2007</a>). Therefore, where LOCF data were used in the trial, if less than 50% of the data had been assumed, we reproduced these data and indicated that they were the product of LOCF assumptions. </p> </section> </section> </section> <section id="CD010631-sec-0086"> <h4 class="title">Assessment of heterogeneity</h4> <section id="CD010631-sec-0087"> <h5 class="title">1. Clinical heterogeneity</h5> <p>We considered all included studies initially, without seeing comparison data, to judge clinical heterogeneity. We simply inspected all studies for clearly outlying people or situations which we had not predicted would arise and discussed these. </p> </section> <section id="CD010631-sec-0088"> <h5 class="title">2. Methodological heterogeneity</h5> <p>We considered all included studies initially, without seeing comparison data, to judge methodological heterogeneity. We simply inspected all studies for clearly outlying methods which we had not predicted would arise, and discussed. </p> </section> <section id="CD010631-sec-0089"> <h5 class="title">3. Statistical heterogeneity</h5> <section id="CD010631-sec-0090"> <h6 class="title">3.1 Visual inspection</h6> <p>We visually inspected graphs to investigate the possibility of statistical heterogeneity.</p> </section> <section id="CD010631-sec-0091"> <h6 class="title">3.2 Employing the I² statistic</h6> <p>We investigated heterogeneity between studies by considering the I² statistic alongside the Chi² test P value. The I² statistic provides an estimate of the percentage of inconsistency thought to be due to chance (<a href="./references#CD010631-bbs2-0145" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. ">Higgins 2003</a>). The importance of the observed I² statistic value depends on: i. magnitude and direction of effects; and ii. strength of evidence for heterogeneity (e.g. P value from the Chi² test, or a CI for I² statistic). We interpreted an I² statistic estimate ≥ around 50% accompanied by a statistically significant Chi² test as evidence of substantial levels of heterogeneity (Section 9.5.2 ‐ <a href="./references#CD010631-bbs2-0132" title="DeeksJJ , HigginsJPT , AltmanDG , on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org2011. ">Deeks 2011</a>). When we found substantial levels of heterogeneity in the primary outcome, we explored reasons for heterogeneity (<a href="#CD010631-sec-0096">Subgroup analysis and investigation of heterogeneity</a>). </p> </section> </section> </section> <section id="CD010631-sec-0092"> <h4 class="title">Assessment of reporting biases</h4> <section id="CD010631-sec-0093"> <h5 class="title">1. Protocol versus full study</h5> <p>Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results. These are described in Section 10.1 (<a href="./references#CD010631-bbs2-0182" title="SterneJAC , EggerM , MoherD , on behalf of the Cochrane Bias Methods Group. Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org2011. ">Sterne 2011</a>). We tried to locate protocols of included RCTs. If the protocol was available, we compared outcomes in the protocol and in the published report. If the protocol was unavailable, we compared outcomes listed in the methods section of the trial report with actually reported results. </p> </section> <section id="CD010631-sec-0094"> <h5 class="title">2. Funnel plot</h5> <p>Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results (<a href="./references#CD010631-bbs2-0138" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta‐analysis detected by a simple, graphical test. BMJ1997;315(7109):629‐34. ">Egger 1997</a>). These are again described in Section 10 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010631-bbs2-0146" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). We are aware that funnel plots may be useful in investigating reporting biases but are of limited power to detect small‐study effects. We did not use funnel plots for outcomes where there were 10 or fewer studies, or where all studies were of similar sizes. In other cases, where funnel plots are possible, we sought statistical advice in their interpretation. </p> </section> </section> <section id="CD010631-sec-0095"> <h4 class="title">Data synthesis</h4> <p>We understand that there is no closed argument for preference for use of fixed‐effect or random‐effects models. The random‐effects method incorporates an assumption that the different studies are estimating different, yet related, intervention effects. This often seems to be true to us and the random‐effects model takes into account differences between studies even if there is no statistically significant heterogeneity. However, there is a disadvantage to the random‐effects model. It puts added weight onto small studies which often are the most biased ones. Depending on the direction of effect, these studies can either inflate or deflate the effect size. We used the random‐effects model for all analyses. </p> </section> <section id="CD010631-sec-0096"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <section id="CD010631-sec-0097"> <h5 class="title">1. Subgroup analyses</h5> <section id="CD010631-sec-0098"> <h6 class="title">1.1 Primary outcomes</h6> <p>We did not anticipate any subgroup analyses.</p> </section> <section id="CD010631-sec-0099"> <h6 class="title">1.2 Clinical state, stage or problem</h6> <p>We proposed to provide an overview of the effects of chlorpromazine versus atypical antipsychotic drugs for people with schizophrenia in general in this Cochrane review. In addition, we tried to report data on subgroups of people in the same clinical state, stage and with similar problems. </p> </section> </section> <section id="CD010631-sec-0100"> <h5 class="title">2. Investigation of heterogeneity</h5> <p>We reported if inconsistency in trial results was high. First, we investigated whether data had been entered correctly. Second, if data were correct, we visually inspected the graph and successively removed outlying studies to see if homogeneity was restored. For this Cochrane review, we decided that should this occur with data contributing to the summary finding of no more than around 10% of the total weighting, we presented these data. If not, we did not pool these data and discussed any issues. We know of no supporting research for this 10% cut‐off but are investigating use of prediction intervals as an alternative to this unsatisfactory state. </p> <p>If we observed obvious unanticipated clinical or methodological heterogeneity, we simply stated hypotheses regarding these for future reviews or versions of this Cochrane review. We did not anticipate undertaking analyses relating to these. </p> </section> </section> <section id="CD010631-sec-0101"> <h4 class="title">Sensitivity analysis</h4> <section id="CD010631-sec-0102"> <h5 class="title">1. Implication of randomisation</h5> <p>We aimed to include trials in a sensitivity analysis if they were described in some way as to imply randomisation. For the primary outcomes, we included these studies. If there was no substantive difference when we added the implied randomised studies to those with better description of randomisation, then we used relevant data from these studies. </p> </section> <section id="CD010631-sec-0103"> <h5 class="title">2. Assumptions for lost binary data</h5> <p>Where assumptions have to be made regarding people lost to follow‐up (see <a href="#CD010631-sec-0079">Dealing with missing data</a>), we compared the findings of the primary outcomes when we used our assumption compared with completer data only. If there was a substantial difference, we reported results and discussed them but continued to employ our assumption. </p> <p>Where assumptions had to be made regarding missing SDs data (see <a href="#CD010631-sec-0079">Dealing with missing data</a>), we compared the findings on primary outcomes when we used our assumption compared with completer data only. We performed a sensitivity analysis testing how prone results were to change when 'completer' data only were compared to the imputed data using the above assumption. If there was a substantial difference, we reported results and discussed them but continued to employ our assumption. </p> </section> <section id="CD010631-sec-0104"> <h5 class="title">3. Risk of bias</h5> <p>We analysed the effects of excluding trials that we judged to be at 'high' risk of bias across one or more of the domains of randomisation (implied as randomised with no further detail available), allocation concealment, blinding and outcome reporting for the meta‐analysis of the primary outcome. If the exclusion of trials at 'high' risk of bias did not substantially alter the direction of effect or the precision of the effect estimates, then we included data from these trials in the analysis. </p> </section> <section id="CD010631-sec-0105"> <h5 class="title">4. Imputed values</h5> <p>We had also planned to undertake a sensitivity analysis to assess the effects of including data from trials where we used imputed values for ICC in calculating the design effect in cluster‐RCTs. However, we did not impute any values in this Cochrane review. </p> </section> <section id="CD010631-sec-0106"> <h5 class="title">5. Fixed‐effect and random‐effects</h5> <p>We synthesised all data using a random‐effects model. However, we also synthesised data for the primary outcome using a fixed‐effect model to evaluate whether this altered the significance of the results. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD010631-sec-0107" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD010631-sec-0107"></div> <section id="CD010631-sec-0108"> <h3 class="title">Description of studies</h3> <section id="CD010631-sec-0109"> <h4 class="title">Results of the search</h4> <p>We identified 444 references following our literature search, of which we excluded 298 after screening by title/abstract. For this Cochrane review with the three comparisons of olanzapine, risperidone and quetiapine, we obtained and scrutinised 146 full‐text articles. Of these, 42 articles did not meet the inclusion criteria (see <a href="./references#CD010631-sec-0546" title="">Characteristics of excluded studies</a>) and were excluded. We included 71 trials (<a href="#CD010631-fig-0001">Figure 1</a>). In the same literature search, we identified 33 more studies comparing chlorpromazine to atypical antipsychotics, including aripiprazole, clotiapine, clozapine, iloperidone, remoxipride, sulpiride, ziprasidone and zotepine. We will include all of these comparisons in a future update of this Cochrane review. </p> <div class="figure" id="CD010631-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD010631-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD010631-sec-0110"> <h4 class="title">Included studies</h4> <section id="CD010631-sec-0111"> <h5 class="title">1. Chlorpromazine versus olanzapine</h5> <p>For this comparison, we included 12 studies (total N = 919; chlorpromazine N = 432 and olanzapine N = 487). </p> <section id="CD010631-sec-0112"> <h6 class="title">1. Trial length</h6> <p>Most included studies were eight weeks in duration (<a href="./references#CD010631-bbs2-0004" title="ChangFW , WangCH , ZhaoZ . Clinical effects of olanzapine vs chlorpromazine in treating positive symptoms of schizophrenia. Chinese Journal of New Drugs and Clinical Remedies2003;22(6):357‐9. ">vs OLZ ‐ Chang 2003</a>; <a href="./references#CD010631-bbs2-0005" title="ChenF . Olanzapine and chlorpromazine in the treatment of schizophrenia. Journal of Clinical Psychiatric Medicine2006;16:303‐4. ">vs OLZ ‐ Chen 2006</a>; <a href="./references#CD010631-bbs2-0006" title="HeJ , AnQ . A comparative trial of olanzapine versus chlorpromazine in the treatment of schizophrenia. Shandong Mental Health Archive2003;16:78‐80. ">vs OLZ ‐ He 2003</a>; <a href="./references#CD010631-bbs2-0008" title="LuoC , YangJW , RenJP . Comparative study of the effect of olanzapine on serum lipid in schizophrenia. Journal of Clinical Psychiatric Medicine2007;17:401‐2. ">vs OLZ ‐ Luo 2007</a>; <a href="./references#CD010631-bbs2-0009" title="WangCH , ZhaoZ , LiY , PanM , LiuX . Evaluation of proximal therapeutic effect and distal social function restoration of olanzapine on schizophrenia patients. Zhongguo lin chuang kang fu [Chinese Journal of Clinical Rehabilitation]2002;6(17):2664‐5. ">vs OLZ ‐ Wang 2002</a>; <a href="./references#CD010631-bbs2-0010" title="WangQ , LiL , WangT . A comparative study of olanzapine in treatment of schizophrenia. Journal of Psychiatry2008;21:373‐5. ">vs OLZ ‐ Wang 2008</a>; <a href="./references#CD010631-bbs2-0012" title="ZhaoZ , YanF , FengY . A comparative study on olanzapine and chlorpromazine in the treatment of schizophrenia. China Journal of Health Psychology2006;14:41‐2. ">vs OLZ ‐ Zhao 2006</a>), with three studies at six weeks in duration (<a href="./references#CD010631-bbs2-0001" title="DossenbachM . Sleep quality and early morning wakefulness of schizophrenic patients treated with olanzapine compared to chlorpromazine. European Neuropsychopharmacology2000;10(Supplement 3):S328‐9. EliLilly , Company . Study F1D‐VI‐HGCQ olanzapine versus chlorpromazine in Turkey. Unpublished document internal to Eli‐Lilly2000:1‐560. KostakogluE , AlptekinK , KivicikBB , MartenyiF , TuncaZ , GogusA , et al. Sleep quality and early morning wakefulness of schizophrenia patients treated with olanzapine compared to chlorpromazine [Errata]. European Neuropsychopharmacology2001;11(Suppl 3):S369. MrazK , GogusA , TuncaZ , MartenyiF , DossenbachM . Olanzapine versus chlorpromazine in Turkey. Schizophrenia Research (Abstracts of the Winter Workshop on Schizophrenia; February 5‐11, 2000; Davos, Switzerland). 2000. ">HGCQ (Turkey) 2000</a>; <a href="./references#CD010631-bbs2-0002" title="EliLilly , Company . Study HGDV olanzapine (versus chlorpromazine in Morocco). Unpublished document internal to Eli‐Lilly and Company2001:1‐512. HGDV/Morocco . Data supplied to the Cochrane Schizophrenia Group. Data on file1999. ">HGDV (Morocco) 1999</a>; <a href="./references#CD010631-bbs2-0007" title="EliLilly , Company . HGDT olanzapine versus chlorpromazine in Egypt. Unpublished document internal to Eli Lilly and Company2001:1‐513. LozaN , El‐DosokyAM , OkashaTA , KhalilAH , HasanNM , DossenbachM , et al. Olanzapine compared to chlorpromazine in acute schizophrenia. European Neuropsychopharmacology1999;9(Suppl 5):S291. ">vs OLZ ‐ Loza 1999 (HGDT)</a>). The final two studies were 12 weeks (<a href="./references#CD010631-bbs2-0011" title="WuY , LuWH , YiZH , WangJ , SongBF , ShiDQ , et al. Controlled study of olanzapine versus chlorpromazine for the quality of life of patients with schizophrenia. Sichuan Mental Health Journal2008;21(1):8‐11. ">vs OLZ ‐ Wu 2008</a>) and two years (<a href="./references#CD010631-bbs2-0003" title="AnBF , LiY , WangCH . Olanzapine on effect of executive dysfunction in schizophrenia. Journal of Clinical Psychiatry2006;16(3):144‐5. ">vs OLZ ‐ An 2006</a>) in duration. Therefore most included studies provided data for our short term outcome, with only one study providing any data for the long term. </p> </section> <section id="CD010631-sec-0113"> <h6 class="title">2. Design</h6> <p>All included studies were parallel arm RCTs. Four out of the 12 studies provided information as to randomisation methods, which included methods such as computer‐generated randomisation and random number tables (<a href="./references#CD010631-bbs2-0001" title="DossenbachM . Sleep quality and early morning wakefulness of schizophrenic patients treated with olanzapine compared to chlorpromazine. European Neuropsychopharmacology2000;10(Supplement 3):S328‐9. EliLilly , Company . Study F1D‐VI‐HGCQ olanzapine versus chlorpromazine in Turkey. Unpublished document internal to Eli‐Lilly2000:1‐560. KostakogluE , AlptekinK , KivicikBB , MartenyiF , TuncaZ , GogusA , et al. Sleep quality and early morning wakefulness of schizophrenia patients treated with olanzapine compared to chlorpromazine [Errata]. European Neuropsychopharmacology2001;11(Suppl 3):S369. MrazK , GogusA , TuncaZ , MartenyiF , DossenbachM . Olanzapine versus chlorpromazine in Turkey. Schizophrenia Research (Abstracts of the Winter Workshop on Schizophrenia; February 5‐11, 2000; Davos, Switzerland). 2000. ">HGCQ (Turkey) 2000</a>; <a href="./references#CD010631-bbs2-0002" title="EliLilly , Company . Study HGDV olanzapine (versus chlorpromazine in Morocco). Unpublished document internal to Eli‐Lilly and Company2001:1‐512. HGDV/Morocco . Data supplied to the Cochrane Schizophrenia Group. Data on file1999. ">HGDV (Morocco) 1999</a>; <a href="./references#CD010631-bbs2-0004" title="ChangFW , WangCH , ZhaoZ . Clinical effects of olanzapine vs chlorpromazine in treating positive symptoms of schizophrenia. Chinese Journal of New Drugs and Clinical Remedies2003;22(6):357‐9. ">vs OLZ ‐ Chang 2003</a>; <a href="./references#CD010631-bbs2-0008" title="LuoC , YangJW , RenJP . Comparative study of the effect of olanzapine on serum lipid in schizophrenia. Journal of Clinical Psychiatric Medicine2007;17:401‐2. ">vs OLZ ‐ Luo 2007</a>). </p> </section> <section id="CD010631-sec-0114"> <h6 class="title">3. Participants</h6> <p>All included participants had a diagnosis of schizophrenia; diagnostic criteria used included DSM‐IV (<a href="./references#CD010631-bbs2-0001" title="DossenbachM . Sleep quality and early morning wakefulness of schizophrenic patients treated with olanzapine compared to chlorpromazine. European Neuropsychopharmacology2000;10(Supplement 3):S328‐9. EliLilly , Company . Study F1D‐VI‐HGCQ olanzapine versus chlorpromazine in Turkey. Unpublished document internal to Eli‐Lilly2000:1‐560. KostakogluE , AlptekinK , KivicikBB , MartenyiF , TuncaZ , GogusA , et al. Sleep quality and early morning wakefulness of schizophrenia patients treated with olanzapine compared to chlorpromazine [Errata]. European Neuropsychopharmacology2001;11(Suppl 3):S369. MrazK , GogusA , TuncaZ , MartenyiF , DossenbachM . Olanzapine versus chlorpromazine in Turkey. Schizophrenia Research (Abstracts of the Winter Workshop on Schizophrenia; February 5‐11, 2000; Davos, Switzerland). 2000. ">HGCQ (Turkey) 2000</a>; <a href="./references#CD010631-bbs2-0002" title="EliLilly , Company . Study HGDV olanzapine (versus chlorpromazine in Morocco). Unpublished document internal to Eli‐Lilly and Company2001:1‐512. HGDV/Morocco . Data supplied to the Cochrane Schizophrenia Group. Data on file1999. ">HGDV (Morocco) 1999</a>; <a href="./references#CD010631-bbs2-0007" title="EliLilly , Company . HGDT olanzapine versus chlorpromazine in Egypt. Unpublished document internal to Eli Lilly and Company2001:1‐513. LozaN , El‐DosokyAM , OkashaTA , KhalilAH , HasanNM , DossenbachM , et al. Olanzapine compared to chlorpromazine in acute schizophrenia. European Neuropsychopharmacology1999;9(Suppl 5):S291. ">vs OLZ ‐ Loza 1999 (HGDT)</a>) and CCMD (<a href="./references#CD010631-bbs2-0003" title="AnBF , LiY , WangCH . Olanzapine on effect of executive dysfunction in schizophrenia. Journal of Clinical Psychiatry2006;16(3):144‐5. ">vs OLZ ‐ An 2006</a>; <a href="./references#CD010631-bbs2-0010" title="WangQ , LiL , WangT . A comparative study of olanzapine in treatment of schizophrenia. Journal of Psychiatry2008;21:373‐5. ">vs OLZ ‐ Wang 2008</a>; <a href="./references#CD010631-bbs2-0011" title="WuY , LuWH , YiZH , WangJ , SongBF , ShiDQ , et al. Controlled study of olanzapine versus chlorpromazine for the quality of life of patients with schizophrenia. Sichuan Mental Health Journal2008;21(1):8‐11. ">vs OLZ ‐ Wu 2008</a>; <a href="./references#CD010631-bbs2-0012" title="ZhaoZ , YanF , FengY . A comparative study on olanzapine and chlorpromazine in the treatment of schizophrenia. China Journal of Health Psychology2006;14:41‐2. ">vs OLZ ‐ Zhao 2006</a>). Diagnostic criteria were unclear in the remaining studies, with participants described either as having 'schizophrenia' (<a href="./references#CD010631-bbs2-0004" title="ChangFW , WangCH , ZhaoZ . Clinical effects of olanzapine vs chlorpromazine in treating positive symptoms of schizophrenia. Chinese Journal of New Drugs and Clinical Remedies2003;22(6):357‐9. ">vs OLZ ‐ Chang 2003</a>; <a href="./references#CD010631-bbs2-0005" title="ChenF . Olanzapine and chlorpromazine in the treatment of schizophrenia. Journal of Clinical Psychiatric Medicine2006;16:303‐4. ">vs OLZ ‐ Chen 2006</a>; <a href="./references#CD010631-bbs2-0006" title="HeJ , AnQ . A comparative trial of olanzapine versus chlorpromazine in the treatment of schizophrenia. Shandong Mental Health Archive2003;16:78‐80. ">vs OLZ ‐ He 2003</a>) or 'first‐episode schizophrenia (<a href="./references#CD010631-bbs2-0008" title="LuoC , YangJW , RenJP . Comparative study of the effect of olanzapine on serum lipid in schizophrenia. Journal of Clinical Psychiatric Medicine2007;17:401‐2. ">vs OLZ ‐ Luo 2007</a>; <a href="./references#CD010631-bbs2-0009" title="WangCH , ZhaoZ , LiY , PanM , LiuX . Evaluation of proximal therapeutic effect and distal social function restoration of olanzapine on schizophrenia patients. Zhongguo lin chuang kang fu [Chinese Journal of Clinical Rehabilitation]2002;6(17):2664‐5. ">vs OLZ ‐ Wang 2002</a>). </p> </section> <section id="CD010631-sec-0115"> <h6 class="title">4. Setting</h6> <p>Nine of the included studies were undertaken in China, and included both inpatient and outpatient settings. Other studies were completed in Turkey (<a href="./references#CD010631-bbs2-0001" title="DossenbachM . Sleep quality and early morning wakefulness of schizophrenic patients treated with olanzapine compared to chlorpromazine. European Neuropsychopharmacology2000;10(Supplement 3):S328‐9. EliLilly , Company . Study F1D‐VI‐HGCQ olanzapine versus chlorpromazine in Turkey. Unpublished document internal to Eli‐Lilly2000:1‐560. KostakogluE , AlptekinK , KivicikBB , MartenyiF , TuncaZ , GogusA , et al. Sleep quality and early morning wakefulness of schizophrenia patients treated with olanzapine compared to chlorpromazine [Errata]. European Neuropsychopharmacology2001;11(Suppl 3):S369. MrazK , GogusA , TuncaZ , MartenyiF , DossenbachM . Olanzapine versus chlorpromazine in Turkey. Schizophrenia Research (Abstracts of the Winter Workshop on Schizophrenia; February 5‐11, 2000; Davos, Switzerland). 2000. ">HGCQ (Turkey) 2000</a>), Morocco (<a href="./references#CD010631-bbs2-0002" title="EliLilly , Company . Study HGDV olanzapine (versus chlorpromazine in Morocco). Unpublished document internal to Eli‐Lilly and Company2001:1‐512. HGDV/Morocco . Data supplied to the Cochrane Schizophrenia Group. Data on file1999. ">HGDV (Morocco) 1999</a>) and Egypt (<a href="./references#CD010631-bbs2-0007" title="EliLilly , Company . HGDT olanzapine versus chlorpromazine in Egypt. Unpublished document internal to Eli Lilly and Company2001:1‐513. LozaN , El‐DosokyAM , OkashaTA , KhalilAH , HasanNM , DossenbachM , et al. Olanzapine compared to chlorpromazine in acute schizophrenia. European Neuropsychopharmacology1999;9(Suppl 5):S291. ">vs OLZ ‐ Loza 1999 (HGDT)</a>). </p> </section> <section id="CD010631-sec-0116"> <h6 class="title">5. Study size</h6> <p>Study sizes ranged from 30 (<a href="./references#CD010631-bbs2-0001" title="DossenbachM . Sleep quality and early morning wakefulness of schizophrenic patients treated with olanzapine compared to chlorpromazine. European Neuropsychopharmacology2000;10(Supplement 3):S328‐9. EliLilly , Company . Study F1D‐VI‐HGCQ olanzapine versus chlorpromazine in Turkey. Unpublished document internal to Eli‐Lilly2000:1‐560. KostakogluE , AlptekinK , KivicikBB , MartenyiF , TuncaZ , GogusA , et al. Sleep quality and early morning wakefulness of schizophrenia patients treated with olanzapine compared to chlorpromazine [Errata]. European Neuropsychopharmacology2001;11(Suppl 3):S369. MrazK , GogusA , TuncaZ , MartenyiF , DossenbachM . Olanzapine versus chlorpromazine in Turkey. Schizophrenia Research (Abstracts of the Winter Workshop on Schizophrenia; February 5‐11, 2000; Davos, Switzerland). 2000. ">HGCQ (Turkey) 2000</a>) to 100 participants (<a href="./references#CD010631-bbs2-0011" title="WuY , LuWH , YiZH , WangJ , SongBF , ShiDQ , et al. Controlled study of olanzapine versus chlorpromazine for the quality of life of patients with schizophrenia. Sichuan Mental Health Journal2008;21(1):8‐11. ">vs OLZ ‐ Wu 2008</a>); and the mean sample size was 77 participants. </p> </section> <section id="CD010631-sec-0117"> <h6 class="title">6. Interventions</h6> <section id="CD010631-sec-0118"> <p><b>6.1 Chlorpromazine</b></p> <p>Chlorpromazine doses ranged from 25 to 600 mg/day (<a href="./references#CD010631-bbs2-0009" title="WangCH , ZhaoZ , LiY , PanM , LiuX . Evaluation of proximal therapeutic effect and distal social function restoration of olanzapine on schizophrenia patients. Zhongguo lin chuang kang fu [Chinese Journal of Clinical Rehabilitation]2002;6(17):2664‐5. ">vs OLZ ‐ Wang 2002</a>) to 200 to 800 mg/day (<a href="./references#CD010631-bbs2-0001" title="DossenbachM . Sleep quality and early morning wakefulness of schizophrenic patients treated with olanzapine compared to chlorpromazine. European Neuropsychopharmacology2000;10(Supplement 3):S328‐9. EliLilly , Company . Study F1D‐VI‐HGCQ olanzapine versus chlorpromazine in Turkey. Unpublished document internal to Eli‐Lilly2000:1‐560. KostakogluE , AlptekinK , KivicikBB , MartenyiF , TuncaZ , GogusA , et al. Sleep quality and early morning wakefulness of schizophrenia patients treated with olanzapine compared to chlorpromazine [Errata]. European Neuropsychopharmacology2001;11(Suppl 3):S369. MrazK , GogusA , TuncaZ , MartenyiF , DossenbachM . Olanzapine versus chlorpromazine in Turkey. Schizophrenia Research (Abstracts of the Winter Workshop on Schizophrenia; February 5‐11, 2000; Davos, Switzerland). 2000. ">HGCQ (Turkey) 2000</a>; <a href="./references#CD010631-bbs2-0002" title="EliLilly , Company . Study HGDV olanzapine (versus chlorpromazine in Morocco). Unpublished document internal to Eli‐Lilly and Company2001:1‐512. HGDV/Morocco . Data supplied to the Cochrane Schizophrenia Group. Data on file1999. ">HGDV (Morocco) 1999</a>; <a href="./references#CD010631-bbs2-0005" title="ChenF . Olanzapine and chlorpromazine in the treatment of schizophrenia. Journal of Clinical Psychiatric Medicine2006;16:303‐4. ">vs OLZ ‐ Chen 2006</a>; <a href="./references#CD010631-bbs2-0007" title="EliLilly , Company . HGDT olanzapine versus chlorpromazine in Egypt. Unpublished document internal to Eli Lilly and Company2001:1‐513. LozaN , El‐DosokyAM , OkashaTA , KhalilAH , HasanNM , DossenbachM , et al. Olanzapine compared to chlorpromazine in acute schizophrenia. European Neuropsychopharmacology1999;9(Suppl 5):S291. ">vs OLZ ‐ Loza 1999 (HGDT)</a>). Doses tended to be fairy consistent between studies. </p> </section> <section id="CD010631-sec-0119"> <p><b>6.2 Olanzapine</b></p> <p>Olanzapine doses between studies were largely uniform, with a range in 10 of the included studies of 5 mg/day to 20 mg/day, and in <a href="./references#CD010631-bbs2-0008" title="LuoC , YangJW , RenJP . Comparative study of the effect of olanzapine on serum lipid in schizophrenia. Journal of Clinical Psychiatric Medicine2007;17:401‐2. ">vs OLZ ‐ Luo 2007</a> the range was 5 mg/day to 25 mg/day, with <a href="./references#CD010631-bbs2-0010" title="WangQ , LiL , WangT . A comparative study of olanzapine in treatment of schizophrenia. Journal of Psychiatry2008;21:373‐5. ">vs OLZ ‐ Wang 2008</a> using a range of 5 mg/day to 15 mg/day. </p> </section> </section> <section id="CD010631-sec-0120"> <h6 class="title">7. Outcomes</h6> <section id="CD010631-sec-0121"> <p><b>7.1 General remarks</b></p> <p>The included studies for this comparison provided generally well‐reported outcomes, including clinical response, global state outcomes, relapse rates and adverse events. Death was not reported in any of the included studies for any reason. </p> </section> <section id="CD010631-sec-0122"> <p><b>7.2 Acceptability and efficacy</b></p> <p>Each included study provided data regarding mental and global state outcomes (widely accepted rating scales, including the BPRS, PANSS and CGI). However, some of these data were skewed and were presented in an additional table. </p> </section> <section id="CD010631-sec-0123"> <p><b>7.3 Adverse events</b></p> <p>Adverse events, including extrapyramidal averse effects, anticholinergic effect, cardiovascular effects, gastrointestinal effects and 'others' were generally well‐reported in the included studies. </p> </section> <section id="CD010631-sec-0124"> <p><b>7.4 Outcome scales</b></p> </section> <section id="CD010631-sec-0125"> <p><b>7.4.1 Global state</b></p> <p><i>i) Clinical Global Impression (CGI)</i> </p> <p>This is a rating instrument that enables clinicians to quantify severity of illness and overall clinical improvement during therapy (<a href="./references#CD010631-bbs2-0143" title="GuyW . ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: National Institute of Mental Health. DHEW Publication NO (ADM), 1976:124‐585. ">Guy 1976</a>). A 7‐point scoring system is usually used, with low scores indicating decreased severity or greater recovery, or both. </p> </section> <section id="CD010631-sec-0126"> <p><b>7.4.2 Mental state</b></p> <p><i>i) Brief Psychiatric Rating Scale (BPRS)</i> </p> <p>This scale is used to assess the severity of abnormal mental states (<a href="./references#CD010631-bbs2-0174" title="OverallJE , GorhamDR . The brief psychiatric rating scale. Psychological Reports1962;10:799‐812. ">Overall 1962</a>). The original scale has 16 items, but a revised 18‐item scale is commonly used. Each item is defined on a seven‐point scale varying from 'not present' to 'extremely severe', scoring from zero to six or one to seven. Scores can range from 0 to 108 or 18 to 126, respectively. High scores indicate more severe symptoms. The BPRS‐positive cluster comprises four items, which are conceptual disorganisation, suspiciousness, hallucinatory behaviour and unusual thought content. The BPRS‐negative cluster comprises only three items, which are emotional withdrawal, motor retardation and blunted affect. </p> <p><i>ii) Hamilton Anxiety Scale (HAMA)</i> </p> <p>HAMA is a rating scale developed to quantify the severity of anxiety symptomatology and consists of 14 items, each defined by a series of symptoms (<a href="./references#CD010631-bbs2-0165" title="MaierW , BullerR , PhilippM , HeuserI . The Hamilton Anxiety Scale: reliability, validity and sensitivity to change in anxiety and depressive disorders. Journal of Affective Disorders1988;14(1):61‐8. [DOI: 10.1016/0165‐0327(88)90072‐9] ">Maier 1988</a>). Each item is rated on a 5‐point scale, ranging from zero (not present) to four (severe). </p> <p><i>iii) Montgomery–Åsberg Depression Rating Scale (MADRS)</i> </p> <p>The MADRS is a 10‐ item clinician‐administered diagnostic questionnaire used to measure the severity of depressive episodes (<a href="./references#CD010631-bbs2-0171" title="MontgomerySA , AsbergM . A new depression scale designed to be sensitive to change. British Journal of Psychiatry1979;134:382‐9. ">Montgomery 1979</a>). There are 10 items (including apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts and suicidal thoughts), each rated zero (absent) to six (severe). Overall scores range from zero to 60. </p> <p><i>iv) Nurses' Observation Scale for Inpatient Evaluation (NOSIE)</i> </p> <p>This scale assesses the behaviour of patients on an inpatient unit (<a href="./references#CD010631-bbs2-0149" title="HonigfeldG , KlettCJ . The nurses' observation scale for inpatient evaluation: a new scale for measuring improvement in chronic schizophrenia. Journal of Clinical Psychology1965;21:65‐71. ">Honigfeld 1965</a>). The scale has 30 items, each rated from zero (not present) to four (markedly present), and includes such behaviours as 'gets angry or annoyed easily', 'cries' or 'is impatient'. </p> <p><i>iv) Positive and Negative Syndrome Scale (PANSS)</i> </p> <p>The PANSS was originated as a method for evaluating positive, negative and other symptom dimensions in schizophrenia (<a href="./references#CD010631-bbs2-0155" title="KaySR , FiszbeinA , OplerLA . The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin1987;13(2):261‐76. ">Kay 1987</a>). The scale has 30 items, and each item can be rated on a 7‐point scoring system varying from one (absent) to seven (extreme). This scale can be divided into three subscales for measuring the severity of general psychopathology, positive symptoms (PANSS‐P) and negative symptoms (PANSS‐N). A low score indicates low levels of symptoms. </p> <p><i>v) Scale for Assessment of Positive Symptoms (SAPS)</i> </p> <p>This scale measures the positive symptoms of schizophrenia and is split into four items including hallucinations, delusions, bizarre behaviour and positive formal thought disorder, each rated on a scale of zero (absent) to five (severe) (<a href="./references#CD010631-bbs2-0120" title="AndreasenNC . Scale for the Assessment of Positive Symptoms (SANS). Iowa City: University of Iowa, 1984. ">Andreasen 1984</a>). </p> <p><i>7.4.3 Functioning</i> </p> <p><i>i) Wisconsin Card Sorting Test</i> (<i>WCST‐IQ/MQ)</i> </p> <p>The WCST is a neuropsychological test in which participants are expected to organise a set of specifically‐designed cards, without instruction (<a href="./references#CD010631-bbs2-0170" title="MonchiO , PetridesM , PetreV , WorsleyK , DagherA . Wisconsin Card Sorting revisited: distinct neural circuits participating in different stages of the task identified by event‐related functional magnetic resonance imaging. The Journal of Neuroscience2001;21(19):7733‐41. ">Monchi 2001</a>). The test is a measure of executive functioning, assessing primarily strategic planning, organized searching, utilizing environmental feedback to shift cognitive sets, directing behavior toward achieving a goal, and modulating impulsive responding. </p> </section> <section id="CD010631-sec-0127"> <p><b>7.4.4 Adverse events</b></p> <p><i>i) Extrapyramidal Symptom Rating Scale (ESRS)</i> </p> <p>The ESRS is a physical examination with 12 items that include both subjective and objective assessments (<a href="./references#CD010631-bbs2-0129" title="ChouinardG , Ross‐ChouinardA , AnnableL , JonesB . Extrapyramidal Symptom Rating Scale (abstract). Canadian Journal of Neurogical Sciences1980;7:233. ">Chouinard 1980</a>). </p> <p><i>iii) Leeds Sleep Evaluation Questionnaire (LSEQ)</i> </p> <p>The LSEQ is a 10‐item, self‐rating measurement designed to assess changes in sleep quality over the course of psychopharmacological treatment (<a href="./references#CD010631-bbs2-0175" title="ParrottAC , HindmarchI . The Leeds Sleep Evaluation Questionnaire in psychopharmacological Investigations ‐ a review. Psychopharmacology1980;71(2):173‐9. ">Parrott 1980</a>). Four domains are rated, including 'ease of initiating sleep', 'quality of sleep', 'ease of waking' and 'behaviour following wakefulness'. </p> </section> <section id="CD010631-sec-0128"> <p><b>7.4.5 Quality of life</b></p> <p><i>i) Gothenburg Quality of Life Instrument (GQOLI/ GQOL1 ‐ 74)</i> </p> <p>This scale assesses overall sleep quality; participants respond on a 7‐point Linkert‐type scale with one (excellent) and seven (very poor) (<a href="./references#CD010631-bbs2-0183" title="SullivanM , KarlssonJ , BengtssonC , FurunesB , LapidusL , LissnerL . The Göteborg Quality of Life Instrument – a psychometric evaluation of assessments of symptoms and well‐being among the women in a general population. Scandinavian Journal of Primary Health Care1993;11(4):267‐75. ">Sullivan 1993</a>). Participants also rate other aspects of quality of life, including a self‐evaluation of their economic situation, social and friendship situation and home/family situation. </p> <p><i>ii) Quality of life scale (QoL)</i> </p> <p>The QoL scale is a 16‐item instrument that measures six conceptual domains of quality of life: material and physical well‐being, relationships with other people, social, community and civic activities, personal development and fulfilment, recreation and independence (<a href="./references#CD010631-bbs2-0140" title="FlanaganJC . Measurement of the quality of life: Current state of the art. Archives of Physical Medicine and Rehabilitation1982;63(2):56‐9. ">Flanagan 1982</a>). Scores range from 16 to 112, with a higher score indicating a better outcome. </p> </section> <section id="CD010631-sec-0129"> <p><b>7.5 Missing outcomes</b></p> <p>Studies did not provide vast amounts of data, nor even measured in many instances, outcomes including service involvement, functioning, behaviour, satisfaction with treatment, or economic outcomes. </p> </section> </section> </section> <section id="CD010631-sec-0130"> <h5 class="title">2. Chlorpromazine versus risperidone</h5> <p>For this comparison, we included 14 studies, with a total of 991 participants (chlorpromazine N = 474; risperidone N = 517). </p> <section id="CD010631-sec-0131"> <h6 class="title">1. Trial length</h6> <p>Duration of included studies ranged from three weeks (<a href="./references#CD010631-bbs2-0064" title="LiuGR , ZhangYH . Risperidone and chlorpromazine on schizophrenia blood pressure, heart rate. Occupation and Health2005;21:443‐5. ">vs RPD ‐ Liu 2005</a>) to five months (<a href="./references#CD010631-bbs2-0058" title="ChangSL , WangGH . Clinical observation of risperidone and chlorpromazine in the treatment of schizophrenia. Anhui Medical and Pharmaceutical Journal1998; Vol. 2:25‐6. ">vs RPD ‐ Chang 1998</a>). The average length of studies was around eight weeks, therefore all included studies provided only short term data. </p> </section> <section id="CD010631-sec-0132"> <h6 class="title">2. Design</h6> <p>All included studies were parallel‐arm RCTs. No included study adequately described randomisation methods. </p> </section> <section id="CD010631-sec-0133"> <h6 class="title">3. Participants</h6> <p>All participants were diagnosed with schizophrenia according to Chinese Classification of Mental Disorders (CCMD) criteria (<a href="./references#CD010631-bbs2-0128" title="ChenYF . Chinese classification of mental disorders (CCMD‐3): towards integration in international classification. Psychopathology2002;35(2‐3):171‐5. ">Chen 2002</a>). </p> </section> <section id="CD010631-sec-0134"> <h6 class="title">4. Setting</h6> <p>All included studies were undertaken in China with inpatient and outpatient settings both represented. </p> </section> <section id="CD010631-sec-0135"> <h6 class="title">5. Study size</h6> <p>Sample sizes between studies ranged from 32 (<a href="./references#CD010631-bbs2-0063" title="LiuY , HuangX , XieL . A comparative study of risperidone and chlorpromazine in the treatment of the negative symptoms of schizophrenia. Journal of Medicine and Pharmacy2000;19:323‐4. ">vs RPD ‐ Liu 2000</a>) to 107 participants (<a href="./references#CD010631-bbs2-0065" title="LuoX , JiangK , GuN , YangX , ZhuS . Comparison of effects and factors between risperidone and chlorpromazine on schizophrenia. Chinese Journal of New Drugs and Clinical Remedies2001;20:264‐6. ">vs RPD ‐ Luo 2001</a>), with a mean sample size of 70 participants. </p> </section> <section id="CD010631-sec-0136"> <h6 class="title">6. Interventions</h6> <section id="CD010631-sec-0137"> <p><b>6.1 Chlorpromazine</b></p> <p>All studies used different dosage ranges, and included 25 to 450 mg/day (<a href="./references#CD010631-bbs2-0068" title="WangX , HuX , YangJ . Effect of chlorpromazine and risperidone on cognitive function of the patients with first episode schizophrenia. Chinese Journal of Health Psychology2005;13:342‐4. ">vs RPD ‐ Wang 2005</a>); 100 to 450 mg/day (<a href="./references#CD010631-bbs2-0062" title="LinWX . Risperidone and chlorpromazine in the treatment of clinical controlled study of 70 patients with schizophrenia. Modern Chinese Practical Medicine Journal2005;4:27‐8. ">vs RPD ‐ Lin 2005</a>); 300/400 to 600 mg/day (<a href="./references#CD010631-bbs2-0069" title="WuS , XingG . A comparative trial on the efficacy of risperidone vs chlorpromazine in chronic schizophrenia. Health Psychology Journal2002;10:364‐5. ">vs RPD ‐ Wu 2002</a>; <a href="./references#CD010631-bbs2-0070" title="WuY , LuW , YiZ . A comparative study of risperidone and chlorpromazine on quality of life in patients with schizophrenia. Shandong Archive of Psychiatry2004;17:137‐40. ">vs RPD ‐ Wu 2004</a>); and 100 to 700 mg/day (<a href="./references#CD010631-bbs2-0065" title="LuoX , JiangK , GuN , YangX , ZhuS . Comparison of effects and factors between risperidone and chlorpromazine on schizophrenia. Chinese Journal of New Drugs and Clinical Remedies2001;20:264‐6. ">vs RPD ‐ Luo 2001</a>). Not all studies reported mean doses, with only <a href="./references#CD010631-bbs2-0059" title="CuiL . Risperidone and chlorpromazine in the treatment of schizophrenia, double‐blind, controlled study, and serum prolactin efficacy. Hebei Archive of Psychiatry2001;14:205‐8. ">vs RPD ‐ Cui 2001</a> and <a href="./references#CD010631-bbs2-0060" title="FengYX , SunF . A comparative study on the effects of risperidone and chlorpromazine upon the life quality of patients with schizophrenia. Health Psychology Journal2003;11:117‐8. ">vs RPD ‐ Feng 2003</a> using a mean dose of 426 mg/day and 355 mg/day respectively. </p> </section> <section id="CD010631-sec-0138"> <p><b>6.2 Risperidone</b></p> <p>Risperidone doses also varied between studies, with the highest range of 1 mg/day to 9 mg/day used in <a href="./references#CD010631-bbs2-0066" title="MaZ H , LiuA Y , ZhouC M , ZhangZ . A comparative study of risperidone and chlorpromazine in the treatment of schizophrenia. Medical Journal of Chinese People Health2004;16:202‐4. ">vs RPD ‐ Ma 2004</a>; most included studies used a range of risperidone up to 6 mg/day (<a href="./references#CD010631-bbs2-0058" title="ChangSL , WangGH . Clinical observation of risperidone and chlorpromazine in the treatment of schizophrenia. Anhui Medical and Pharmaceutical Journal1998; Vol. 2:25‐6. ">vs RPD ‐ Chang 1998</a>; <a href="./references#CD010631-bbs2-0061" title="HeM , FengY , ChenR . A controlled comparative study on risperidone and chlorpromazine in treatment of schizophrenia. Chinese New Drugs Journal1999;8:185‐7. ">vs RPD ‐ He 1999</a>; <a href="./references#CD010631-bbs2-0068" title="WangX , HuX , YangJ . Effect of chlorpromazine and risperidone on cognitive function of the patients with first episode schizophrenia. Chinese Journal of Health Psychology2005;13:342‐4. ">vs RPD ‐ Wang 2005</a>; <a href="./references#CD010631-bbs2-0069" title="WuS , XingG . A comparative trial on the efficacy of risperidone vs chlorpromazine in chronic schizophrenia. Health Psychology Journal2002;10:364‐5. ">vs RPD ‐ Wu 2002</a>; <a href="./references#CD010631-bbs2-0070" title="WuY , LuW , YiZ . A comparative study of risperidone and chlorpromazine on quality of life in patients with schizophrenia. Shandong Archive of Psychiatry2004;17:137‐40. ">vs RPD ‐ Wu 2004</a>; <a href="./references#CD010631-bbs2-0071" title="ZhengZS , HuangJM , YuXY . Efficacy of risperidone and chlorpromazine in the treatment of schizophrenia. Chinese Hospital Pharmacy Journal2001;21:99‐100. ">vs RPD ‐ Zheng 2001</a>). Again, only two studies described the mean doses used in the studies (<a href="./references#CD010631-bbs2-0059" title="CuiL . Risperidone and chlorpromazine in the treatment of schizophrenia, double‐blind, controlled study, and serum prolactin efficacy. Hebei Archive of Psychiatry2001;14:205‐8. ">vs RPD ‐ Cui 2001</a>; <a href="./references#CD010631-bbs2-0060" title="FengYX , SunF . A comparative study on the effects of risperidone and chlorpromazine upon the life quality of patients with schizophrenia. Health Psychology Journal2003;11:117‐8. ">vs RPD ‐ Feng 2003</a>) of 4.19 mg/day and 3.62 mg/day respectively. </p> </section> </section> <section id="CD010631-sec-0139"> <h6 class="title">7. Outcomes</h6> <section id="CD010631-sec-0140"> <p><b>7.1 General remarks</b></p> <p>The included studies for this comparison provided generally well‐reported outcomes, including clinical response, global state outcomes and adverse events. Death was not reported in any of the included studies for any reason. </p> </section> <section id="CD010631-sec-0141"> <p><b>7.2 Acceptability and efficacy</b></p> <p>Data regarding mental and global state outcomes were measured using widely accepted rating scales, including the BPRS, PANSS and CGI. However some of these data were skewed and were presented in an additional table. </p> </section> <section id="CD010631-sec-0142"> <p><b>7.3 Adverse events</b></p> <p>Adverse events, including extrapyramidal averse effects, anticholinergic effect, cardiovascular effects, gastrointestinal effects and 'others' were generally well reported in the included studies. </p> </section> <section id="CD010631-sec-0143"> <p><b>7.4 Outcome scales presenting useable data</b></p> </section> <section id="CD010631-sec-0144"> <p><b>7.4.1 Global state</b></p> <p><i>i) Clinical Global Impression (CGI)</i> </p> <p>This is a rating instrument that enables clinicians to quantify severity of illness and overall clinical improvement during therapy (<a href="./references#CD010631-bbs2-0143" title="GuyW . ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: National Institute of Mental Health. DHEW Publication NO (ADM), 1976:124‐585. ">Guy 1976</a>). A 7‐point scoring system is usually used with low scores indicating decreased severity or greater recovery, or both. </p> </section> <section id="CD010631-sec-0145"> <p><b>7.4.2 Mental state</b></p> <p><i>i) Brief Psychiatric Rating Scale (BPRS)</i> </p> <p>This scale is used to assess the severity of abnormal mental states (<a href="./references#CD010631-bbs2-0174" title="OverallJE , GorhamDR . The brief psychiatric rating scale. Psychological Reports1962;10:799‐812. ">Overall 1962</a>). The original scale has 16 items, but a revised 18‐item scale is commonly used. Each item is defined on a 7‐point scale varying from 'not present' to 'extremely severe', scoring from zero to six or one to seven. Scores can range from zero to 108 or 18 to 126, respectively. High scores indicate more severe symptoms. The BPRS‐positive cluster comprises four items, which are conceptual disorganisation, suspiciousness, hallucinatory behaviour and unusual thought content. The BPRS‐negative cluster comprises only three items, which are emotional withdrawal, motor retardation and blunted affect. </p> <p><i>ii) Positive and Negative Syndrome Scale (PANSS)</i> </p> <p>The PANSS was originated as a method for evaluating positive, negative and other symptom dimensions in schizophrenia (<a href="./references#CD010631-bbs2-0155" title="KaySR , FiszbeinA , OplerLA . The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin1987;13(2):261‐76. ">Kay 1987</a>). The scale has 30 items, and each item can be rated on a 7‐point scoring system varying from one (absent) to seven (extreme). This scale can be divided into three subscales for measuring the severity of general psychopathology, positive symptoms (PANSS‐P) and negative symptoms (PANSS‐N). A low score indicates low levels of symptoms. </p> <p><i>iii) Scale for Assessment of Negative Symptoms (SANS)</i> </p> <p>The SANS measures the incidence and severity of negative symptoms using a 25‐item scale, using a six‐point scoring system, of zero ( = better) to five ( = worse), where a higher score equals a more severe experience of negative symptoms (<a href="./references#CD010631-bbs2-0119" title="AndreasenNC . Negative symptoms in schizophrenia. Definition and reliability. Archives of General Psychiatry1982;39(7):784‐8. ">Andreasen 1982</a>). </p> <p><i>iv) Scale for Assessment of Positive Symptoms (SAPS)</i> </p> <p>This scale measures the positive symptoms of schizophrenia and is split into four items including hallucinations, delusions, bizarre behaviour and positive formal thought disorder, each rated on a scale of zero (absent) to five (severe) (<a href="./references#CD010631-bbs2-0120" title="AndreasenNC . Scale for the Assessment of Positive Symptoms (SANS). Iowa City: University of Iowa, 1984. ">Andreasen 1984</a>). </p> </section> <section id="CD010631-sec-0146"> <p><b>7.4.3 Functioning</b></p> <p><i>i) Wisconsin Card Sorting Test (WCST‐IQ/MQ)</i> </p> <p>The WCST is a neuropsychological test in which participants are expected to organise a set of specifically‐designed cards, without instruction (<a href="./references#CD010631-bbs2-0170" title="MonchiO , PetridesM , PetreV , WorsleyK , DagherA . Wisconsin Card Sorting revisited: distinct neural circuits participating in different stages of the task identified by event‐related functional magnetic resonance imaging. The Journal of Neuroscience2001;21(19):7733‐41. ">Monchi 2001</a>). The test is a measure of executive functioning, assessing primarily strategic planning, organized searching, utilizing environmental feedback to shift cognitive sets, directing behavior toward achieving a goal, and modulating impulsive responding. </p> </section> <section id="CD010631-sec-0147"> <p><b>7.4.4 Adverse events</b></p> <p><i>i) Treatment‐Emergent Signs and Symptoms (TESS)</i> </p> <p>The <a href="./references#CD010631-bbs2-0152" title="ICH Expert Working Group. ICH harmonised tripartite guideline: structure and content of clinical study reports. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use 30 November 1995. ">ICH E3 1995</a> guideline has stated that 'treatment‐emergent signs and symptoms' (TESS) are to be defined as "events not seen at baseline and events that worsened even if present at baseline". It can be difficult to document this accurately taking into account variables in time, dosage, adverse events and severity. Generally, TESS scores for particular adverse events are categorised as 'mild', 'moderate' or 'severe', with an appropriate action taken (e.g. none, discontinued, dose changed', hospitalisation and additional medication given). It is not often that studies publish continuous data from these measurements, with the more common presentation of dichotomised TESS ratings. </p> </section> <section id="CD010631-sec-0148"> <p><b>7.4.5 Quality of life</b></p> <p><i>i) Quality of life scale (QoL)</i> </p> <p>The QoL scale is a 16‐item instrument that measures six conceptual domains of quality of life: material and physical well‐being; relationships with other people; social, community and civic activities; personal development and fulfilment; recreation and independence (<a href="./references#CD010631-bbs2-0140" title="FlanaganJC . Measurement of the quality of life: Current state of the art. Archives of Physical Medicine and Rehabilitation1982;63(2):56‐9. ">Flanagan 1982</a>). Scores range from 16 to 112, with a higher score indicating a better outcome. </p> </section> <section id="CD010631-sec-0149"> <p><b>7.5 Missing outcomes</b></p> <p>Studies did not report any data for relapse rates, service use, behaviour, satisfaction with care or treatment, or economic outcomes. </p> </section> </section> </section> <section id="CD010631-sec-0150"> <h5 class="title">3. Chlorpromazine versus quetiapine</h5> <p>For this comparison, we included 45 studies with a total of 4388 participants (chlorpromazine N = 2183; quetiapine N = 2205). </p> <section id="CD010631-sec-0151"> <h6 class="title">1. Trial length</h6> <p>Thirty‐seven of the 45 studies were under eight weeks in length. The shortest study was 42 days in length (<a href="./references#CD010631-bbs2-0042" title="PengZG , ZhouJX , KuangWH , LiJ , HuangMS . A randomized double ‐ blind controlled study on the efficacy of quetiapine and chlorpromazine in treatment of schizophrenia. West China Journal of Pharmaceutical Sciences2006;21(6):606‐8. ">vs QTP ‐ Peng 2006</a>). The longest study was six months long (<a href="./references#CD010631-bbs2-0036" title="LiM , HuF , WangS . A study of quetiapine and chlorpromazine on the effects and quality of life in the treatment of schizophrenia. Shandong Archives of Psychiatry2003;16(3):135‐7. ">vs QTP ‐ Li 2003</a>) and was the only study to provide data at the medium term. All other outcomes were reported at short term (&lt; six months). </p> </section> <section id="CD010631-sec-0152"> <h6 class="title">2. Design</h6> <p>All included studies were parallel‐arm RCTs. No included study adequately described randomisation methods. </p> </section> <section id="CD010631-sec-0153"> <h6 class="title">3. Participants</h6> <p>All participants had a diagnosis of schizophrenia, with diagnosis using the Chinese Classification of Mental Disorders (CCMD) employed in 42 included studies. Two studies used DSM criteria to diagnose schizophrenia (<a href="./references#CD010631-bbs2-0030" title="HuJM , LiYi , LiTao , WangHM , LiuXH , HuoKJ . The effects of antipsychotics on serum prolactin in the first‐episode schizophrenia patients. West China Journal of Pharmaceutical Sciences2003;18(6):467‐9. ">vs QTP ‐ Hu 2003</a>; <a href="./references#CD010631-bbs2-0043" title="PeuskensJ , LinkCGG . A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatrica Scandinavica1997;96(4):265‐73. ">vs QTP ‐ Peuskens 1997</a>), and one study used a combination of CCMD and ICD‐10 criteria (<a href="./references#CD010631-bbs2-0056" title="ZhouSB , SunXD , LiYM . A comparative study on quetiapine and chlorpromazine in the treatment of schizophrenia. Medical Journal of Chinese People's Health2004;16(11):657‐9. ">vs QTP ‐ Zhou 2004</a>). </p> </section> <section id="CD010631-sec-0154"> <h6 class="title">4. Setting</h6> <p>All included studies were undertaken in China with both inpatient and outpatient settings represented. </p> </section> <section id="CD010631-sec-0155"> <h6 class="title">5. Study size</h6> <p>Sample sizes between studies ranged from 30 (<a href="./references#CD010631-bbs2-0035" title="KongDL , ZhangSQ , ShuMQ . Effects of quetiapine and chlorpromazine on serum prolactin of schizophrenics. Journal of Clinical Psychosomatic Diseases2003;9(4):200‐1. ">vs QTP ‐ Kong 2003</a>) to 237 participants (<a href="./references#CD010631-bbs2-0052" title="ZhangHY , WangX , LiuC , ShuL , LiH , GuN , et al. A comparison study on efficacy and safety of quetiapine and chlorpromazine in the treatment of schizophrenia. Chinese Journal of Clinical Pharmacology2003;19(3):163‐6. ">vs QTP ‐ Zhang 2003</a>). </p> </section> <section id="CD010631-sec-0156"> <h6 class="title">6. Interventions</h6> <section id="CD010631-sec-0157"> <p><b>6.1 Chlorpromazine</b></p> <p>The most common dose range between groups was between 300 to 600 mg/day. Only one study stated dosages used were 'less than 1000 mg/day' (<a href="./references#CD010631-bbs2-0028" title="GuoZ , LiuJ , YangJ . Efficacy quetiapine in the treatment of schizophrenic patients and effect on the quality of life. Chinese Journal of Health Psychology2008;16(5):544‐6. ">vs QTP ‐ Guo 2008</a>), with other maximum doses stated as 750 mg/day (<a href="./references#CD010631-bbs2-0043" title="PeuskensJ , LinkCGG . A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatrica Scandinavica1997;96(4):265‐73. ">vs QTP ‐ Peuskens 1997</a>). </p> </section> <section id="CD010631-sec-0158"> <p><b>6.2 Quetiapine</b></p> <p>Quetiapine doses were mostly between 300 and 700 mg/day. One study did not state the dosages used in either group (<a href="./references#CD010631-bbs2-0055" title="ZhouJ , LiJ , KuangW . Comparison between quetiapine and chlorpromazine in cognitive function of schizophrenic patients. Chinese Mental Health Journal2003;17(10):699‐701. ">vs QTP ‐ Zhou 2003</a>). </p> </section> </section> <section id="CD010631-sec-0159"> <h6 class="title">7. Outcomes</h6> <section id="CD010631-sec-0160"> <p><b>7.1 General remarks</b></p> <p>The included studies for this comparison generally provided well‐reported outcomes, including clinical response, global state outcomes and adverse events. Death was not reported in any of the included studies for any reason. Most outcomes were reported using measurement scales, although we ensured they had been peer‐reviewed as the lack of dichotomous outcomes makes valuable interpretation of these results difficult. </p> </section> <section id="CD010631-sec-0161"> <p><b>7.2 Acceptability and efficacy</b></p> <p>Data regarding mental and global state outcomes were reported using widely accepted rating scales, including the BPRS, PANSS and CGI. However some of these data were skewed and were presented in an additional table. </p> </section> <section id="CD010631-sec-0162"> <p><b>7.3 Adverse events</b></p> <p>Adverse events, including extrapyramidal averse effects, anticholinergic effect, cardiovascular effects, gastrointestinal effects and 'others' were generally well reported in the included studies. </p> </section> <section id="CD010631-sec-0163"> <p><b>7.4 Outcome scales</b></p> </section> <section id="CD010631-sec-0164"> <p><b>7.4.1 Global state</b></p> <p><i>i) Clinical Global Impression (CGI)</i> </p> <p>This is a rating instrument that enables clinicians to quantify severity of illness and overall clinical improvement during therapy (<a href="./references#CD010631-bbs2-0143" title="GuyW . ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: National Institute of Mental Health. DHEW Publication NO (ADM), 1976:124‐585. ">Guy 1976</a>). A 7‐point scoring system is usually used with low scores indicating decreased severity or greater recovery, or both. </p> </section> <section id="CD010631-sec-0165"> <p><b>7.4.2 Mental state</b></p> <p><i>i) Brief Psychiatric Rating Scale (BPRS)</i> </p> <p>This scale is used to assess the severity of abnormal mental states (<a href="./references#CD010631-bbs2-0174" title="OverallJE , GorhamDR . The brief psychiatric rating scale. Psychological Reports1962;10:799‐812. ">Overall 1962</a>). The original scale has 16 items, but a revised 18‐item scale is commonly used. Each item is defined on a 7‐point scale varying from 'not present' to 'extremely severe', scoring from zero to six or one to seven. Scores can range from zero to 108 or 18 to 126, respectively. High scores indicate more severe symptoms. The BPRS‐positive cluster comprises four items, which are conceptual disorganisation, suspiciousness, hallucinatory behaviour and unusual thought content. The BPRS‐negative cluster comprises only three items, which are emotional withdrawal, motor retardation and blunted affect. </p> <p><i>ii) Hamilton Rating Scale for Depression (HAMD)</i> </p> <p>The HAMD rates severity of depression in adults including items of mood, feelings of guilt, suicide ideation, insomnia, agitation or retardation, anxiety, weight loss and somatic symptoms (<a href="./references#CD010631-bbs2-0144" title="HamiltonM . A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry1960;23:56‐62. ">Hamilton 1960</a>). There are 20 items rated on a Linket‐type scale, where zero equals an absence of symptoms and a higher score indicates a worse outcome. </p> <p><i>iii) Positive and Negative Syndrome Scale (PANSS)</i> </p> <p>The PANSS was originated as a method for evaluating positive, negative and other symptom dimensions in schizophrenia (<a href="./references#CD010631-bbs2-0155" title="KaySR , FiszbeinA , OplerLA . The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin1987;13(2):261‐76. ">Kay 1987</a>). The scale has 30 items, and each item can be rated on a 7‐point scoring system varying from one (absent) to seven (extreme). This scale can be divided into three subscales for measuring the severity of general psychopathology, positive symptoms (PANSS‐P) and negative symptoms (PANSS‐N). A low score indicates low levels of symptoms. </p> </section> <section id="CD010631-sec-0166"> <p><b>7.4.3 Functioning</b></p> <p><i>i) Wisconsin Card Sorting Test</i> (<i>WCST‐IQ/MQ)</i> </p> <p>The WCST is a neuropsychological test in which participants are expected to organise a set of specifically‐designed cards, without instruction (<a href="./references#CD010631-bbs2-0170" title="MonchiO , PetridesM , PetreV , WorsleyK , DagherA . Wisconsin Card Sorting revisited: distinct neural circuits participating in different stages of the task identified by event‐related functional magnetic resonance imaging. The Journal of Neuroscience2001;21(19):7733‐41. ">Monchi 2001</a>). The test is a measure of executive functioning, assessing primarily strategic planning, organized searching, utilizing environmental feedback to shift cognitive sets, directing behaviour toward achieving a goal and modulating impulsive responding. </p> <p><i>ii) Wechsler Memory Scale‐revised</i> (<i>WMS‐RC)</i> </p> <p>The WMS‐RC is a neuropsychological test that is used to measure a person's memory functions (<a href="./references#CD010631-bbs2-0189" title="WechslerD , HoldnackJA , DrozdickLW . Wechsler Memory Scale – Fourth Edition (WMS‐IV). San Antonio: Pearson, 2009. ">WMS‐IV 2009</a>). The scale consists of seven subtests: spatial addition, symbol span, design memory, general cognitive screener, logical memory, verbal paired associates and visual reproduction. A high score indicates a better outcome. </p> </section> <section id="CD010631-sec-0167"> <p><b>7.4.4 Adverse events</b></p> <p><i>i) Treatment‐Emergent Signs and Symptoms (TESS)</i> </p> <p>The <a href="./references#CD010631-bbs2-0152" title="ICH Expert Working Group. ICH harmonised tripartite guideline: structure and content of clinical study reports. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use 30 November 1995. ">ICH E3 1995</a> guideline has stated that 'treatment‐emergent signs and symptoms' (TESS) are to be defined as "events not seen at baseline and events that worsened even if present at baseline". It can be difficult to document this accurately taking into account variables in time, dosage, adverse events and severity. Generally, TESS scores for particular adverse events are categorised as 'mild', 'moderate' or 'severe', with an appropriate action taken (e.g. none, discontinued, dose changed' hospitalisation, and additional medication given). It is not often that studies publish continuous data from these measurements, with the more common presentation of dichotomised TESS ratings. </p> </section> <section id="CD010631-sec-0168"> <p><b>7.4.5 Quality of life</b></p> <p><i>i) Gothenburg Quality of Life Instrument (GQOLI/ GQOL1‐74)</i> </p> <p>This scale assesses overall sleep quality; participants respond on a 7‐point Linkert‐type scale ranging from one('excellent') and seven ('very poor') (<a href="./references#CD010631-bbs2-0183" title="SullivanM , KarlssonJ , BengtssonC , FurunesB , LapidusL , LissnerL . The Göteborg Quality of Life Instrument – a psychometric evaluation of assessments of symptoms and well‐being among the women in a general population. Scandinavian Journal of Primary Health Care1993;11(4):267‐75. ">Sullivan 1993</a>). Participants also rate other aspects of quality of life, including a self‐evaluation of their economic situation, social and friendship situation and home/family situation. </p> </section> <section id="CD010631-sec-0169"> <p><b>7.5 Missing outcomes</b></p> </section> </section> </section> </section> <section id="CD010631-sec-0170"> <h4 class="title">Excluded studies</h4> <p>We excluded 42 studies; for details please consult the <a href="./references#CD010631-sec-0546" title="">Characteristics of excluded studies</a> section, </p> </section> </section> <section id="CD010631-sec-0171"> <h3 class="title">Risk of bias in included studies</h3> <p>For a graphical overview, please see <a href="#CD010631-fig-0002">Figure 2</a> and <a href="#CD010631-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD010631-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study." data-id="CD010631-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study. </p> </div> </div> </div> <div class="figure" id="CD010631-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies." data-id="CD010631-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD010631-sec-0172"> <h4 class="title">Allocation</h4> <section id="CD010631-sec-0173"> <h5 class="title">1. Chlorpromazine versus olanzapine</h5> <p>Only four included studies provided adequate information regarding randomisation, which included methods such as a computer‐generated randomisation and random number tables (<a href="./references#CD010631-bbs2-0001" title="DossenbachM . Sleep quality and early morning wakefulness of schizophrenic patients treated with olanzapine compared to chlorpromazine. European Neuropsychopharmacology2000;10(Supplement 3):S328‐9. EliLilly , Company . Study F1D‐VI‐HGCQ olanzapine versus chlorpromazine in Turkey. Unpublished document internal to Eli‐Lilly2000:1‐560. KostakogluE , AlptekinK , KivicikBB , MartenyiF , TuncaZ , GogusA , et al. Sleep quality and early morning wakefulness of schizophrenia patients treated with olanzapine compared to chlorpromazine [Errata]. European Neuropsychopharmacology2001;11(Suppl 3):S369. MrazK , GogusA , TuncaZ , MartenyiF , DossenbachM . Olanzapine versus chlorpromazine in Turkey. Schizophrenia Research (Abstracts of the Winter Workshop on Schizophrenia; February 5‐11, 2000; Davos, Switzerland). 2000. ">HGCQ (Turkey) 2000</a>; <a href="./references#CD010631-bbs2-0002" title="EliLilly , Company . Study HGDV olanzapine (versus chlorpromazine in Morocco). Unpublished document internal to Eli‐Lilly and Company2001:1‐512. HGDV/Morocco . Data supplied to the Cochrane Schizophrenia Group. Data on file1999. ">HGDV (Morocco) 1999</a>; <a href="./references#CD010631-bbs2-0004" title="ChangFW , WangCH , ZhaoZ . Clinical effects of olanzapine vs chlorpromazine in treating positive symptoms of schizophrenia. Chinese Journal of New Drugs and Clinical Remedies2003;22(6):357‐9. ">vs OLZ ‐ Chang 2003</a>; <a href="./references#CD010631-bbs2-0008" title="LuoC , YangJW , RenJP . Comparative study of the effect of olanzapine on serum lipid in schizophrenia. Journal of Clinical Psychiatric Medicine2007;17:401‐2. ">vs OLZ ‐ Luo 2007</a>). We judged each of these studies as at 'low' risk of bias. The remaining studies in this comparison were rated as at 'unclear' risk of bias, as 'randomisation' or 'random allocated' was stated, however no description was provided. However, three studies were rated as a 'high' risk of bias due to the lack of allocation concealment (<a href="./references#CD010631-bbs2-0001" title="DossenbachM . Sleep quality and early morning wakefulness of schizophrenic patients treated with olanzapine compared to chlorpromazine. European Neuropsychopharmacology2000;10(Supplement 3):S328‐9. EliLilly , Company . Study F1D‐VI‐HGCQ olanzapine versus chlorpromazine in Turkey. Unpublished document internal to Eli‐Lilly2000:1‐560. KostakogluE , AlptekinK , KivicikBB , MartenyiF , TuncaZ , GogusA , et al. Sleep quality and early morning wakefulness of schizophrenia patients treated with olanzapine compared to chlorpromazine [Errata]. European Neuropsychopharmacology2001;11(Suppl 3):S369. MrazK , GogusA , TuncaZ , MartenyiF , DossenbachM . Olanzapine versus chlorpromazine in Turkey. Schizophrenia Research (Abstracts of the Winter Workshop on Schizophrenia; February 5‐11, 2000; Davos, Switzerland). 2000. ">HGCQ (Turkey) 2000</a>; <a href="./references#CD010631-bbs2-0002" title="EliLilly , Company . Study HGDV olanzapine (versus chlorpromazine in Morocco). Unpublished document internal to Eli‐Lilly and Company2001:1‐512. HGDV/Morocco . Data supplied to the Cochrane Schizophrenia Group. Data on file1999. ">HGDV (Morocco) 1999</a>; <a href="./references#CD010631-bbs2-0007" title="EliLilly , Company . HGDT olanzapine versus chlorpromazine in Egypt. Unpublished document internal to Eli Lilly and Company2001:1‐513. LozaN , El‐DosokyAM , OkashaTA , KhalilAH , HasanNM , DossenbachM , et al. Olanzapine compared to chlorpromazine in acute schizophrenia. European Neuropsychopharmacology1999;9(Suppl 5):S291. ">vs OLZ ‐ Loza 1999 (HGDT)</a>); each study stated that "the [study drug] bottles were labelled 'Olanzapine' or 'Chlorpromazine' in addition to the study number". We rated all other studies as 'unclear' for allocation bias. </p> </section> <section id="CD010631-sec-0174"> <h5 class="title">2. Chlorpromazine versus risperidone</h5> <p>None of the included studies provided details as to randomisation methods and therefore we rated each as at 'unclear' risk of bias, since 'randomisation' or 'random allocated' was stated but no description was provided. </p> </section> <section id="CD010631-sec-0175"> <h5 class="title">3. Chlorpromazine versus quetiapine</h5> <p>Only eight of the 45 included studies provided adequate data as to randomisation methods; five studies used a random number table (<a href="./references#CD010631-bbs2-0018" title="ChenJ , ZhaoJ , LiL . Multi‐center, double blind control study of domestic manufactured quetiapine on schizophrenia. Chinese Journal of Psychiatry2001;34(4):193‐6. ZhaoJP , ChenJD , ChenYG , ShuL , MaC . A double‐blind and double‐dummy comparative study of quetiapine and chlorpromazine in the treatment of schizophrenia. Chinese New Drugs Journal2002;11(2):149‐51. ">vs QTP ‐ Chen 2001</a>; <a href="./references#CD010631-bbs2-0028" title="GuoZ , LiuJ , YangJ . Efficacy quetiapine in the treatment of schizophrenic patients and effect on the quality of life. Chinese Journal of Health Psychology2008;16(5):544‐6. ">vs QTP ‐ Guo 2008</a>; <a href="./references#CD010631-bbs2-0042" title="PengZG , ZhouJX , KuangWH , LiJ , HuangMS . A randomized double ‐ blind controlled study on the efficacy of quetiapine and chlorpromazine in treatment of schizophrenia. West China Journal of Pharmaceutical Sciences2006;21(6):606‐8. ">vs QTP ‐ Peng 2006</a>; <a href="./references#CD010631-bbs2-0049" title="WangH , PengD , BaiY . Efficacy of quetiapine in the treatment of female patients with schizophrenia. Shanghai Archives of Psychiatry2005;17(2):83‐6. ">vs QTP ‐ Wang 2005</a>; <a href="./references#CD010631-bbs2-0055" title="ZhouJ , LiJ , KuangW . Comparison between quetiapine and chlorpromazine in cognitive function of schizophrenic patients. Chinese Mental Health Journal2003;17(10):699‐701. ">vs QTP ‐ Zhou 2003</a>), two studies randomised by tossing a coin (<a href="./references#CD010631-bbs2-0023" title="GuoBY , WangYB . Control studies on efficacy of quetiapine vs chlorpromazine in first ‐ episode schizophrenics. Journal of Clinical Psychosomatic Diseases2003;9(2):75‐7. ">vs QTP ‐ Guo 2003a</a>; <a href="./references#CD010631-bbs2-0051" title="ZhangS , LiY , XuJ . A double‐blind study of domestic quetiapine and chlorpromazine in the treatment of schizophrenia. Shandong Archives of Psychiatry2002;15(3):149‐51. ">vs QTP ‐ Zhang 2002</a>) and one study randomised through computer‐generated random numbers (<a href="./references#CD010631-bbs2-0052" title="ZhangHY , WangX , LiuC , ShuL , LiH , GuN , et al. A comparison study on efficacy and safety of quetiapine and chlorpromazine in the treatment of schizophrenia. Chinese Journal of Clinical Pharmacology2003;19(3):163‐6. ">vs QTP ‐ Zhang 2003</a>). We rated these studies at 'low' risk of bias, with the remaining studies rated at 'unclear' risk. </p> </section> </section> <section id="CD010631-sec-0176"> <h4 class="title">Blinding</h4> <section id="CD010631-sec-0177"> <h5 class="title">1. Chlorpromazine versus olanzapine</h5> <p>We rated four studies at 'high' risk of bias for blinding and detection bias (<a href="./references#CD010631-bbs2-0001" title="DossenbachM . Sleep quality and early morning wakefulness of schizophrenic patients treated with olanzapine compared to chlorpromazine. European Neuropsychopharmacology2000;10(Supplement 3):S328‐9. EliLilly , Company . Study F1D‐VI‐HGCQ olanzapine versus chlorpromazine in Turkey. Unpublished document internal to Eli‐Lilly2000:1‐560. KostakogluE , AlptekinK , KivicikBB , MartenyiF , TuncaZ , GogusA , et al. Sleep quality and early morning wakefulness of schizophrenia patients treated with olanzapine compared to chlorpromazine [Errata]. European Neuropsychopharmacology2001;11(Suppl 3):S369. MrazK , GogusA , TuncaZ , MartenyiF , DossenbachM . Olanzapine versus chlorpromazine in Turkey. Schizophrenia Research (Abstracts of the Winter Workshop on Schizophrenia; February 5‐11, 2000; Davos, Switzerland). 2000. ">HGCQ (Turkey) 2000</a>; <a href="./references#CD010631-bbs2-0002" title="EliLilly , Company . Study HGDV olanzapine (versus chlorpromazine in Morocco). Unpublished document internal to Eli‐Lilly and Company2001:1‐512. HGDV/Morocco . Data supplied to the Cochrane Schizophrenia Group. Data on file1999. ">HGDV (Morocco) 1999</a>; <a href="./references#CD010631-bbs2-0007" title="EliLilly , Company . HGDT olanzapine versus chlorpromazine in Egypt. Unpublished document internal to Eli Lilly and Company2001:1‐513. LozaN , El‐DosokyAM , OkashaTA , KhalilAH , HasanNM , DossenbachM , et al. Olanzapine compared to chlorpromazine in acute schizophrenia. European Neuropsychopharmacology1999;9(Suppl 5):S291. ">vs OLZ ‐ Loza 1999 (HGDT)</a>; <a href="./references#CD010631-bbs2-0009" title="WangCH , ZhaoZ , LiY , PanM , LiuX . Evaluation of proximal therapeutic effect and distal social function restoration of olanzapine on schizophrenia patients. Zhongguo lin chuang kang fu [Chinese Journal of Clinical Rehabilitation]2002;6(17):2664‐5. ">vs OLZ ‐ Wang 2002</a>). Each of these were open label studies where both participant and study investigator knew what was being given and received. All other studies were rated at 'unclear' risk of bias. </p> </section> <section id="CD010631-sec-0178"> <h5 class="title">2. Chlorpromazine versus risperidone</h5> <p>Only two studies were rated at 'low' risk of bias for performance and detection bias in blinding (<a href="./references#CD010631-bbs2-0059" title="CuiL . Risperidone and chlorpromazine in the treatment of schizophrenia, double‐blind, controlled study, and serum prolactin efficacy. Hebei Archive of Psychiatry2001;14:205‐8. ">vs RPD ‐ Cui 2001</a>; <a href="./references#CD010631-bbs2-0060" title="FengYX , SunF . A comparative study on the effects of risperidone and chlorpromazine upon the life quality of patients with schizophrenia. Health Psychology Journal2003;11:117‐8. ">vs RPD ‐ Feng 2003</a>). Double blinding was used via, identical study drugs, dispensed by an independent pharmacist. All other studies were rated as at 'unclear' risk of bias. </p> </section> <section id="CD010631-sec-0179"> <h5 class="title">3. Chlorpromazine versus quetiapine</h5> <p>We rated only one study as at 'low' risk of bias, since it specified assessor blinding (<a href="./references#CD010631-bbs2-0042" title="PengZG , ZhouJX , KuangWH , LiJ , HuangMS . A randomized double ‐ blind controlled study on the efficacy of quetiapine and chlorpromazine in treatment of schizophrenia. West China Journal of Pharmaceutical Sciences2006;21(6):606‐8. ">vs QTP ‐ Peng 2006</a>). All other studies were rated at 'unclear' risk of bias. </p> </section> </section> <section id="CD010631-sec-0180"> <h4 class="title">Incomplete outcome data</h4> <section id="CD010631-sec-0181"> <h5 class="title">1. Chlorpromazine versus olanzapine</h5> <p>All studies apart from one were rated at 'low' risk of attrition bias either because all participants were stated to have complete the study, or those that left the study early were included in the final analysis. We rated only one study as a 'high' risk of bias because 13 and 11 people dropped out of the olanzapine and chlorpromazine groups respectively (<a href="./references#CD010631-bbs2-0010" title="WangQ , LiL , WangT . A comparative study of olanzapine in treatment of schizophrenia. Journal of Psychiatry2008;21:373‐5. ">vs OLZ ‐ Wang 2008</a>). These people were excluded from the final analysis and reasons for dropout were not given. </p> </section> <section id="CD010631-sec-0182"> <h5 class="title">2. Chlorpromazine versus risperidone</h5> <p>We rated all but two studies as at 'low' risk of attrition bias either because all participants were stated to have completed the study, or those that left the study early were included in the final analysis. We rated two studies as at 'unclear' risk (<a href="./references#CD010631-bbs2-0060" title="FengYX , SunF . A comparative study on the effects of risperidone and chlorpromazine upon the life quality of patients with schizophrenia. Health Psychology Journal2003;11:117‐8. ">vs RPD ‐ Feng 2003</a>; <a href="./references#CD010631-bbs2-0068" title="WangX , HuX , YangJ . Effect of chlorpromazine and risperidone on cognitive function of the patients with first episode schizophrenia. Chinese Journal of Health Psychology2005;13:342‐4. ">vs RPD ‐ Wang 2005</a>) as there were dropouts, however it was unclear whether these were included in the final analysis. </p> </section> <section id="CD010631-sec-0183"> <h5 class="title">3. Chlorpromazine versus quetiapine</h5> <p>Thirty‐seven included studies were rated as at 'low' risk of attrition bias either because all participants were stated to have complete the study, or those that left the study early were included in the final analysis. We rated eight studies as at 'high' risk of attrition bias (<a href="./references#CD010631-bbs2-0017" title="CaoD , XieSP , ChenQB , YuanYG , FangQ . Characteristics of the sexual disturbance caused by chlorpromazine, risperidone, quetiapine and olanzapine and their associations with the changes of blood glucose and blood lipids in male patients with schizophrenia. Chinese Journal of Clinical Rehabilitation [Zhongguo Lin Chuang Kang Fu]2005;9(36):63‐8. ">vs QTP ‐ Cao 2005</a>; <a href="./references#CD010631-bbs2-0021" title="ChengXF . Control observation of quetiapine vs chlorpromazine in schizophrenia. Journal of Clinical Psychosomatic Diseases2003;9(2):78‐80. ">vs QTP ‐ Cheng 2003</a>; <a href="./references#CD010631-bbs2-0024" title="GuoP , GuoH , YangC . A comparative study on the effects of quetiapine and chlorpromazine upon the life quality of patients with schizophrenia. Nervous Diseases and Mental Hygiene2003;3(6):454‐5. ">vs QTP ‐ Guo 2003b</a>; <a href="./references#CD010631-bbs2-0031" title="JiJ , OuW . Comparative study between the quality of life and its curative effect in schizophrenic patients treated with quetiapine or chlorpromazine. Sichuan Mental Health2004;17(2):73‐5. ">vs QTP ‐ Ji 2004</a>; <a href="./references#CD010631-bbs2-0036" title="LiM , HuF , WangS . A study of quetiapine and chlorpromazine on the effects and quality of life in the treatment of schizophrenia. Shandong Archives of Psychiatry2003;16(3):135‐7. ">vs QTP ‐ Li 2003</a>; <a href="./references#CD010631-bbs2-0041" title="NCT00882518 . Efficacy and safety of quetiapine fumarate in the treatment of schizophrenic patients. http://www.clinicaltrials.gov (accessed 28 February 2012). ">vs QTP ‐ NCT00882518</a>; <a href="./references#CD010631-bbs2-0049" title="WangH , PengD , BaiY . Efficacy of quetiapine in the treatment of female patients with schizophrenia. Shanghai Archives of Psychiatry2005;17(2):83‐6. ">vs QTP ‐ Wang 2005</a>; <a href="./references#CD010631-bbs2-0050" title="YangL , YuanYG . Quetiapine and chlorpromazine in the treatment of people with schizophrenia. Medical Journal of Chinese People's Health2007;19(12):1050‐1. ">vs QTP ‐ Yang 2007</a>) either because it was unclear if these were included in the final analysis, or dropouts were excluded from the analysis. </p> </section> </section> <section id="CD010631-sec-0184"> <h4 class="title">Selective reporting</h4> <section id="CD010631-sec-0185"> <h5 class="title">1. Chlorpromazine versus olanzapine</h5> <p>We rated five studies at 'high' risk of bias for selective reporting (<a href="./references#CD010631-bbs2-0001" title="DossenbachM . Sleep quality and early morning wakefulness of schizophrenic patients treated with olanzapine compared to chlorpromazine. European Neuropsychopharmacology2000;10(Supplement 3):S328‐9. EliLilly , Company . Study F1D‐VI‐HGCQ olanzapine versus chlorpromazine in Turkey. Unpublished document internal to Eli‐Lilly2000:1‐560. KostakogluE , AlptekinK , KivicikBB , MartenyiF , TuncaZ , GogusA , et al. Sleep quality and early morning wakefulness of schizophrenia patients treated with olanzapine compared to chlorpromazine [Errata]. European Neuropsychopharmacology2001;11(Suppl 3):S369. MrazK , GogusA , TuncaZ , MartenyiF , DossenbachM . Olanzapine versus chlorpromazine in Turkey. Schizophrenia Research (Abstracts of the Winter Workshop on Schizophrenia; February 5‐11, 2000; Davos, Switzerland). 2000. ">HGCQ (Turkey) 2000</a>; <a href="./references#CD010631-bbs2-0004" title="ChangFW , WangCH , ZhaoZ . Clinical effects of olanzapine vs chlorpromazine in treating positive symptoms of schizophrenia. Chinese Journal of New Drugs and Clinical Remedies2003;22(6):357‐9. ">vs OLZ ‐ Chang 2003</a>; <a href="./references#CD010631-bbs2-0005" title="ChenF . Olanzapine and chlorpromazine in the treatment of schizophrenia. Journal of Clinical Psychiatric Medicine2006;16:303‐4. ">vs OLZ ‐ Chen 2006</a>; <a href="./references#CD010631-bbs2-0007" title="EliLilly , Company . HGDT olanzapine versus chlorpromazine in Egypt. Unpublished document internal to Eli Lilly and Company2001:1‐513. LozaN , El‐DosokyAM , OkashaTA , KhalilAH , HasanNM , DossenbachM , et al. Olanzapine compared to chlorpromazine in acute schizophrenia. European Neuropsychopharmacology1999;9(Suppl 5):S291. ">vs OLZ ‐ Loza 1999 (HGDT)</a>; <a href="./references#CD010631-bbs2-0009" title="WangCH , ZhaoZ , LiY , PanM , LiuX . Evaluation of proximal therapeutic effect and distal social function restoration of olanzapine on schizophrenia patients. Zhongguo lin chuang kang fu [Chinese Journal of Clinical Rehabilitation]2002;6(17):2664‐5. ">vs OLZ ‐ Wang 2002</a>) due to pre‐specified outcomes in each study not being fully reported, or partially reported. One study was rated as at 'unclear' risk of bias (<a href="./references#CD010631-bbs2-0011" title="WuY , LuWH , YiZH , WangJ , SongBF , ShiDQ , et al. Controlled study of olanzapine versus chlorpromazine for the quality of life of patients with schizophrenia. Sichuan Mental Health Journal2008;21(1):8‐11. ">vs OLZ ‐ Wu 2008</a>) as it was not explicit whether all outcomes were reported. We rated all remaining studies as at 'low' risk of bias. </p> </section> <section id="CD010631-sec-0186"> <h5 class="title">2. Chlorpromazine versus risperidone</h5> <p>We rated two studies as at 'high' risk of bias for selective reporting due to pre‐specified outcomes in each study not being fully reported or partially reported (<a href="./references#CD010631-bbs2-0062" title="LinWX . Risperidone and chlorpromazine in the treatment of clinical controlled study of 70 patients with schizophrenia. Modern Chinese Practical Medicine Journal2005;4:27‐8. ">vs RPD ‐ Lin 2005</a>; <a href="./references#CD010631-bbs2-0071" title="ZhengZS , HuangJM , YuXY . Efficacy of risperidone and chlorpromazine in the treatment of schizophrenia. Chinese Hospital Pharmacy Journal2001;21:99‐100. ">vs RPD ‐ Zheng 2001</a>). Two studies were rated as at 'unclear' risk of bias as it was not explicit whether all outcomes were reported (<a href="./references#CD010631-bbs2-0060" title="FengYX , SunF . A comparative study on the effects of risperidone and chlorpromazine upon the life quality of patients with schizophrenia. Health Psychology Journal2003;11:117‐8. ">vs RPD ‐ Feng 2003</a>; <a href="./references#CD010631-bbs2-0063" title="LiuY , HuangX , XieL . A comparative study of risperidone and chlorpromazine in the treatment of the negative symptoms of schizophrenia. Journal of Medicine and Pharmacy2000;19:323‐4. ">vs RPD ‐ Liu 2000</a>). We rated all other studies as at 'low' risk of bias. </p> </section> <section id="CD010631-sec-0187"> <h5 class="title">3. Chlorpromazine versus quetiapine</h5> <p>Twelve studies were rated as at 'high' risk of bias for selective reporting due to pre‐specified outcomes in each study not being fully reported, or partially reported (<a href="./references#CD010631-bbs2-0013" title="AiL . A comparative study of efficacy and safety of seroquel versus chlorpromazine in the treatment of schizophrenia. Heilongjiang Medical Journal2007;31(4):285. ">vs QTP ‐ Ai 2007</a>; <a href="./references#CD010631-bbs2-0019" title="ChenF , ChenY , ZhouB , ChengF , LiuY , ZhoXW , et al. Quetiapine treatment in schizophrenia curative effect and quality of life. Journal of Clinical Psychiatry [Linchuang Jingshen Yixue Zazhi]2007;17(5):319‐20. ">vs QTP ‐ Chen 2007</a>; <a href="./references#CD010631-bbs2-0020" title="ChenS . Quetiapine and chlorpromazine in the treatment of schizophrenia. Medical Journal of Chinese People's Health2008;20(7):660. ">vs QTP ‐ Chen 2008</a>; <a href="./references#CD010631-bbs2-0022" title="DengYF , LiuCY , LiuZR , ZhangW . 利培酮合用氯硝西泮治疗精神分裂症急性期兴奋状态疗效观察. 中国实用内科杂志2004;24:496‐7. ">vs QTP ‐ Deng 2004</a>; <a href="./references#CD010631-bbs2-0027" title="GuoJ , CaoC , WuD . Effect of quetiapine and chlorpromazine on cognitive function in first‐episode schizophrenic. Chinese Journal of Health Psychology2007;15(7):583‐4. ">vs QTP ‐ Guo 2007</a>; <a href="./references#CD010631-bbs2-0032" title="JiangKD , BaiYL , PengDH , TangMQ , FanJX , MaJS . A random and controlled study of quetiapine and chlorpromazine in patients with schizophrenia. Journal of Clinical Psychiatry [Linchuang Jingshen Yixue Zazhi]2006;16(6):352‐3. ">vs QTP ‐ Jiang 2006</a>; <a href="./references#CD010631-bbs2-0033" title="JiangGQ , LuoJ . A controlled study of quetiapine and chlorpromazine for schizophrenia. Chongqing Journal of Medicine2008;37(16):1835‐6. ">vs QTP ‐ Jiang 2008</a>; <a href="./references#CD010631-bbs2-0034" title="JinS , LiuS , SangW , ZhaoM . Seroquel and chlorpromazine in treatment of schizophrenia: a random, controlled trial. China Pharmaceuticals2007;16(19):56‐7. ">vs QTP ‐ Jin 2007</a>; <a href="./references#CD010631-bbs2-0040" title="NaiX , HuX , QiuS . Effect of quetiapine on cognition function of patients with first episode schizophrenia. Journal of Medical Forum2007;28(2):38‐9. ">vs QTP ‐ Nai 2007</a>; <a href="./references#CD010631-bbs2-0046" title="WanC , LanSZ , ZhuXJ , LiaoB , WanJ . A double blind controlled study of quetiapine and chlorpromazine for schizophrenia. Journal of Yichun University2002;24(2):55‐6. ">vs QTP ‐ Wan 2002</a>; <a href="./references#CD010631-bbs2-0052" title="ZhangHY , WangX , LiuC , ShuL , LiH , GuN , et al. A comparison study on efficacy and safety of quetiapine and chlorpromazine in the treatment of schizophrenia. Chinese Journal of Clinical Pharmacology2003;19(3):163‐6. ">vs QTP ‐ Zhang 2003</a>; <a href="./references#CD010631-bbs2-0057" title="ZouX , ZhouY , ZhangW . Study on quetiapine and chlorpromazine in treatment of schizophrenia. China Pharmaceuticals2006;15(12):51‐2. ">vs QTP ‐ Zou 2006</a>). We rated one study as at 'unclear' risk of bias as it was not explicit whether all outcomes were reported (<a href="./references#CD010631-bbs2-0038" title="LiuSF , QinX . Quetiapine for late onset schizophrenia. Shandong Archive of Psychiatry2003;16(3):164. ">vs QTP ‐ Liu 2003</a>). We rated all other studies as at 'low' risk of bias. See <a href="#CD010631-fig-0004">Figure 4</a>. </p> <div class="figure" id="CD010631-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 3 Chlorpromazine vs Quetiapine, outcome: 3.1 Clinical response: no significant clinical response." data-id="CD010631-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 3 Chlorpromazine vs Quetiapine, outcome: 3.1 Clinical response: no significant clinical response. </p> </div> </div> </div> </section> </section> <section id="CD010631-sec-0188"> <h4 class="title">Other potential sources of bias</h4> <section id="CD010631-sec-0189"> <h5 class="title">1. Chlorpromazine versus olanzapine</h5> <p>All studies were rated at 'low' risk of other potential sources of bias, since we did not detect any obvious bias. </p> </section> <section id="CD010631-sec-0190"> <h5 class="title">2. Chlorpromazine versus risperidone</h5> <p>We rated all studies at 'low' risk of other potential sources of bias, since we did not detect any obvious bias. </p> </section> <section id="CD010631-sec-0191"> <h5 class="title">3. Chlorpromazine versus quetiapine</h5> <p>We rated two studies at 'high' risk of bias as they were both funded by the pharmaceutical company AstraZeneca, the manufacturers of quetiapine (<a href="./references#CD010631-bbs2-0043" title="PeuskensJ , LinkCGG . A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatrica Scandinavica1997;96(4):265‐73. ">vs QTP ‐ Peuskens 1997</a>; <a href="./references#CD010631-bbs2-0041" title="NCT00882518 . Efficacy and safety of quetiapine fumarate in the treatment of schizophrenic patients. http://www.clinicaltrials.gov (accessed 28 February 2012). ">vs QTP ‐ NCT00882518</a>). All remaining studies were rated at 'low' risk of other potential sources of bias, since we did not detect any obvious bias. </p> </section> </section> </section> <section id="CD010631-sec-0192"> <h3 class="title" id="CD010631-sec-0192">Effects of interventions</h3> <p>See: <a href="./full#CD010631-tbl-0001"><b>Summary of findings for the main comparison</b> CHLORPROMAZINE versus OLANZAPINE for schizophrenia</a>; <a href="./full#CD010631-tbl-0002"><b>Summary of findings 2</b> CHLORPROMAZINE versus RISPERIDONE for schizophrenia</a>; <a href="./full#CD010631-tbl-0003"><b>Summary of findings 3</b> CHLORPROMAZINE versus QUETIAPINE for schizophrenia</a> </p> <section id="CD010631-sec-0193"> <h4 class="title">Comparison 1: CHLORPROMAZINE versus OLANZAPINE</h4> <section id="CD010631-sec-0194"> <h5 class="title">1.1 Clinical response: 1. No significant clinical response</h5> <section id="CD010631-sec-0195"> <h6 class="title">1.1.1 short term ‐ up to 6 months</h6> <p>In this subgroup we found three relevant trials (N = 204). There was a statistically significant difference (P = 0.002) in favour of olanzapine (RR 2.34, 95% CI 1.37 to 3.99; <a href="./references#CD010631-fig-0005" title="">Analysis 1.1</a>). </p> </section> <section id="CD010631-sec-0196"> <h6 class="title">1.1.2 long term ‐ over 12 months</h6> <p>We only found one relevant trial in this subgroup (N = 70) (<a href="./references#CD010631-bbs2-0003" title="AnBF , LiY , WangCH . Olanzapine on effect of executive dysfunction in schizophrenia. Journal of Clinical Psychiatry2006;16(3):144‐5. ">vs OLZ ‐ An 2006</a>). There was no significant difference between chlorpromazine and olanzapine (RR 1.83, 95% CI 0.76 to 4.41; <a href="./references#CD010631-fig-0005" title="">Analysis 1.1</a>). </p> </section> <section id="CD010631-sec-0197"> <h6 class="title">1.1.3 total</h6> <p>Overall there was a statistically significant difference in favour of olanzapine in both short and long term (4 RCTs, N = 274; RR 2.19, 95% CI 1.39 to 3.45; P = 0.0008; <a href="./references#CD010631-fig-0005" title="">Analysis 1.1</a>) </p> </section> </section> <section id="CD010631-sec-0198"> <h5 class="title">1.2 Clinical response: 2. Average endpoint score of CGI (high = poor) ‐ short term (up to 6 months) </h5> <p>In this subgroup we included three trials (N = 110). There was a statistically significant difference in favour of olanzapine (MD 0.93, 95% CI 0.36 to 1.51; P = 0.002; <a href="./references#CD010631-fig-0006" title="">Analysis 1.2</a>). This subgroup had moderate levels of heterogeneity (Chi² test = 3.9; df = 2; P = 0.142; I² statistic = 49%). </p> </section> <section id="CD010631-sec-0199"> <h5 class="title">1.3 Clinical response: 3. Relapse ‐ long term (over 12 months)</h5> <p>In this subgroup we only found one relevant trial (N = 70) (<a href="./references#CD010631-bbs2-0003" title="AnBF , LiY , WangCH . Olanzapine on effect of executive dysfunction in schizophrenia. Journal of Clinical Psychiatry2006;16(3):144‐5. ">vs OLZ ‐ An 2006</a>). There was no significant difference between chlorpromazine and olanzapine (RR 1.5, 95% CI 0.46 to 4.86; <a href="./references#CD010631-fig-0007" title="">Analysis 1.3</a>). </p> </section> <section id="CD010631-sec-0200"> <h5 class="title">1.4 Mental state: 1. Average endpoint score of various scales (high = poor) ‐ short term (up to 6 months) </h5> <section id="CD010631-sec-0201"> <h6 class="title">1.4.1 BPRS total</h6> <p>In this subgroup we found four relevant trials (N = 245). There was no significant difference between chlorpromazine and olanzapine (MD 3.21, 95% CI −0.62 to 7.05; <a href="./references#CD010631-fig-0008" title="">Analysis 1.4</a>). This subgroup had important levels of heterogeneity (Chi² test = 23.38; df = 3; P = 0.0; I² statistic = 87%). </p> </section> <section id="CD010631-sec-0202"> <h6 class="title">1.4.2 BPRS activation subscale</h6> <p>In this subgroup we found two relevant trials (N = 299). There was a statistically significant difference in favour of olanzapine (MD 0.47, 95% CI 0.27 to 0.67; P &lt; 0.00001; <a href="./references#CD010631-fig-0008" title="">Analysis 1.4</a>). </p> </section> <section id="CD010631-sec-0203"> <h6 class="title">1.4.3 BPRS anxiety‐depression subscale</h6> <p>In this subgroup we only included one trial (N = 213) (<a href="./references#CD010631-bbs2-0010" title="WangQ , LiL , WangT . A comparative study of olanzapine in treatment of schizophrenia. Journal of Psychiatry2008;21:373‐5. ">vs OLZ ‐ Wang 2008</a>). There was a statistically significant difference in favour of olanzapine (MD 1.57, 95% CI 1.36 to 1.78; P &lt; 0.00001; <a href="./references#CD010631-fig-0008" title="">Analysis 1.4</a>). </p> </section> <section id="CD010631-sec-0204"> <h6 class="title">1.4.4 BPRS hostile‐suspiciousness subscale</h6> <p>In this subgroup we found two relevant trials (N = 299). There was no significant difference between chlorpromazine and olanzapine (MD −0.31, 95% CI −1.98 to 1.35; <a href="./references#CD010631-fig-0008" title="">Analysis 1.4</a>). This subgroup had important levels of heterogeneity (Chi² test = 16.24; df = 1; P = 0.0; I² statistic = 94%). </p> </section> <section id="CD010631-sec-0205"> <h6 class="title">1.4.5 BPRS thinking disorder subscale</h6> <p>We found two relevant trials in this subgroup (N = 299). There was no significant difference between chlorpromazine and olanzapine (MD −0.8, 95% CI −2.66 to 1.06; <a href="./references#CD010631-fig-0008" title="">Analysis 1.4</a>). This subgroup had important levels of heterogeneity (Chi² test = 16.59; df = 1; P = 0.0; I² statistic = 94%). </p> </section> <section id="CD010631-sec-0206"> <h6 class="title">1.4.6 BPRS withdraw‐retardation subscale</h6> <p>In this subgroup we found two relevant trials (N = 299). There was no significant difference between chlorpromazine and olanzapine (MD −0.49 95% CI −2.25 to 1.26; <a href="./references#CD010631-fig-0008" title="">Analysis 1.4</a>). This subgroup had important levels of heterogeneity (Chi² test = 53.34; df = 1; P = 0.0; I² statistic = 98%). </p> </section> <section id="CD010631-sec-0207"> <h6 class="title">1.4.7 NOSIE total</h6> <p>We only included one trial in this subgroup (N = 213) (<a href="./references#CD010631-bbs2-0010" title="WangQ , LiL , WangT . A comparative study of olanzapine in treatment of schizophrenia. Journal of Psychiatry2008;21:373‐5. ">vs OLZ ‐ Wang 2008</a>). There was a statistically significant difference in favour of chlorpromazine (MD −18.36, 95% CI −22.39 to −14.33; P &lt; 0.00001; <a href="./references#CD010631-fig-0008" title="">Analysis 1.4</a>). </p> </section> <section id="CD010631-sec-0208"> <h6 class="title">1.4.8 PANSS total</h6> <p>In this subgroup we included six trials (N = 351). There was a statistically significant difference in favour of olanzapine (MD 10.46, 95% CI 4.49 to 16.43; P = 0.006; <a href="./references#CD010631-fig-0008" title="">Analysis 1.4</a>). This subgroup had important levels of heterogeneity (Chi² test = 15.31; df = 5; P = 0.009; I² statistic = 67%). </p> </section> <section id="CD010631-sec-0209"> <h6 class="title">1.4.9 PANSS general pathology subscale</h6> <p>In this subgroup we only found one relevant trial (N = 100) (<a href="./references#CD010631-bbs2-0011" title="WuY , LuWH , YiZH , WangJ , SongBF , ShiDQ , et al. Controlled study of olanzapine versus chlorpromazine for the quality of life of patients with schizophrenia. Sichuan Mental Health Journal2008;21(1):8‐11. ">vs OLZ ‐ Wu 2008</a>). There was no significant difference between chlorpromazine and olanzapine (MD 1.31, 95% CI −0.32 to 2.94; <a href="./references#CD010631-fig-0008" title="">Analysis 1.4</a>). </p> </section> <section id="CD010631-sec-0210"> <h6 class="title">1.4.10 PANSS negative symptom subscale</h6> <p>In this subgroup we found two relevant trials (N = 141). There was a statistically significant difference in favour of olanzapine (MD 2.38, 95% CI 0.31 to 4.45; P = 0.02; <a href="./references#CD010631-fig-0008" title="">Analysis 1.4</a>). </p> </section> <section id="CD010631-sec-0211"> <h6 class="title">1.4.11 PANSS positive symptom subscale</h6> <p>We found two relevant trials in this subgroup (N = 161). There was no significant difference between chlorpromazine and olanzapine (MD 0.91, 95% CI −0.30 to 2.11; <a href="./references#CD010631-fig-0008" title="">Analysis 1.4</a>). </p> </section> <section id="CD010631-sec-0212"> <h6 class="title">1.4.12 SAPS total</h6> <p>In this subgroup we only found one relevant trial (n = 86) (<a href="./references#CD010631-bbs2-0005" title="ChenF . Olanzapine and chlorpromazine in the treatment of schizophrenia. Journal of Clinical Psychiatric Medicine2006;16:303‐4. ">vs OLZ ‐ Chen 2006</a>). There was no significant difference between chlorpromazine and olanzapine (MD −2.1, 95% CI −4.53 to 0.33; <a href="./references#CD010631-fig-0008" title="">Analysis 1.4</a>). </p> </section> </section> <section id="CD010631-sec-0213"> <h5 class="title">1.5 Mental state: 3. Average endpoint score (BPRS, high = poor) ‐ medium term (7 ‐ 12 months) </h5> <p>In this subgroup we only found one relevant trial (N = 60) (<a href="./references#CD010631-bbs2-0009" title="WangCH , ZhaoZ , LiY , PanM , LiuX . Evaluation of proximal therapeutic effect and distal social function restoration of olanzapine on schizophrenia patients. Zhongguo lin chuang kang fu [Chinese Journal of Clinical Rehabilitation]2002;6(17):2664‐5. ">vs OLZ ‐ Wang 2002</a>). There was a statistically significant difference in favour of olanzapine (MD 8.60, 95% CI 5.94 to 11.26; P &lt; 0.00001; <a href="./references#CD010631-fig-0009" title="">Analysis 1.5</a>). </p> </section> <section id="CD010631-sec-0214"> <h5 class="title">1.6 Mental state: 2. Average endpoint score of various scales (high = poor) ‐ skewed data </h5> <p>Data using the various mental state scales, including the BPRS, PANSS, MADRS and HAMA, were skewed and are best inspected by viewing (<a href="./references#CD010631-fig-0010" title="">Analysis 1.6</a>). </p> </section> <section id="CD010631-sec-0215"> <h5 class="title">1.7 Service involvement: 1. Re‐hospitalisation</h5> <section id="CD010631-sec-0216"> <h6 class="title">1.7.1 long term (over 12 months)</h6> <p>We found only one trial in this subgroup (N = 70) (<a href="./references#CD010631-bbs2-0003" title="AnBF , LiY , WangCH . Olanzapine on effect of executive dysfunction in schizophrenia. Journal of Clinical Psychiatry2006;16(3):144‐5. ">vs OLZ ‐ An 2006</a>). There was no significant difference between chlorpromazine and olanzapine (RR 1.50, 95% CI 0.46 to 4.86; <a href="./references#CD010631-fig-0011" title="">Analysis 1.7</a>). </p> </section> </section> <section id="CD010631-sec-0217"> <h5 class="title">1.8 Functioning: 1. Executive function ‐ average endpoint score (WCST, high = poor)</h5> <section id="CD010631-sec-0218"> <h6 class="title">1.8.1 short term (up to 6 months)</h6> <p>In this subgroup we only found one relevant trial (N = 53) (<a href="./references#CD010631-bbs2-0003" title="AnBF , LiY , WangCH . Olanzapine on effect of executive dysfunction in schizophrenia. Journal of Clinical Psychiatry2006;16(3):144‐5. ">vs OLZ ‐ An 2006</a>). There was a statistically significant difference in favour of olanzapine (MD 10.96, 95% CI 1.01 to 20.91; P = 0.03; <a href="./references#CD010631-fig-0012" title="">Analysis 1.8</a>). </p> </section> </section> <section id="CD010631-sec-0219"> <h5 class="title">1.9 Adverse effects: 1. Anticholinergic ‐ short term (up to 6 months)</h5> <section id="CD010631-sec-0220"> <h6 class="title">1.9.1 blurred vision</h6> <p>In this subgroup we found three relevant trials (N = 241). There was no significant difference between chlorpromazine and olanzapine (RR 2.59, 95% CI 0.66 to 10.22; <a href="./references#CD010631-fig-0013" title="">Analysis 1.9</a>). This subgroup had moderate levels of heterogeneity (Chi² test = 3.4; df = 2; P = 0.183; I² statistic = 41%). </p> </section> <section id="CD010631-sec-0221"> <h6 class="title">1.9.2 dry mouth</h6> <p>In this subgroup we found five relevant trials (N = 536). There was no significant difference between chlorpromazine and olanzapine (RR 1.13, 95% CI 0.29 to 4.45; <a href="./references#CD010631-fig-0013" title="">Analysis 1.9</a>). This subgroup had important levels of heterogeneity (Chi² test = 18.59; df = 4; P = 0.001; I² statistic = 78%). </p> </section> <section id="CD010631-sec-0222"> <h6 class="title">1.9.3 excessive sweating</h6> <p>We included two relevant trials in this subgroup (N = 180). There was no significant difference between chlorpromazine and olanzapine (RR 3.00, 95% CI 0.62 to 14.46; <a href="./references#CD010631-fig-0013" title="">Analysis 1.9</a>). </p> </section> <section id="CD010631-sec-0223"> <h6 class="title">1.9.4 hypersalivation</h6> <p>In this subgroup we found two relevant trials (N = 166). There was a statistically significant difference in favour of olanzapine (RR 10.99, 95% CI 4.14 to 29.17; P &lt; 0.00001; <a href="./references#CD010631-fig-0013" title="">Analysis 1.9</a>). </p> </section> <section id="CD010631-sec-0224"> <h6 class="title">1.9.5 stuffy nose</h6> <p>In this subgroup we only found one relevant trial (N = 80) (<a href="./references#CD010631-bbs2-0006" title="HeJ , AnQ . A comparative trial of olanzapine versus chlorpromazine in the treatment of schizophrenia. Shandong Mental Health Archive2003;16:78‐80. ">vs OLZ ‐ He 2003</a>). There was a statistically significant difference in favour of olanzapine (RR 3.00, 95% CI 1.06 to 8.52; P = 0.04; <a href="./references#CD010631-fig-0013" title="">Analysis 1.9</a>). </p> </section> </section> <section id="CD010631-sec-0225"> <h5 class="title">1.10 Adverse effects: 2. Cardiovascular ‐ short term (up to 6 months)</h5> <section id="CD010631-sec-0226"> <h6 class="title">1.10.1 abnormal ECG</h6> <p>In this subgroup we found two relevant trials (N = 180). There was no significant difference between chlorpromazine and olanzapine (RR 3.60, 95% CI 0.60 to 21.55; <a href="./references#CD010631-fig-0014" title="">Analysis 1.10</a>). </p> </section> <section id="CD010631-sec-0227"> <h6 class="title">1.10.2 apathism ‐ short term (up to six months)</h6> <p>In this subgroup we included only one relevant trial (N = 100) (<a href="./references#CD010631-bbs2-0011" title="WuY , LuWH , YiZH , WangJ , SongBF , ShiDQ , et al. Controlled study of olanzapine versus chlorpromazine for the quality of life of patients with schizophrenia. Sichuan Mental Health Journal2008;21(1):8‐11. ">vs OLZ ‐ Wu 2008</a>). There was a statistically significant difference in favour of olanzapine (RR 5.00, 95% CI 1.15 to 21.67; P = 0.03; <a href="./references#CD010631-fig-0014" title="">Analysis 1.10</a>). </p> </section> <section id="CD010631-sec-0228"> <h6 class="title">1.10.3 blood pressure (drop)</h6> <p>We included two trials in this subgroup (N = 180). There was a statistically significant difference in favour of olanzapine (RR 8.82, 95% CI 1.13 to 68.52 <a href="./references#CD010631-fig-0014" title="">Analysis 1.10</a>. </p> </section> <section id="CD010631-sec-0229"> <h6 class="title">1.10.4 orthostatic hypotension</h6> <p>In this subgroup we found five relevant trials (N = 561). There was a statistically significant difference in favour of olanzapine (RR 9.78, 95% CI 2.68 to 35.71; P = 0.006; <a href="./references#CD010631-fig-0014" title="">Analysis 1.10</a>). </p> </section> <section id="CD010631-sec-0230"> <h6 class="title">1.10.5 palpitation</h6> <p>In this subgroup we only found one relevant trial (N = 237) (<a href="./references#CD010631-bbs2-0010" title="WangQ , LiL , WangT . A comparative study of olanzapine in treatment of schizophrenia. Journal of Psychiatry2008;21:373‐5. ">vs OLZ ‐ Wang 2008</a>). There was a statistically significant difference in favour of olanzapine (RR 40.66, 95% CI 2.49 to 664.56; P = 0.009; <a href="./references#CD010631-fig-0014" title="">Analysis 1.10</a>). </p> </section> <section id="CD010631-sec-0231"> <h6 class="title">1.10.6 tachycardia</h6> <p>In this subgroup we found three relevant trials (N = 241). There was a statistically significant difference in favour of olanzapine (RR 3.53, 95% CI 1.66 to 7.48; P = 0.001; <a href="./references#CD010631-fig-0014" title="">Analysis 1.10</a>). </p> </section> </section> <section id="CD010631-sec-0232"> <h5 class="title">1.11 Adverse effects: 3. Central nervous system ‐ short term (up to 6 months)</h5> <section id="CD010631-sec-0233"> <h6 class="title">1.11.1 dizziness</h6> <p>We included two trials in this subgroup (N = 180). There was a statistically significant difference in favour of olanzapine (RR 3.85, 95% CI 1.11 to 13.32; P = 0.03; <a href="./references#CD010631-fig-0015" title="">Analysis 1.11</a>). </p> </section> <section id="CD010631-sec-0234"> <h6 class="title">1.11.2 drowsiness</h6> <p>In this subgroup we found five relevant trials (N = 536). There was a statistically significant difference in favour of olanzapine (RR 2.46, 95% CI 1.66 to 3.64; P &lt; 0.00001; <a href="./references#CD010631-fig-0015" title="">Analysis 1.11</a>). </p> </section> <section id="CD010631-sec-0235"> <h6 class="title">1.11.3 fatigue</h6> <p>In this subgroup we found two relevant trials (N = 161). There was no significant difference between chlorpromazine and olanzapine (RR 1.00, 95% CI 0.13 to 7.66; <a href="./references#CD010631-fig-0015" title="">Analysis 1.11</a>). This subgroup had moderate levels of heterogeneity (Chi² test = 1.79; df = 1; P = 0.181; I² statistic = 44%). </p> </section> </section> <section id="CD010631-sec-0236"> <h5 class="title">1.12 Adverse effects: 4. Gastrointestinal ‐ short term (up to 6 months)</h5> <section id="CD010631-sec-0237"> <h6 class="title">1.12.1 appetite loss</h6> <p>In this subgroup we found two relevant trials (N = 180). There was a statistically significant difference in favour of olanzapine (RR 11.01, 95% CI 2.82 to 42.94; P = 0.0006; <a href="./references#CD010631-fig-0016" title="">Analysis 1.12</a>). This subgroup had moderate levels of heterogeneity (Chi² test = 1.78; df = 1; P = 0.182; I² statistic = 44%). </p> </section> <section id="CD010631-sec-0238"> <h6 class="title">1.12.2 constipation</h6> <p>In this subgroup we found six relevant trials (N = 622). There was a statistically significant difference in favour of olanzapine (RR 4.29, 95% CI 2.61 to 7.05; P &lt; 0.00001; <a href="./references#CD010631-fig-0016" title="">Analysis 1.12</a>). </p> </section> <section id="CD010631-sec-0239"> <h6 class="title">1.12.3 diarrhoea</h6> <p>We found only one trial in this subgroup (N = 80) (<a href="./references#CD010631-bbs2-0006" title="HeJ , AnQ . A comparative trial of olanzapine versus chlorpromazine in the treatment of schizophrenia. Shandong Mental Health Archive2003;16:78‐80. ">vs OLZ ‐ He 2003</a>). There was no significant difference between chlorpromazine and olanzapine (RR 5.00, 95% CI 0.25 to 100.97; <a href="./references#CD010631-fig-0016" title="">Analysis 1.12</a>). </p> </section> <section id="CD010631-sec-0240"> <h6 class="title">1.12.4 dysphagia</h6> <p>We found only one relevant trial in this subgroup (N = 100) (<a href="./references#CD010631-bbs2-0011" title="WuY , LuWH , YiZH , WangJ , SongBF , ShiDQ , et al. Controlled study of olanzapine versus chlorpromazine for the quality of life of patients with schizophrenia. Sichuan Mental Health Journal2008;21(1):8‐11. ">vs OLZ ‐ Wu 2008</a>). There was no significant difference between chlorpromazine and olanzapine (RR 3.00, 95% CI 0.13 to 71.92; <a href="./references#CD010631-fig-0016" title="">Analysis 1.12</a>). </p> </section> <section id="CD010631-sec-0241"> <h6 class="title">1.12.5 nausea/vomiting</h6> <p>We included two relevant trials in this subgroup (N = 180). There was no significant difference between chlorpromazine and olanzapine (RR 1.49, 95% CI 0.43 to 5.20; <a href="./references#CD010631-fig-0016" title="">Analysis 1.12</a>). </p> </section> </section> <section id="CD010631-sec-0242"> <h5 class="title">1.13 Adverse effects: 5. Haematology ‐ ‐ short term (up to 6 months)</h5> <section id="CD010631-sec-0243"> <h6 class="title">1.13.1 abnormal haemogram</h6> <p>In this subgroup we found two relevant trials (N = 180). There was no significant difference between chlorpromazine and olanzapine (RR 4.00, 95% CI 0.87 to 18.31; <a href="./references#CD010631-fig-0017" title="">Analysis 1.13</a>). </p> </section> <section id="CD010631-sec-0244"> <h6 class="title">1.13.2 leukopenia</h6> <p>In this subgroup we only found one relevant trial (N = 86) (<a href="./references#CD010631-bbs2-0005" title="ChenF . Olanzapine and chlorpromazine in the treatment of schizophrenia. Journal of Clinical Psychiatric Medicine2006;16:303‐4. ">vs OLZ ‐ Chen 2006</a>). There was no significant difference between chlorpromazine and olanzapine (RR 6.69, 95% CI 0.36 to 125.71; <a href="./references#CD010631-fig-0017" title="">Analysis 1.13</a>). </p> </section> </section> <section id="CD010631-sec-0245"> <h5 class="title">1.14 Adverse effects: 6. Hepatitic ‐ short term (up to 6 months)</h5> <section id="CD010631-sec-0246"> <h6 class="title">1.14.1 abnormal liver function</h6> <p>In this subgroup we only found one relevant trial (N = 100) (<a href="./references#CD010631-bbs2-0011" title="WuY , LuWH , YiZH , WangJ , SongBF , ShiDQ , et al. Controlled study of olanzapine versus chlorpromazine for the quality of life of patients with schizophrenia. Sichuan Mental Health Journal2008;21(1):8‐11. ">vs OLZ ‐ Wu 2008</a>). There was no significant difference between chlorpromazine and olanzapine (RR 5.00, 95% CI 0.25 to 101.58; <a href="./references#CD010631-fig-0018" title="">Analysis 1.14</a>). </p> </section> <section id="CD010631-sec-0247"> <h6 class="title">1.14.2 abnormal transaminase</h6> <p>In this subgroup we found two relevant trials (N = 147). There was no significant difference between chlorpromazine and olanzapine (RR 0.88, 95% CI 0.01 to 150.45; <a href="./references#CD010631-fig-0018" title="">Analysis 1.14</a>). This subgroup had important levels of heterogeneity (Chi² test = 6.56; df = 1; P = 0.01; I² statistic = 85%). </p> </section> </section> <section id="CD010631-sec-0248"> <h5 class="title">1.15 Adverse effects: 7a Metabolic ‐ weight gain ‐ short term (up to 6 months)</h5> <p>In this subgroup we found five relevant trials (N = 536). There was no significant difference between chlorpromazine and olanzapine (RR 0.70, 95% CI 0.25 to 1.96; <a href="./references#CD010631-fig-0019" title="">Analysis 1.15</a> ). This subgroup had important levels of heterogeneity (Chi² test = 12.17; df = 4; P = 0.016; I² statistic = 67%). </p> </section> <section id="CD010631-sec-0249"> <h5 class="title">1.16 Adverse effects: 7b. Metabolic ‐ weight gain ‐ continuous measures</h5> <section id="CD010631-sec-0250"> <h6 class="title">1.16.1 short term (up to to 6 months)</h6> <p>In this subgroup we found four relevant trials (N = 160). There was a statistically significant difference in favour of chlorpromazine (MD −5.11, 95% CI −9.15 to −1.07; P = 0.01; <a href="./references#CD010631-fig-0020" title="">Analysis 1.16</a>). </p> </section> <section id="CD010631-sec-0251"> <h6 class="title">1.16.1 medium term (7 to 12 months)</h6> <p>We included only one trial in this subgroup (N = 50) (<a href="./references#CD010631-bbs2-0008" title="LuoC , YangJW , RenJP . Comparative study of the effect of olanzapine on serum lipid in schizophrenia. Journal of Clinical Psychiatric Medicine2007;17:401‐2. ">vs OLZ ‐ Luo 2007</a>). There was no significant difference between chlorpromazine and olanzapine (MD 0.59, 95% CI −11.87 to 13.05; <a href="./references#CD010631-fig-0020" title="">Analysis 1.16</a>). </p> </section> </section> <section id="CD010631-sec-0252"> <h5 class="title">1.17 Adverse effects: 7c. Metabolic ‐ other ‐ continuous measures</h5> <section id="CD010631-sec-0253"> <h6 class="title">1.17.1 cholesterol (TC) ‐ short term (up to 6 months)</h6> <p>In this subgroup we included one relevant trial (N = 50) (<a href="./references#CD010631-bbs2-0008" title="LuoC , YangJW , RenJP . Comparative study of the effect of olanzapine on serum lipid in schizophrenia. Journal of Clinical Psychiatric Medicine2007;17:401‐2. ">vs OLZ ‐ Luo 2007</a>). There was no significant difference between chlorpromazine and olanzapine (MD −0.40, 95% CI −1.02 to 0.22; <a href="./references#CD010631-fig-0021" title="">Analysis 1.17</a>). </p> </section> <section id="CD010631-sec-0254"> <h6 class="title">1.17.2 high‐density lipoprotein (HDL) ‐ short term (up to 6 months)</h6> <p>We only found one trial in this subgroup (N = 50) (<a href="./references#CD010631-bbs2-0008" title="LuoC , YangJW , RenJP . Comparative study of the effect of olanzapine on serum lipid in schizophrenia. Journal of Clinical Psychiatric Medicine2007;17:401‐2. ">vs OLZ ‐ Luo 2007</a>). There was no significant difference between chlorpromazine and olanzapine (MD 0.05, 95% CI −0.12 to 0.22; <a href="./references#CD010631-fig-0021" title="">Analysis 1.17</a>). </p> </section> <section id="CD010631-sec-0255"> <h6 class="title">1.17.3 low‐density lipoprotein (LDL) ‐ short term (up to 6 months)</h6> <p>We found only one relevant trial in this subgroup (N = 50) (<a href="./references#CD010631-bbs2-0008" title="LuoC , YangJW , RenJP . Comparative study of the effect of olanzapine on serum lipid in schizophrenia. Journal of Clinical Psychiatric Medicine2007;17:401‐2. ">vs OLZ ‐ Luo 2007</a>). There was no significant difference between chlorpromazine and olanzapine (MD −0.01, 95% CI −0.31 to 0.29; <a href="./references#CD010631-fig-0021" title="">Analysis 1.17</a>). </p> </section> <section id="CD010631-sec-0256"> <h6 class="title">1.17.4 low‐density lipoprotein (LDL) ‐ medium term (7 to 12 months)</h6> <p>In this subgroup we only found one relevant trial (N = 50) (<a href="./references#CD010631-bbs2-0008" title="LuoC , YangJW , RenJP . Comparative study of the effect of olanzapine on serum lipid in schizophrenia. Journal of Clinical Psychiatric Medicine2007;17:401‐2. ">vs OLZ ‐ Luo 2007</a>). There was no significant difference between chlorpromazine and olanzapine (MD 0.06, 95% CI −0.41 to 0.53; <a href="./references#CD010631-fig-0020" title="">Analysis 1.16</a>). </p> </section> </section> <section id="CD010631-sec-0257"> <h5 class="title">1.18 Adverse effects: 7d. Metabolic ‐ other ‐ average endpoint scores ‐ skewed data</h5> <p>Data for endpoint scores in cholesterol, high‐density lipoprotein and triglyceride are skewed and are best inspected by viewing <a href="./references#CD010631-fig-0022" title="">Analysis 1.18</a>. </p> </section> <section id="CD010631-sec-0258"> <h5 class="title">1.19 Adverse effects: 8a. Movement disorders ‐ extrapyramidal symptoms ‐ short term (up to 6 months) </h5> <section id="CD010631-sec-0259"> <h6 class="title">1.19.1 akathisia</h6> <p>In this subgroup we found three relevant trials (N = 417). There was no significant difference between chlorpromazine and olanzapine (RR 1.86, 95% CI 0.29 to 11.84; <a href="./references#CD010631-fig-0023" title="">Analysis 1.19</a>). This subgroup had important levels of heterogeneity (Chi² test = 5.51; df = 2; P = 0.064; I² statistic = 64%). </p> </section> <section id="CD010631-sec-0260"> <h6 class="title">1.19.2 any EPS symptoms</h6> <p>In this subgroup we found two relevant trials (N = 298). There was a statistically significant difference in favour of olanzapine (RR 34.47, 95% CI 4.79 to 248.3; P = 0.0004; <a href="./references#CD010631-fig-0023" title="">Analysis 1.19</a>). </p> </section> <section id="CD010631-sec-0261"> <h6 class="title">1.19.3 muscle stiffness</h6> <p>In this subgroup we found two relevant trials (N = 180). There was no significant difference between chlorpromazine and olanzapine (RR 6.13, 95% CI 0.73 to 51.45; <a href="./references#CD010631-fig-0023" title="">Analysis 1.19</a>). </p> </section> <section id="CD010631-sec-0262"> <h6 class="title">1.19.4 tremor</h6> <p>In this subgroup we found two relevant trials (N = 180). There was no significant difference between chlorpromazine and olanzapine (RR 6.78, 95% CI 0.84 to 54.57; <a href="./references#CD010631-fig-0023" title="">Analysis 1.19</a>). </p> </section> </section> <section id="CD010631-sec-0263"> <h5 class="title">1.20 Adverse effects: 8b. Movement disorders ‐ extrapyramidal symptoms ‐ average endpoint score (ESRS, high = poor) </h5> <section id="CD010631-sec-0264"> <h6 class="title">1.20.1 short term (up to 6 months)</h6> <p>We included two relevant trials in this subgroup (N = 80). There was a statistically significant difference in favour of olanzapine (MD 0.9, 95% CI 0.14 to 1.66; P = 0.02; <a href="./references#CD010631-fig-0024" title="">Analysis 1.20</a>) </p> </section> </section> <section id="CD010631-sec-0265"> <h5 class="title">1.21 Adverse effects: 9a. Various other ‐ sleep ‐ average endpoint score (LSEQ, high = better) ‐ short term (up to 6 months) </h5> <section id="CD010631-sec-0266"> <h6 class="title">1.21.1 awaking from sleep</h6> <p>We found only one relevant trial in this subgroup (N = 30) (<a href="./references#CD010631-bbs2-0001" title="DossenbachM . Sleep quality and early morning wakefulness of schizophrenic patients treated with olanzapine compared to chlorpromazine. European Neuropsychopharmacology2000;10(Supplement 3):S328‐9. EliLilly , Company . Study F1D‐VI‐HGCQ olanzapine versus chlorpromazine in Turkey. Unpublished document internal to Eli‐Lilly2000:1‐560. KostakogluE , AlptekinK , KivicikBB , MartenyiF , TuncaZ , GogusA , et al. Sleep quality and early morning wakefulness of schizophrenia patients treated with olanzapine compared to chlorpromazine [Errata]. European Neuropsychopharmacology2001;11(Suppl 3):S369. MrazK , GogusA , TuncaZ , MartenyiF , DossenbachM . Olanzapine versus chlorpromazine in Turkey. Schizophrenia Research (Abstracts of the Winter Workshop on Schizophrenia; February 5‐11, 2000; Davos, Switzerland). 2000. ">HGCQ (Turkey) 2000</a>). There was no significant difference between chlorpromazine and olanzapine (MD −5.30, 95% CI −21.91 to 11.31; <a href="./references#CD010631-fig-0025" title="">Analysis 1.21</a>). </p> </section> <section id="CD010631-sec-0267"> <h6 class="title">1.21.2 getting to sleep score</h6> <p>In this subgroup we only found one relevant trial (N = 30) (<a href="./references#CD010631-bbs2-0001" title="DossenbachM . Sleep quality and early morning wakefulness of schizophrenic patients treated with olanzapine compared to chlorpromazine. European Neuropsychopharmacology2000;10(Supplement 3):S328‐9. EliLilly , Company . Study F1D‐VI‐HGCQ olanzapine versus chlorpromazine in Turkey. Unpublished document internal to Eli‐Lilly2000:1‐560. KostakogluE , AlptekinK , KivicikBB , MartenyiF , TuncaZ , GogusA , et al. Sleep quality and early morning wakefulness of schizophrenia patients treated with olanzapine compared to chlorpromazine [Errata]. European Neuropsychopharmacology2001;11(Suppl 3):S369. MrazK , GogusA , TuncaZ , MartenyiF , DossenbachM . Olanzapine versus chlorpromazine in Turkey. Schizophrenia Research (Abstracts of the Winter Workshop on Schizophrenia; February 5‐11, 2000; Davos, Switzerland). 2000. ">HGCQ (Turkey) 2000</a>). There was no significant difference between chlorpromazine and olanzapine (MD −0.60, 95% CI −19.88 to 18.68; <a href="./references#CD010631-fig-0025" title="">Analysis 1.21</a>). </p> </section> <section id="CD010631-sec-0268"> <h6 class="title">1.21.3 quality of sleep</h6> <p>In this subgroup we only found one relevant trial (N = 30) (<a href="./references#CD010631-bbs2-0001" title="DossenbachM . Sleep quality and early morning wakefulness of schizophrenic patients treated with olanzapine compared to chlorpromazine. European Neuropsychopharmacology2000;10(Supplement 3):S328‐9. EliLilly , Company . Study F1D‐VI‐HGCQ olanzapine versus chlorpromazine in Turkey. Unpublished document internal to Eli‐Lilly2000:1‐560. KostakogluE , AlptekinK , KivicikBB , MartenyiF , TuncaZ , GogusA , et al. Sleep quality and early morning wakefulness of schizophrenia patients treated with olanzapine compared to chlorpromazine [Errata]. European Neuropsychopharmacology2001;11(Suppl 3):S369. MrazK , GogusA , TuncaZ , MartenyiF , DossenbachM . Olanzapine versus chlorpromazine in Turkey. Schizophrenia Research (Abstracts of the Winter Workshop on Schizophrenia; February 5‐11, 2000; Davos, Switzerland). 2000. ">HGCQ (Turkey) 2000</a>). There was no significant difference between chlorpromazine and olanzapine (MD −15.00, 95% CI −33.07 to 3.07; <a href="./references#CD010631-fig-0025" title="">Analysis 1.21</a>). </p> </section> </section> <section id="CD010631-sec-0269"> <h5 class="title">1.22 Adverse effects: 9b. Various other ‐ sleep ‐ average length of sleep (hour/day)</h5> <section id="CD010631-sec-0270"> <h6 class="title">1.22.1 short term (up to 6 months)</h6> <p>We found one trial in this subgroup (N = 50) (<a href="./references#CD010631-bbs2-0008" title="LuoC , YangJW , RenJP . Comparative study of the effect of olanzapine on serum lipid in schizophrenia. Journal of Clinical Psychiatric Medicine2007;17:401‐2. ">vs OLZ ‐ Luo 2007</a>). There was a statistically significant difference in favour of olanzapine (MD 3.63, 95% CI 2.08 to 5.18; P &lt; 0.00001; <a href="./references#CD010631-fig-0026" title="">Analysis 1.22</a>). </p> </section> <section id="CD010631-sec-0271"> <h6 class="title">1.22.2 medium term (7 to 12 months)</h6> <p>In this subgroup we only found one relevant trial (N = 50) (<a href="./references#CD010631-bbs2-0008" title="LuoC , YangJW , RenJP . Comparative study of the effect of olanzapine on serum lipid in schizophrenia. Journal of Clinical Psychiatric Medicine2007;17:401‐2. ">vs OLZ ‐ Luo 2007</a>). There was a statistically significant difference in favour of olanzapine (MD 4.41, 95% CI 2.82 to 6.00; P &lt; 0.00001; <a href="./references#CD010631-fig-0026" title="">Analysis 1.22</a>). </p> </section> </section> <section id="CD010631-sec-0272"> <h5 class="title">1.23 Adverse effects: 9c. Various other ‐ sleep ‐ average score ‐ behaviour following waking ‐ skewed data </h5> <p>Data for this study are skewed and are best inspected by viewing <a href="./references#CD010631-fig-0027" title="">Analysis 1.23</a>. </p> </section> <section id="CD010631-sec-0273"> <h5 class="title">1.24 Adverse effects: 9d. Various other ‐ rash</h5> <section id="CD010631-sec-0274"> <h6 class="title">1.24.1 short term (up to 6 months)</h6> <p>We included one relevant trial in this subgroup (N = 30) (<a href="./references#CD010631-bbs2-0001" title="DossenbachM . Sleep quality and early morning wakefulness of schizophrenic patients treated with olanzapine compared to chlorpromazine. European Neuropsychopharmacology2000;10(Supplement 3):S328‐9. EliLilly , Company . Study F1D‐VI‐HGCQ olanzapine versus chlorpromazine in Turkey. Unpublished document internal to Eli‐Lilly2000:1‐560. KostakogluE , AlptekinK , KivicikBB , MartenyiF , TuncaZ , GogusA , et al. Sleep quality and early morning wakefulness of schizophrenia patients treated with olanzapine compared to chlorpromazine [Errata]. European Neuropsychopharmacology2001;11(Suppl 3):S369. MrazK , GogusA , TuncaZ , MartenyiF , DossenbachM . Olanzapine versus chlorpromazine in Turkey. Schizophrenia Research (Abstracts of the Winter Workshop on Schizophrenia; February 5‐11, 2000; Davos, Switzerland). 2000. ">HGCQ (Turkey) 2000</a>). There was no significant difference between chlorpromazine and olanzapine (RR 2.00, 95% CI 0.14 to 28.76; <a href="./references#CD010631-fig-0028" title="">Analysis 1.24</a>). </p> </section> </section> <section id="CD010631-sec-0275"> <h5 class="title">1.25 Quality of life: 1a. Average endpoint scores (various scales, high = better) ‐ short term (up to 6 months) </h5> <section id="CD010631-sec-0276"> <h6 class="title">1.25.1 GQOLI ‐ living condition</h6> <p>In this subgroup we only found one relevant trial (N = 61) (<a href="./references#CD010631-bbs2-0012" title="ZhaoZ , YanF , FengY . A comparative study on olanzapine and chlorpromazine in the treatment of schizophrenia. China Journal of Health Psychology2006;14:41‐2. ">vs OLZ ‐ Zhao 2006</a>). There was no significant difference between chlorpromazine and olanzapine (MD −1.00, 95% CI −4.21 to 2.21; <a href="./references#CD010631-fig-0029" title="">Analysis 1.25</a>). </p> </section> <section id="CD010631-sec-0277"> <h6 class="title">1.25.2 GQOLI ‐ physical health</h6> <p>In this subgroup we only found one relevant trial (N = 61) (<a href="./references#CD010631-bbs2-0012" title="ZhaoZ , YanF , FengY . A comparative study on olanzapine and chlorpromazine in the treatment of schizophrenia. China Journal of Health Psychology2006;14:41‐2. ">vs OLZ ‐ Zhao 2006</a>). There was a statistically significant difference in favour of olanzapine (MD −10.10, 95% CI −13.93 to −6.27; P &lt; 0.00001; <a href="./references#CD010631-fig-0029" title="">Analysis 1.25</a>). </p> </section> <section id="CD010631-sec-0278"> <h6 class="title">1.25.3 GQOLI ‐ psychological health</h6> <p>In this subgroup we only found one relevant trial (N = 61) (<a href="./references#CD010631-bbs2-0012" title="ZhaoZ , YanF , FengY . A comparative study on olanzapine and chlorpromazine in the treatment of schizophrenia. China Journal of Health Psychology2006;14:41‐2. ">vs OLZ ‐ Zhao 2006</a>). There was a statistically significant difference in favour of olanzapine (MD −22.60, 95% CI −25.94 to −19.26; P &lt; 0.00001; <a href="./references#CD010631-fig-0029" title="">Analysis 1.25</a>). </p> </section> <section id="CD010631-sec-0279"> <h6 class="title">1.25.4 GQOLI ‐ social function</h6> <p>In this subgroup we only found one relevant trial (N = 61) (<a href="./references#CD010631-bbs2-0012" title="ZhaoZ , YanF , FengY . A comparative study on olanzapine and chlorpromazine in the treatment of schizophrenia. China Journal of Health Psychology2006;14:41‐2. ">vs OLZ ‐ Zhao 2006</a>). There was a statistically significant difference in favour of olanzapine (MD −18.20, 95% CI −20.51 to −15.89; P &lt; 0.00001; <a href="./references#CD010631-fig-0029" title="">Analysis 1.25</a>). </p> </section> </section> <section id="CD010631-sec-0280"> <h5 class="title">1.26 Quality of life: 1b. Average endpoint score (QoL, high = better) ‐ skewed data</h5> <p>Data for this outcome are skewed, and are best inspected by viewing Analysis 1.25.</p> </section> <section id="CD010631-sec-0281"> <h5 class="title">1.27 Leaving the study early ‐ short term (up to 6 months)</h5> <section id="CD010631-sec-0282"> <h6 class="title">1.27.1 due to any reason</h6> <p>In this subgroup we found three relevant trials (N = 139). There was no significant difference between chlorpromazine and olanzapine (RR 1.69, 95% CI 0.45 to 6.40; <a href="./references#CD010631-fig-0031" title="">Analysis 1.27</a>). This subgroup had moderate levels of heterogeneity (Chi² test = 3.64; df = 2; P = 0.162; I² statistic = 45%). </p> </section> <section id="CD010631-sec-0283"> <h6 class="title">1.27.2 due to lack of efficacy</h6> <p>In this subgroup we found two relevant trials (N = 71). There was no significant difference between chlorpromazine and olanzapine (RR 0.47, 95% CI 0.08 to 2.66; <a href="./references#CD010631-fig-0031" title="">Analysis 1.27</a>). </p> </section> </section> </section> <section id="CD010631-sec-0284"> <h4 class="title">Comparison 2: CHLORPROMAZINE versus RISPERIDONE</h4> <section id="CD010631-sec-0285"> <h5 class="title">2.1 Clinical response: 1. No significant clinical response</h5> <section id="CD010631-sec-0286"> <h6 class="title">2.1.1 short term (up to 6 months)</h6> <p>In this subgroup we found seven relevant trials (N = 475). There was no significant difference between chlorpromazine and risperidone (RR 0.84, 95% CI 0.53 to 1.34; <a href="./references#CD010631-fig-0032" title="">Analysis 2.1</a>). </p> </section> </section> <section id="CD010631-sec-0287"> <h5 class="title">2.2 Global state: 1. Average endpoint score (CGI‐CI, high = poor) ‐ skewed data</h5> <p>Data for this outcome are skewed and are best inspected by viewing <a href="./references#CD010631-fig-0033" title="">Analysis 2.2</a>. </p> </section> <section id="CD010631-sec-0288"> <h5 class="title">2.3 Global state: 2. Need of additional benzhexol</h5> <section id="CD010631-sec-0289"> <h6 class="title">2.3.1 short term (up to 6 months)</h6> <p>We included two trials in this subgroup (N = 137). There was no significant difference between chlorpromazine and risperidone (RR 1.20, 95% CI 0.26 to 5.53; <a href="./references#CD010631-fig-0034" title="">Analysis 2.3</a>). This subgroup had important levels of heterogeneity (Chi² test = 2.36; df = 1; P = 0.124; I² statistic = 58%). </p> </section> </section> <section id="CD010631-sec-0290"> <h5 class="title">2.4 Mental state: 1a. Average endpoint score (various scales, high = poor) short term (up to 6 months) </h5> <section id="CD010631-sec-0291"> <h6 class="title">2.4.1 BPRS total</h6> <p>In this subgroup we found four relevant trials (N = 247). There was no significant difference between chlorpromazine and risperidone (MD 0.90, 95% CI −3.49 to 5.28; <a href="./references#CD010631-fig-0035" title="">Analysis 2.4</a>). This subgroup had important levels of heterogeneity (Chi² test = 14.61; df = 3; P = 0.002; I² statistic = 79%). </p> </section> <section id="CD010631-sec-0292"> <h6 class="title">2.4.2 BPRS activation subscale</h6> <p>In this subgroup we found two relevant trials (N = 130). There was no significant difference between chlorpromazine and risperidone (MD 0.41, 95% CI −0.81 to 1.63; <a href="./references#CD010631-fig-0035" title="">Analysis 2.4</a>). This subgroup had important levels of heterogeneity (Chi² test = 4.41; df = 1; P = 0.036; I² statistic = 77%). </p> </section> <section id="CD010631-sec-0293"> <h6 class="title">2.4.3 BPRS anxiety‐depression subscale</h6> <p>In this subgroup we found two relevant trials (N = 130). There was no significant difference between chlorpromazine and risperidone (MD 0.09, 95% CI −1.56 to 1.73; <a href="./references#CD010631-fig-0035" title="">Analysis 2.4</a>). This subgroup had important levels of heterogeneity (Chi² test = 11.14; df = 1; P = 0.001; I² statistic = 91%). </p> </section> <section id="CD010631-sec-0294"> <h6 class="title">2.4.4 BPRS hostile‐suspiciousness subscale</h6> <p>We found two relevant trials in this subgroup (N = 130). There was no significant difference between chlorpromazine and risperidone groups (MD 0.89, 95% CI −1.41 to 3.18; <a href="./references#CD010631-fig-0035" title="">Analysis 2.4</a>). This subgroup had important levels of heterogeneity (Chi² test = 12.36; df = 1; P = 0.0; I² statistic = 92%). </p> </section> <section id="CD010631-sec-0295"> <h6 class="title">2.4.5 NORS total</h6> <p>In this subgroup we only found one relevant trial (N = 39) (<a href="./references#CD010631-bbs2-0061" title="HeM , FengY , ChenR . A controlled comparative study on risperidone and chlorpromazine in treatment of schizophrenia. Chinese New Drugs Journal1999;8:185‐7. ">vs RPD ‐ He 1999</a>). There was no significant difference between chlorpromazine and risperidone (MD 1.80, 95% CI −2.53 to 6.13; <a href="./references#CD010631-fig-0035" title="">Analysis 2.4</a>). </p> </section> <section id="CD010631-sec-0296"> <h6 class="title">2.4.6 PANSS total</h6> <p>In this subgroup we found five relevant trials (N = 397). There was no significant difference between chlorpromazine and risperidone (MD −1.95, 95% CI −5.58 to 1.69; <a href="./references#CD010631-fig-0035" title="">Analysis 2.4</a>). This subgroup had important levels of heterogeneity (Chi² test = 8.7; df = 4; P = 0.069; I² statistic = 54%). </p> </section> <section id="CD010631-sec-0297"> <h6 class="title">2.4.7 PANSS positive symptom subscale</h6> <p>In this subgroup we found four relevant trials (N = 337). There was no significant difference between chlorpromazine and risperidone (MD 0.03, 95% CI −1.67 to 1.74; <a href="./references#CD010631-fig-0035" title="">Analysis 2.4</a>). This subgroup had important levels of heterogeneity (Chi² test = 11.12; df = 3; P = 0.011; I² statistic = 73%). </p> </section> <section id="CD010631-sec-0298"> <h6 class="title">2.4.8 PANSS negative symptom subscale</h6> <p>We found three relevant trials in this subgroup (N = 230). There was no significant difference between chlorpromazine and risperidone (MD 3.16, 95% CI −1.57 to 7.89; <a href="./references#CD010631-fig-0035" title="">Analysis 2.4</a>). This subgroup had important levels of heterogeneity (Chi² test = 40.11; df = 2; P = 0.0; I² statistic = 95%). </p> </section> <section id="CD010631-sec-0299"> <h6 class="title">2.4.9 PANSS general pathology subscale</h6> <p>In this subgroup we found three relevant trials (N = 267). There was no significant difference between chlorpromazine and risperidone (MD −0.85, 95% CI −2.15 to 0.46; <a href="./references#CD010631-fig-0035" title="">Analysis 2.4</a>). </p> </section> <section id="CD010631-sec-0300"> <h6 class="title">2.4.10 SANS total</h6> <p>In this subgroup we found two relevant trials (N = 71). There was no significant difference between chlorpromazine and risperidone (MD 10.89, 95% CI −4.49 to 26.27; <a href="./references#CD010631-fig-0035" title="">Analysis 2.4</a>). This subgroup had important levels of heterogeneity (Chi² test = 13.51; df = 1; P = 0.0; I² statistic = 93%). </p> </section> </section> <section id="CD010631-sec-0301"> <h5 class="title">2.5 Mental state: 1b. Average endpoint score (various scales, high = poor) ‐ skewed data </h5> <p>Data for this outcome are skewed and are best inspected by viewing <a href="./references#CD010631-fig-0036" title="">Analysis 2.5</a>. </p> </section> <section id="CD010631-sec-0302"> <h5 class="title">2.6 Mental state: 2. Average change score ‐ decreased rate (various scales, high = poor) ‐ short term (up to 6 months) </h5> <section id="CD010631-sec-0303"> <h6 class="title">2.6.1 PANSS total</h6> <p>In this subgroup we only found one relevant trial (N = 57) (<a href="./references#CD010631-bbs2-0067" title="WangQ , JiaC . Controlled study of risperidone and chlorpromazine in the treatment of schizophrenia. Health Psychology Journal2002;10:226‐8. ">vs RPD ‐ Wang 2002</a>). There was no significant difference between chlorpromazine and risperidone (MD −0.11, 95% CI −0.23 to 0.01; <a href="./references#CD010631-fig-0037" title="">Analysis 2.6</a>). </p> </section> <section id="CD010631-sec-0304"> <h6 class="title">2.6.2 PANSS negative subscale</h6> <p>In this subgroup we only found one relevant trial (N = 57) (<a href="./references#CD010631-bbs2-0067" title="WangQ , JiaC . Controlled study of risperidone and chlorpromazine in the treatment of schizophrenia. Health Psychology Journal2002;10:226‐8. ">vs RPD ‐ Wang 2002</a>). There was no significant difference between chlorpromazine and risperidone (MD −0.21, 95% CI −0.44 to 0.02; <a href="./references#CD010631-fig-0037" title="">Analysis 2.6</a>). </p> </section> <section id="CD010631-sec-0305"> <h6 class="title">2.6.3 PANSS positive subscale</h6> <p>We only found one relevant trial in this subgroup (N = 57) (<a href="./references#CD010631-bbs2-0067" title="WangQ , JiaC . Controlled study of risperidone and chlorpromazine in the treatment of schizophrenia. Health Psychology Journal2002;10:226‐8. ">vs RPD ‐ Wang 2002</a>). There was no significant difference between chlorpromazine and risperidone (MD −0.07, 95% CI −0.36 to 0.22; <a href="./references#CD010631-fig-0037" title="">Analysis 2.6</a>). </p> </section> </section> <section id="CD010631-sec-0306"> <h5 class="title">2.7 Functioning: average endpoint score (WCST subscales, high = good) ‐ short term (up to 6 months) </h5> <section id="CD010631-sec-0307"> <h6 class="title">2.7.1 WCST‐IQ</h6> <p>In this subgroup we only found one relevant trial (N = 100) (<a href="./references#CD010631-bbs2-0068" title="WangX , HuX , YangJ . Effect of chlorpromazine and risperidone on cognitive function of the patients with first episode schizophrenia. Chinese Journal of Health Psychology2005;13:342‐4. ">vs RPD ‐ Wang 2005</a>). There was a statistically significant difference in favour of risperidone (MD −11.30, 95% CI −18.34 to −4.26; P = 0.002; <a href="./references#CD010631-fig-0038" title="">Analysis 2.7</a>). </p> </section> <section id="CD010631-sec-0308"> <h6 class="title">2.7.2 WCST‐MQ</h6> <p>We only found one relevant trial in this subgroup (N = 100) (<a href="./references#CD010631-bbs2-0068" title="WangX , HuX , YangJ . Effect of chlorpromazine and risperidone on cognitive function of the patients with first episode schizophrenia. Chinese Journal of Health Psychology2005;13:342‐4. ">vs RPD ‐ Wang 2005</a>). There was a statistically significant difference in favour of risperidone (MD −19.6, 95% CI −28.83 to −10.37; P &lt; 0.0001; <a href="./references#CD010631-fig-0038" title="">Analysis 2.7</a>). </p> </section> </section> <section id="CD010631-sec-0309"> <h5 class="title">2.8 Adverse effects: 1. Anticholinergic ‐ short term (up to 6 months)</h5> <section id="CD010631-sec-0310"> <h6 class="title">2.8.1 blurred vision</h6> <p>In this subgroup we found five relevant trials (N = 387). There was a statistically significant difference in favour of risperidone (RR 2.44, 95% CI 1.32 to 4.50; P = 0.004; <a href="./references#CD010631-fig-0039" title="">Analysis 2.8</a>). </p> </section> <section id="CD010631-sec-0311"> <h6 class="title">2.8.2 dry mouth</h6> <p>There were nine relevant trials in this subgroup (N = 852). There was no significant difference between chlorpromazine and risperidone (RR 2.00, 95% CI 0.88 to 4.51; <a href="./references#CD010631-fig-0039" title="">Analysis 2.8</a>). This subgroup had important levels of heterogeneity (Chi² test = 28.49; df = 8; P = 0.0; I² statistic = 72%). </p> </section> <section id="CD010631-sec-0312"> <h6 class="title">2.8.3 excessive sweating</h6> <p>In this subgroup we found two relevant trials (N = 180). There was no significant difference between chlorpromazine and risperidone (RR 3.00, 95% CI 0.62 to 14.46; <a href="./references#CD010631-fig-0039" title="">Analysis 2.8</a>). </p> </section> <section id="CD010631-sec-0313"> <h6 class="title">2.8.4 hypersalivation</h6> <p>In this subgroup we found five relevant trials (N = 373). There was a statistically significant difference in favour of risperidone (RR 8.67, 95% CI 3.80 to 19.8; P &lt; 0.00001; <a href="./references#CD010631-fig-0039" title="">Analysis 2.8</a>). </p> </section> <section id="CD010631-sec-0314"> <h6 class="title">2.8.5 stuffy nose</h6> <p>In this subgroup we only found one relevant trial (N = 80) (<a href="./references#CD010631-bbs2-0006" title="HeJ , AnQ . A comparative trial of olanzapine versus chlorpromazine in the treatment of schizophrenia. Shandong Mental Health Archive2003;16:78‐80. ">vs OLZ ‐ He 2003</a>). There was a statistically significant difference in favour of risperidone (RR 3.00, 95% CI 1.06 to 8.52; P = 0.04; <a href="./references#CD010631-fig-0039" title="">Analysis 2.8</a>). </p> </section> </section> <section id="CD010631-sec-0315"> <h5 class="title">2.9 Adverse effects: 2a. Cardiovascular ‐ short term (up to 6 months)</h5> <section id="CD010631-sec-0316"> <h6 class="title">2.9.1 abnormal ECG</h6> <p>In this subgroup we found three relevant trials (N = 229). There was no significant difference between chlorpromazine and risperidone (RR 2.41, 95% CI 0.96 to 6.06; <a href="./references#CD010631-fig-0040" title="">Analysis 2.9</a>). </p> </section> <section id="CD010631-sec-0317"> <h6 class="title">2.9.2 apathism</h6> <p>In this subgroup we only found one relevant trial (N = 100) (<a href="./references#CD010631-bbs2-0070" title="WuY , LuW , YiZ . A comparative study of risperidone and chlorpromazine on quality of life in patients with schizophrenia. Shandong Archive of Psychiatry2004;17:137‐40. ">vs RPD ‐ Wu 2004</a>). There was a statistically significant difference in favour of risperidone (RR 6.25, 95% CI 2.35 to 16.65; P = 0.0002; <a href="./references#CD010631-fig-0040" title="">Analysis 2.9</a>). </p> </section> <section id="CD010631-sec-0318"> <h6 class="title">2.9.3 bood pressure drop</h6> <p>In this subgroup we found three relevant trials (N = 250). There was a statistically significant difference in favour of risperidone (RR 8.25, 95% CI 2.61 to 26.12; P = 0.0003; <a href="./references#CD010631-fig-0040" title="">Analysis 2.9</a>). </p> </section> <section id="CD010631-sec-0319"> <h6 class="title">2.9.4 bradycardia</h6> <p>In this subgroup we only found one relevant trial (N = 100) (<a href="./references#CD010631-bbs2-0070" title="WuY , LuW , YiZ . A comparative study of risperidone and chlorpromazine on quality of life in patients with schizophrenia. Shandong Archive of Psychiatry2004;17:137‐40. ">vs RPD ‐ Wu 2004</a>). There was no significant difference between chlorpromazine and risperidone (RR 0.50, 95% CI 0.05 to 5.34; <a href="./references#CD010631-fig-0040" title="">Analysis 2.9</a>). </p> </section> <section id="CD010631-sec-0320"> <h6 class="title">2.9.5 orthostatic hypotension</h6> <p>In this subgroup we found five relevant trials (N = 546). There was a statistically significant difference in favour of risperidone (RR 5.74, 95% CI 2.28 to 14.44; P = 0.0002; <a href="./references#CD010631-fig-0040" title="">Analysis 2.9</a>). </p> </section> <section id="CD010631-sec-0321"> <h6 class="title">2.9.6 palpitation</h6> <p>We only found one relevant trial in this subgroup (N = 237) (<a href="./references#CD010631-bbs2-0010" title="WangQ , LiL , WangT . A comparative study of olanzapine in treatment of schizophrenia. Journal of Psychiatry2008;21:373‐5. ">vs OLZ ‐ Wang 2008</a>). There was a statistically significant difference in favour of risperidone (RR 40.66, 95% CI 2.49 to 664.56; P = 0.009; <a href="./references#CD010631-fig-0040" title="">Analysis 2.9</a>). </p> </section> <section id="CD010631-sec-0322"> <h6 class="title">2.9.7 sinus tachycardia</h6> <p>In this subgroup we only found one relevant trial (N = 51) (<a href="./references#CD010631-bbs2-0071" title="ZhengZS , HuangJM , YuXY . Efficacy of risperidone and chlorpromazine in the treatment of schizophrenia. Chinese Hospital Pharmacy Journal2001;21:99‐100. ">vs RPD ‐ Zheng 2001</a>). There was no significant difference between chlorpromazine and risperidone (RR 3.12, 95% CI 0.35 to 28.03; <a href="./references#CD010631-fig-0040" title="">Analysis 2.9</a>). </p> </section> <section id="CD010631-sec-0323"> <h6 class="title">2.9.8 tachycardia</h6> <p>In this subgroup we found seven relevant trials (N = 557). There was a statistically significant difference in favour of risperidone (RR 2.64, 95% CI 1.64 to 4.26; P ≤ 0.0001; <a href="./references#CD010631-fig-0040" title="">Analysis 2.9</a>). </p> </section> </section> <section id="CD010631-sec-0324"> <h5 class="title">2.10 Adverse effects: 2b. Cardiovascular ‐ continuous measures ‐ short term (up to 6 months) </h5> <section id="CD010631-sec-0325"> <h6 class="title">2.10.1 cardiac rate (upright position)</h6> <p>In this subgroup we only found one relevant trial (N = 100) (<a href="./references#CD010631-bbs2-0064" title="LiuGR , ZhangYH . Risperidone and chlorpromazine on schizophrenia blood pressure, heart rate. Occupation and Health2005;21:443‐5. ">vs RPD ‐ Liu 2005</a>). There was no significant difference between chlorpromazine and risperidone (MD 3.90, 95% CI −1.57 to 9.37; <a href="./references#CD010631-fig-0041" title="">Analysis 2.10</a>). </p> </section> <section id="CD010631-sec-0326"> <h6 class="title">2.10.2 cardiac rate (horizontal position)</h6> <p>In this subgroup we only found one relevant trial (N = 100) (<a href="./references#CD010631-bbs2-0064" title="LiuGR , ZhangYH . Risperidone and chlorpromazine on schizophrenia blood pressure, heart rate. Occupation and Health2005;21:443‐5. ">vs RPD ‐ Liu 2005</a>). There was a statistically significant difference in favour of risperidone (MD 7.42, 95% CI 3.47 to 11.37; P = 0.0002; <a href="./references#CD010631-fig-0041" title="">Analysis 2.10</a>). </p> </section> <section id="CD010631-sec-0327"> <h6 class="title">2.10.3 contractive blood pressure (upright position)</h6> <p>In this subgroup we only found one relevant trial (N = 100) (<a href="./references#CD010631-bbs2-0064" title="LiuGR , ZhangYH . Risperidone and chlorpromazine on schizophrenia blood pressure, heart rate. Occupation and Health2005;21:443‐5. ">vs RPD ‐ Liu 2005</a>). There was no significant difference between chlorpromazine and risperidone (MD −1.06, 95% CI −2.20 to 0.08; <a href="./references#CD010631-fig-0041" title="">Analysis 2.10</a>). </p> </section> <section id="CD010631-sec-0328"> <h6 class="title">2.10.4 ontractive blood pressure (horizontal position)</h6> <p>In this subgroup we only found one relevant trial (N = 100) (<a href="./references#CD010631-bbs2-0064" title="LiuGR , ZhangYH . Risperidone and chlorpromazine on schizophrenia blood pressure, heart rate. Occupation and Health2005;21:443‐5. ">vs RPD ‐ Liu 2005</a>). There was a statistically significant difference in favour of risperidone (MD 1.38, 95% CI 0.61 to 2.15; P = 0.0005; <a href="./references#CD010631-fig-0041" title="">Analysis 2.10</a>). </p> </section> <section id="CD010631-sec-0329"> <h6 class="title">2.10.5 diastolic blood pressure (upright position)</h6> <p>In this subgroup we only found one relevant trial (N = 100) (<a href="./references#CD010631-bbs2-0064" title="LiuGR , ZhangYH . Risperidone and chlorpromazine on schizophrenia blood pressure, heart rate. Occupation and Health2005;21:443‐5. ">vs RPD ‐ Liu 2005</a>). There was no significant difference between chlorpromazine and risperidone (MD −0.53, 95% CI −1.29 to 0.23; <a href="./references#CD010631-fig-0041" title="">Analysis 2.10</a>). </p> </section> <section id="CD010631-sec-0330"> <h6 class="title">2.10.6 diastolic blood pressure (horizontal position)</h6> <p>We only found one relevant trial in this subgroup (N = 100) (<a href="./references#CD010631-bbs2-0064" title="LiuGR , ZhangYH . Risperidone and chlorpromazine on schizophrenia blood pressure, heart rate. Occupation and Health2005;21:443‐5. ">vs RPD ‐ Liu 2005</a>). There was no significant difference between chlorpromazine and risperidone (MD 0.39, 95% CI −0.18 to 0.96; <a href="./references#CD010631-fig-0041" title="">Analysis 2.10</a>). </p> </section> </section> <section id="CD010631-sec-0331"> <h5 class="title">2.11 Adverse effects: 3. Central nervous system ‐ short term (up to 6 months)</h5> <section id="CD010631-sec-0332"> <h6 class="title">2.11.1 agitation</h6> <p>In this subgroup we only found one relevant trial (N = 65) (<a href="./references#CD010631-bbs2-0060" title="FengYX , SunF . A comparative study on the effects of risperidone and chlorpromazine upon the life quality of patients with schizophrenia. Health Psychology Journal2003;11:117‐8. ">vs RPD ‐ Feng 2003</a>). There was no significant difference between chlorpromazine and risperidone (RR 0.32, 95% CI 0.01 to 7.66; <a href="./references#CD010631-fig-0042" title="">Analysis 2.11</a>). </p> </section> <section id="CD010631-sec-0333"> <h6 class="title">2.11.2 dizziness</h6> <p>We found four relevant trials in this subgroup (N = 299). There was a statistically significant difference between chlorpromazine and risperidone (RR 2.37, 95% CI 1.38 to 4.07; <a href="./references#CD010631-fig-0042" title="">Analysis 2.11</a>). </p> </section> <section id="CD010631-sec-0334"> <h6 class="title">2.11.3 drowsiness</h6> <p>In this subgroup we found four relevant trials (N = 307). There was a statistically significant difference in favour of risperidone (RR 3.62, 95% CI 1.56 to 8.39; P = 0.003; <a href="./references#CD010631-fig-0042" title="">Analysis 2.11</a>). This subgroup had moderate levels of heterogeneity (Chi² test = 5.14; df = 3; P = 0.162; I² statistic = 42%). </p> </section> <section id="CD010631-sec-0335"> <h6 class="title">2.11.4 fatigue</h6> <p>We only found one relevant trial in this subgroup (N = 100) (<a href="./references#CD010631-bbs2-0070" title="WuY , LuW , YiZ . A comparative study of risperidone and chlorpromazine on quality of life in patients with schizophrenia. Shandong Archive of Psychiatry2004;17:137‐40. ">vs RPD ‐ Wu 2004</a>). There was a statistically significant difference in favour of risperidone (RR 2.69, 95% CI 1.77 to 4.09; P &lt; 0.00001; <a href="./references#CD010631-fig-0042" title="">Analysis 2.11</a>). </p> </section> <section id="CD010631-sec-0336"> <h6 class="title">2.11.4 insomnia</h6> <p>In this subgroup we found five relevant trials (N = 342). There was a statistically significant difference in favour of chlorpromazine (RR 0.33, 95% CI 0.12 to 0.91; P = 0.03; <a href="./references#CD010631-fig-0042" title="">Analysis 2.11</a>). </p> </section> <section id="CD010631-sec-0337"> <h6 class="title">2.11.5 reduced activity</h6> <p>We only found one relevant trial in this subgroup (N = 78) (<a href="./references#CD010631-bbs2-0066" title="MaZ H , LiuA Y , ZhouC M , ZhangZ . A comparative study of risperidone and chlorpromazine in the treatment of schizophrenia. Medical Journal of Chinese People Health2004;16:202‐4. ">vs RPD ‐ Ma 2004</a>). There was no significant difference between chlorpromazine and risperidone (RR 2.00, 95% CI 0.19 to 21.16; <a href="./references#CD010631-fig-0042" title="">Analysis 2.11</a>). </p> </section> </section> <section id="CD010631-sec-0338"> <h5 class="title">2.12 Adverse effects: 4. Gastrointestinal‐ short term (up to 6 months)</h5> <section id="CD010631-sec-0339"> <h6 class="title">2.12.1 constipation</h6> <p>In this subgroup we found nine relevant trials (N = 868). There was a statistically significant difference in favour of risperidone (RR 3.00, 95% CI 2.05 to 4.39; P &lt; 0.00001; <a href="./references#CD010631-fig-0043" title="">Analysis 2.12</a>). </p> </section> <section id="CD010631-sec-0340"> <h6 class="title">2.12.2 diarrhoea</h6> <p>In this subgroup we only found one relevant trial (N = 80) (<a href="./references#CD010631-bbs2-0006" title="HeJ , AnQ . A comparative trial of olanzapine versus chlorpromazine in the treatment of schizophrenia. Shandong Mental Health Archive2003;16:78‐80. ">vs OLZ ‐ He 2003</a>). There was no significant difference between chlorpromazine and risperidone (RR 5.00, 95% CI 0.25 to 100.97; <a href="./references#CD010631-fig-0043" title="">Analysis 2.12</a>). </p> </section> <section id="CD010631-sec-0341"> <h6 class="title">2.12.3 dysphagia</h6> <p>In this subgroup we only found one relevant trial (N = 100) (<a href="./references#CD010631-bbs2-0070" title="WuY , LuW , YiZ . A comparative study of risperidone and chlorpromazine on quality of life in patients with schizophrenia. Shandong Archive of Psychiatry2004;17:137‐40. ">vs RPD ‐ Wu 2004</a>). There was a statistically significant difference (P = 0.04) in favour of risperidone (RR 3.67, 95% CI 1.09 to 12.36; <a href="./references#CD010631-fig-0043" title="">Analysis 2.12</a>). </p> </section> <section id="CD010631-sec-0342"> <h6 class="title">2.12.4 loss of appetite</h6> <p>In this subgroup we found two relevant trials (N = 180). There was a statistically significant difference in favour of risperidone (RR 11.01, 95% CI 2.82 to 42.94; P = 0.0006; <a href="./references#CD010631-fig-0043" title="">Analysis 2.12</a>). This subgroup had moderate levels of heterogeneity (Chi² test = 1.78; df = 1; P = 0.182; I² statistic = 44%). </p> </section> <section id="CD010631-sec-0343"> <h6 class="title">2.12.5 nausea/vomiting</h6> <p>We found four relevant trials in this subgroup (N = 350). There was no significant difference between chlorpromazine and risperidone (RR 0.85, 95% CI 0.37 to 1.91; <a href="./references#CD010631-fig-0043" title="">Analysis 2.12</a>). </p> </section> </section> <section id="CD010631-sec-0344"> <h5 class="title">2.13 Adverse effects: 5. Haematology ‐ short term (up to 6 months)</h5> <section id="CD010631-sec-0345"> <h6 class="title">2.13.1 Abnormal haemogram</h6> <p>In this subgroup we found two relevant trials (N = 180). There was no significant difference between chlorpromazine and risperidone (RR 4.00, 95% CI 0.87 to 18.31; <a href="./references#CD010631-fig-0044" title="">Analysis 2.13</a>). </p> </section> <section id="CD010631-sec-0346"> <h6 class="title">2.13.2 leukopenia</h6> <p>We only found one relevant trial in this subgroup (N = 86) (<a href="./references#CD010631-bbs2-0005" title="ChenF . Olanzapine and chlorpromazine in the treatment of schizophrenia. Journal of Clinical Psychiatric Medicine2006;16:303‐4. ">vs OLZ ‐ Chen 2006</a>). There was no significant difference between chlorpromazine and risperidone (RR 6.69, 95% CI 0.36 to 125.71; <a href="./references#CD010631-fig-0044" title="">Analysis 2.13</a>). </p> </section> </section> <section id="CD010631-sec-0347"> <h5 class="title">2.14 Adverse effects: 6. Hepatitic ‐ short term (up to 6 months)</h5> <section id="CD010631-sec-0348"> <h6 class="title">2.14.1 abnormal liver function ‐ short term (up to six months)</h6> <p>In this subgroup we only found one relevant trial (N = 78) (<a href="./references#CD010631-bbs2-0066" title="MaZ H , LiuA Y , ZhouC M , ZhangZ . A comparative study of risperidone and chlorpromazine in the treatment of schizophrenia. Medical Journal of Chinese People Health2004;16:202‐4. ">vs RPD ‐ Ma 2004</a>). There was no significant difference between chlorpromazine and risperidone (RR 5.00, 95% CI 0.25 to 100.89; <a href="./references#CD010631-fig-0045" title="">Analysis 2.14</a>). </p> </section> <section id="CD010631-sec-0349"> <h6 class="title">2.14.2 abnormal transaminase ‐ short term (up to six months)</h6> <p>We found three relevant trials in this subgroup (N = 229). There was no significant difference between chlorpromazine and risperidone (RR 0.88, 95% CI 0.07 to 11.58; <a href="./references#CD010631-fig-0045" title="">Analysis 2.14</a>). This subgroup had important levels of heterogeneity (Chi² test = 6.3; df = 2; P = 0.043; I² statistic = 68%). </p> </section> </section> <section id="CD010631-sec-0350"> <h5 class="title">2.15 Adverse effects: 7. Metabolic ‐ weight gain</h5> <section id="CD010631-sec-0351"> <h6 class="title">2.15.1 short term (up to six months)</h6> <p>In this subgroup we found four relevant trials (N = 302). There was no significant difference between chlorpromazine and risperidone (RR 1.36, 95% CI 0.52 to 3.59; <a href="./references#CD010631-fig-0046" title="">Analysis 2.15</a>). This subgroup had important levels of heterogeneity (Chi² test = 6.75; df = 3; P = 0.08; I² statistic = 56%). </p> </section> </section> <section id="CD010631-sec-0352"> <h5 class="title">2.16 Adverse effects: 8. Movement disorders ‐ short term (up to 6 months)</h5> <section id="CD010631-sec-0353"> <h6 class="title">2.16.1 akathisia</h6> <p>In this subgroup we found six relevant trials (N = 435). There was a statistically significant difference in favour of risperidone (RR 2.37, 95% CI 1.46 to 3.85; P = 0.0005; <a href="./references#CD010631-fig-0047" title="">Analysis 2.16</a>). </p> </section> <section id="CD010631-sec-0354"> <h6 class="title">2.16.2 any EPS symptoms</h6> <p>In this subgroup we found three relevant trials (N = 235). There was no significant difference between chlorpromazine and risperidone (RR 1.70, 95% CI 0.85 to 3.40; <a href="./references#CD010631-fig-0047" title="">Analysis 2.16</a>). This subgroup had important levels of heterogeneity (Chi² test = 4.33; df = 2; P = 0.115; I² statistic = 54%). </p> </section> <section id="CD010631-sec-0355"> <h6 class="title">2.16.3 dystonia</h6> <p>In this subgroup we found three relevant trials (N = 228). There was no significant difference between chlorpromazine and risperidone (RR 1.61, 95% CI 0.97 to 2.66; <a href="./references#CD010631-fig-0047" title="">Analysis 2.16</a>). </p> </section> <section id="CD010631-sec-0356"> <h6 class="title">2.16.4 muscle stiffness</h6> <p>In this subgroup we found five relevant trials (N = 335). There was no significant difference between chlorpromazine and risperidone (RR 2.96, 95% CI 0.92 to 9.49; <a href="./references#CD010631-fig-0047" title="">Analysis 2.16</a>). This subgroup had important levels of heterogeneity (Chi² test = 8.82; df = 4; P = 0.066; I² statistic = 55%). </p> </section> <section id="CD010631-sec-0357"> <h6 class="title">2.16.5 torsion movements</h6> <p>We only found one relevant trial in this subgroup (N = 78) (<a href="./references#CD010631-bbs2-0066" title="MaZ H , LiuA Y , ZhouC M , ZhangZ . A comparative study of risperidone and chlorpromazine in the treatment of schizophrenia. Medical Journal of Chinese People Health2004;16:202‐4. ">vs RPD ‐ Ma 2004</a>). There was no significant difference between chlorpromazine and risperidone (RR 9.00, 95% CI 0.50 to 161.73; <a href="./references#CD010631-fig-0047" title="">Analysis 2.16</a>). </p> </section> <section id="CD010631-sec-0358"> <h6 class="title">2.16.6 tremor</h6> <p>In this subgroup we found six relevant trials (N = 435). There was a statistically significant difference in favour of risperidone (RR 2.15, 95% CI 1.47 to 3.14, P &lt; 0.0001; <a href="./references#CD010631-fig-0047" title="">Analysis 2.16</a>). </p> </section> </section> <section id="CD010631-sec-0359"> <h5 class="title">2.17 Adverse effects: 9. Average endpoint score (TESS) ‐ skewed data</h5> <p>Data for this outcome are skewed and are best inspected by viewing <a href="./references#CD010631-fig-0048" title="">Analysis 2.17</a>. </p> </section> <section id="CD010631-sec-0360"> <h5 class="title">2.18 Adverse effects: 10. Various ‐ short term (up to 6 months)</h5> <section id="CD010631-sec-0361"> <h6 class="title">2.18.1 concentration (poor)</h6> <p>In this subgroup we only found one relevant trial (N = 100) (<a href="./references#CD010631-bbs2-0070" title="WuY , LuW , YiZ . A comparative study of risperidone and chlorpromazine on quality of life in patients with schizophrenia. Shandong Archive of Psychiatry2004;17:137‐40. ">vs RPD ‐ Wu 2004</a>). There was a statistically significant difference in favour of risperidone (RR 1.95, 95% CI 1.35 to 2.82; P = 0.0003; <a href="./references#CD010631-fig-0049" title="">Analysis 2.18</a>). </p> </section> <section id="CD010631-sec-0362"> <h6 class="title">2.18.2 memory deterioration</h6> <p>In this subgroup we only found one relevant trial (N = 100) (<a href="./references#CD010631-bbs2-0070" title="WuY , LuW , YiZ . A comparative study of risperidone and chlorpromazine on quality of life in patients with schizophrenia. Shandong Archive of Psychiatry2004;17:137‐40. ">vs RPD ‐ Wu 2004</a>). There was a statistically significant difference in favour of risperidone (RR 1.95, 95% CI 1.35 to 2.82; P = 0.0004; <a href="./references#CD010631-fig-0049" title="">Analysis 2.18</a>). </p> </section> <section id="CD010631-sec-0363"> <h6 class="title">2.18.3 sexual dysfunction</h6> <p>In this subgroup we only found one relevant trial (N = 100) (<a href="./references#CD010631-bbs2-0070" title="WuY , LuW , YiZ . A comparative study of risperidone and chlorpromazine on quality of life in patients with schizophrenia. Shandong Archive of Psychiatry2004;17:137‐40. ">vs RPD ‐ Wu 2004</a>). There was a statistically significant difference in favour of risperidone (RR 2.55, 95% CI 1.43 to 4.53; P = 0.002; <a href="./references#CD010631-fig-0049" title="">Analysis 2.18</a>). </p> </section> <section id="CD010631-sec-0364"> <h6 class="title">2.18.4 unspecified</h6> <p>In this subgroup we only found one relevant trial (N = 100) (<a href="./references#CD010631-bbs2-0068" title="WangX , HuX , YangJ . Effect of chlorpromazine and risperidone on cognitive function of the patients with first episode schizophrenia. Chinese Journal of Health Psychology2005;13:342‐4. ">vs RPD ‐ Wang 2005</a>). There was no significant difference between chlorpromazine and risperidone (RR 1.38, 95% CI 0.97 to 1.95; <a href="./references#CD010631-fig-0049" title="">Analysis 2.18</a>). </p> </section> </section> <section id="CD010631-sec-0365"> <h5 class="title">2.19 Quality of life: 1. Average endpoint scale score (QOL, high = good)</h5> <section id="CD010631-sec-0366"> <h6 class="title">2.19.1 short term (up to 6 months)</h6> <p>In this subgroup we only found one relevant trial (N = 100) (<a href="./references#CD010631-bbs2-0070" title="WuY , LuW , YiZ . A comparative study of risperidone and chlorpromazine on quality of life in patients with schizophrenia. Shandong Archive of Psychiatry2004;17:137‐40. ">vs RPD ‐ Wu 2004</a>). There was a statistically significant difference in favour of risperidone (MD −14.20, 95% CI −20.50 to −7.90; P &lt; 0.00001; <a href="./references#CD010631-fig-0050" title="">Analysis 2.19</a>). </p> </section> </section> <section id="CD010631-sec-0367"> <h5 class="title">2.20 Leaving the study early ‐ short term (up to 6 months)</h5> <section id="CD010631-sec-0368"> <h6 class="title">2.20.1 due to adverse events</h6> <p>In this subgroup we only found one relevant trial (N = 41) (<a href="./references#CD010631-bbs2-0061" title="HeM , FengY , ChenR . A controlled comparative study on risperidone and chlorpromazine in treatment of schizophrenia. Chinese New Drugs Journal1999;8:185‐7. ">vs RPD ‐ He 1999</a>). There was no significant difference between chlorpromazine and risperidone (RR 0.21, 95% CI 0.01 to 4.11; <a href="./references#CD010631-fig-0051" title="">Analysis 2.20</a>). </p> </section> </section> </section> <section id="CD010631-sec-0369"> <h4 class="title">Comparison 3: CHLORPROMAZINE versus QUETIAPINE</h4> <section id="CD010631-sec-0370"> <h5 class="title">3.1 Clinical response: No significant clinical response</h5> <section id="CD010631-sec-0371"> <h6 class="title">3.1.1 short term (up to six months)</h6> <p>In this subgroup we found 28 relevant trials (N = 3241). There was no significant difference between chlorpromazine and quetiapine (RR 0.93, 95% CI 0.81 to 1.06; <a href="./references#CD010631-fig-0052" title="">Analysis 3.1</a>). </p> </section> </section> <section id="CD010631-sec-0372"> <h5 class="title">3.2 Global state: 1. Need of additional benzodiazepines/benzhexol</h5> <section id="CD010631-sec-0373"> <h6 class="title">3.2.1 short term (up to 6 months)</h6> <p>In this subgroup we found two relevant trials (N = 290). There was a statistically significant difference in favour of quetiapine (RR 1.39, 95% CI 1.1 to 1.75; <a href="./references#CD010631-fig-0053" title="">Analysis 3.2</a>). </p> </section> </section> <section id="CD010631-sec-0374"> <h5 class="title">3.3 Global state: 2a. Average endpoint scores (various scales, high = poor) ‐ short term (up to 6 months) </h5> <section id="CD010631-sec-0375"> <h6 class="title">3.3.1 CGI‐SI</h6> <p>In this subgroup we found two relevant trials (N = 177). There was no significant difference between chlorpromazine and quetiapine (MD 0.01, 95% CI −0.82 to 0.84; <a href="./references#CD010631-fig-0054" title="">Analysis 3.3</a>. This subgroup had important levels of heterogeneity (Chi² test = 5.67; df = 1; P = 0.017; I² statistic = 82%). </p> </section> <section id="CD010631-sec-0376"> <h6 class="title">3.3.2 CGI‐GI</h6> <p>In this subgroup we found three relevant trials (N = 229). There was no significant difference between chlorpromazine and quetiapine (MD −0.11, 95% CI −0.33 to 0.11; <a href="./references#CD010631-fig-0054" title="">Analysis 3.3</a>). </p> </section> </section> <section id="CD010631-sec-0377"> <h5 class="title">3.4 Global state: 2b. Average endpoint score (CGI‐SI, high = poor) ‐ skewed data</h5> <p>Data for this outcome are skewed and are best inspected by viewing <a href="./references#CD010631-fig-0055" title="">Analysis 3.4</a>. </p> </section> <section id="CD010631-sec-0378"> <h5 class="title">3.5 Global state: 3. Average change scores (CGI‐SI, high = poor)</h5> <section id="CD010631-sec-0379"> <h6 class="title">3.5.1 short term (up to six months)</h6> <p>We only found one relevant trial in this subgroup (N = 384) (<a href="./references#CD010631-bbs2-0041" title="NCT00882518 . Efficacy and safety of quetiapine fumarate in the treatment of schizophrenic patients. http://www.clinicaltrials.gov (accessed 28 February 2012). ">vs QTP ‐ NCT00882518</a>). There was a statistically significant difference in favour of chlorpromazine (MD −0.30, 95% CI −0.32 to −0.28; P &lt; 0.00001; <a href="./references#CD010631-fig-0056" title="">Analysis 3.5</a>). </p> </section> </section> <section id="CD010631-sec-0380"> <h5 class="title">3.6 Mental state: 1a. Average endpoint scores (various scale, high = poor) ‐ short term (up to 6 months) </h5> <section id="CD010631-sec-0381"> <h6 class="title">3.6.1 BPRS total</h6> <p>In this subgroup we found six relevant trials (N = 548). There was no significant difference between chlorpromazine and quetiapine (MD −0.18, 95% CI −1.23 to 0.88; <a href="./references#CD010631-fig-0057" title="">Analysis 3.6</a>). </p> </section> <section id="CD010631-sec-0382"> <h6 class="title">3.6.2 BPRS anxiety‐depression subscale</h6> <p>In this subgroup we only found one relevant trial (N = 60) (<a href="./references#CD010631-bbs2-0050" title="YangL , YuanYG . Quetiapine and chlorpromazine in the treatment of people with schizophrenia. Medical Journal of Chinese People's Health2007;19(12):1050‐1. ">vs QTP ‐ Yang 2007</a>). There was no significant difference between chlorpromazine and quetiapine (MD −0.27, 95% CI −1.16 to 0.62; <a href="./references#CD010631-fig-0057" title="">Analysis 3.6</a>). </p> </section> <section id="CD010631-sec-0383"> <h6 class="title">3.6.3 BPRS activation subscale</h6> <p>In this subgroup we only found one relevant trial (N = 60) (<a href="./references#CD010631-bbs2-0050" title="YangL , YuanYG . Quetiapine and chlorpromazine in the treatment of people with schizophrenia. Medical Journal of Chinese People's Health2007;19(12):1050‐1. ">vs QTP ‐ Yang 2007</a>). There was no significant difference between chlorpromazine and quetiapine (MD 0.22, 95% CI −0.26 to 0.70; <a href="./references#CD010631-fig-0057" title="">Analysis 3.6</a>). </p> </section> <section id="CD010631-sec-0384"> <h6 class="title">3.6.4 BPRS hostile‐suspiciousness subscale</h6> <p>In this subgroup we only found one relevant trial (N = 60) (<a href="./references#CD010631-bbs2-0050" title="YangL , YuanYG . Quetiapine and chlorpromazine in the treatment of people with schizophrenia. Medical Journal of Chinese People's Health2007;19(12):1050‐1. ">vs QTP ‐ Yang 2007</a>). There was no significant difference between chlorpromazine and quetiapine (MD −0.09, 95% CI −1.15 to 0.97; <a href="./references#CD010631-fig-0057" title="">Analysis 3.6</a>). </p> </section> <section id="CD010631-sec-0385"> <h6 class="title">3.6.5 BPRS thinking disorder subscale</h6> <p>We only found one relevant trial in this subgroup (N = 60) (<a href="./references#CD010631-bbs2-0050" title="YangL , YuanYG . Quetiapine and chlorpromazine in the treatment of people with schizophrenia. Medical Journal of Chinese People's Health2007;19(12):1050‐1. ">vs QTP ‐ Yang 2007</a>). There was no significant difference between chlorpromazine and quetiapine (MD −0.15, 95% CI −1.39 to 1.09; <a href="./references#CD010631-fig-0057" title="">Analysis 3.6</a>). </p> </section> <section id="CD010631-sec-0386"> <h6 class="title">3.6.6 BPRS withdraw‐retardation subscale</h6> <p>In this subgroup we only found one relevant trial (N = 60) (<a href="./references#CD010631-bbs2-0050" title="YangL , YuanYG . Quetiapine and chlorpromazine in the treatment of people with schizophrenia. Medical Journal of Chinese People's Health2007;19(12):1050‐1. ">vs QTP ‐ Yang 2007</a>). There was no significant difference between chlorpromazine and quetiapine (MD −0.10, 95% CI −0.76 to 0.56; <a href="./references#CD010631-fig-0057" title="">Analysis 3.6</a>). </p> </section> <section id="CD010631-sec-0387"> <h6 class="title">3.6.7 PANSS total</h6> <p>In this subgroup we found 25 relevant trials (N = 2049). There was no significant difference between chlorpromazine and quetiapine (MD −0.05, 95% CI −2.3 to 2.19; <a href="./references#CD010631-fig-0057" title="">Analysis 3.6</a>). This subgroup had important levels of heterogeneity (Chi² test = 102.88; df = 24; P = 0.0; I² statistic = 77%). </p> </section> <section id="CD010631-sec-0388"> <h6 class="title">3.6.8 PANSS positive symptom</h6> <p>In this subgroup we found 13 relevant trials (N = 1102). There was no significant difference between chlorpromazine and quetiapine (MD 0.39, 95% CI −0.11 to 0.88; <a href="./references#CD010631-fig-0057" title="">Analysis 3.6</a>). </p> </section> <section id="CD010631-sec-0389"> <h6 class="title">3.6.9 PANSS negative symptoms</h6> <p>In this subgroup we found 17 relevant trials (N = 1361). There was a statistically significant difference in favour of quetiapine (MD 1.05, 95% CI 0.13 to 1.98; P = 0.03; <a href="./references#CD010631-fig-0057" title="">Analysis 3.6</a>). This subgroup had important levels of heterogeneity (Chi² test = 54.37; df = 16; P = 0.0; I² statistic = 71%). </p> </section> <section id="CD010631-sec-0390"> <h6 class="title">3.6.10 PANSS general pathology</h6> <p>In this subgroup we found 18 relevant trials (N = 1530). There was no significant difference between chlorpromazine and quetiapine (MD −1.11, 95% CI −3.06 to 0.84; <a href="./references#CD010631-fig-0057" title="">Analysis 3.6</a>). This subgroup had important levels of heterogeneity (Chi² test = 160.66; df = 17; P = 0.0; I² statistic = 89%). </p> </section> <section id="CD010631-sec-0391"> <h6 class="title">3.6.11 HAMD total</h6> <p>In this subgroup we only found one relevant trial (N = 63) (<a href="./references#CD010631-bbs2-0037" title="LiYQ , ZhuangJH . Quetiapine and chlorpromazine in the treatment of schizophrenia with depression. Journal of Qiqi ha‐er Medical College2010;31(3):395. ">vs QTP ‐ Li 2010</a>). There was a statistically significant difference in favour of quetiapine (MD 7.40, 95% CI 5.13 to 9.67; P &lt; 0.00001; <a href="./references#CD010631-fig-0057" title="">Analysis 3.6</a>). </p> </section> </section> <section id="CD010631-sec-0392"> <h5 class="title">3.7 Mental state: 1b. Average endpoint scores (various scales, high = poor) ‐ medium term (6 to 12 months) </h5> <section id="CD010631-sec-0393"> <h6 class="title">3.7.1 PANSS total</h6> <p>In this subgroup we only found one relevant trial (N = 41) (<a href="./references#CD010631-bbs2-0036" title="LiM , HuF , WangS . A study of quetiapine and chlorpromazine on the effects and quality of life in the treatment of schizophrenia. Shandong Archives of Psychiatry2003;16(3):135‐7. ">vs QTP ‐ Li 2003</a>). There was a statistically significant difference in favour of quetiapine (MD 4.90, 95% CI 1.74 to 8.06; P = 0.002; <a href="./references#CD010631-fig-0058" title="">Analysis 3.7</a>). </p> </section> <section id="CD010631-sec-0394"> <h6 class="title">3.7.2 PANSS general pathology</h6> <p>We only found one relevant trial in this subgroup (N = 41) (<a href="./references#CD010631-bbs2-0036" title="LiM , HuF , WangS . A study of quetiapine and chlorpromazine on the effects and quality of life in the treatment of schizophrenia. Shandong Archives of Psychiatry2003;16(3):135‐7. ">vs QTP ‐ Li 2003</a>). There was no significant difference between chlorpromazine and quetiapine (MD −0.20, 95% CI −4.34 to 3.94; <a href="./references#CD010631-fig-0058" title="">Analysis 3.7</a>). </p> </section> <section id="CD010631-sec-0395"> <h6 class="title">3.7.3 PANSS negative symptoms</h6> <p>In this subgroup we only found one relevant trial (N = 77) (<a href="./references#CD010631-bbs2-0036" title="LiM , HuF , WangS . A study of quetiapine and chlorpromazine on the effects and quality of life in the treatment of schizophrenia. Shandong Archives of Psychiatry2003;16(3):135‐7. ">vs QTP ‐ Li 2003</a>). There was a statistically significant difference in favour of quetiapine (MD 2.70, 95% CI 0.44 to 4.96; P = 0.02; <a href="./references#CD010631-fig-0058" title="">Analysis 3.7</a>). </p> </section> </section> <section id="CD010631-sec-0396"> <h5 class="title">3.8 Mental state: 1c. Average endpoint scores (various scales, high = poor) ‐ skewed data </h5> <p>Data for this outcome are skewed and are best inspected be viewing <a href="./references#CD010631-fig-0059" title="">Analysis 3.8</a>. </p> </section> <section id="CD010631-sec-0397"> <h5 class="title">3.9 Mental state: Average change score (various scales, high = poor) ‐ short term (up to 6 months) </h5> <section id="CD010631-sec-0398"> <h6 class="title">3.9.1 PANSS total</h6> <p>In this subgroup we found two relevant trials (N = 426). There was a statistically significant difference in favour of chlorpromazine (MD −2.50, 95% CI −2.82 to −2.19; P &lt; 0.00001; <a href="./references#CD010631-fig-0060" title="">Analysis 3.9</a>). </p> </section> <section id="CD010631-sec-0399"> <h6 class="title">3.9.2 PANSS positive symptoms</h6> <p>In this subgroup we only found one relevant trial (N = 384) (<a href="./references#CD010631-bbs2-0041" title="NCT00882518 . Efficacy and safety of quetiapine fumarate in the treatment of schizophrenic patients. http://www.clinicaltrials.gov (accessed 28 February 2012). ">vs QTP ‐ NCT00882518</a>). There was a statistically significant difference in favour of quetiapine (MD 1.20, 95% CI 1.10 to 1.30, <a href="./references#CD010631-fig-0060" title="">Analysis 3.9</a>). </p> </section> <section id="CD010631-sec-0400"> <h6 class="title">3.9.3 PANSS negative symptom</h6> <p>In this subgroup we only found one relevant trial (N = 384) (<a href="./references#CD010631-bbs2-0041" title="NCT00882518 . Efficacy and safety of quetiapine fumarate in the treatment of schizophrenic patients. http://www.clinicaltrials.gov (accessed 28 February 2012). ">vs QTP ‐ NCT00882518</a>). There was a statistically significant difference) in favour of quetiapine (MD 0.80, 95% CI 0.70 to 0.90; P &lt; 0.00001; <a href="./references#CD010631-fig-0060" title="">Analysis 3.9</a>). </p> </section> <section id="CD010631-sec-0401"> <h6 class="title">3.9.4 PANSS general pathology</h6> <p>In this subgroup we only found one relevant trial (N = 384) (<a href="./references#CD010631-bbs2-0041" title="NCT00882518 . Efficacy and safety of quetiapine fumarate in the treatment of schizophrenic patients. http://www.clinicaltrials.gov (accessed 28 February 2012). ">vs QTP ‐ NCT00882518</a>). There was a statistically significant differenc in favour of quetiapine (MD 1.00, 95% CI 0.85 to 1.15; P &lt; 0.00001; <a href="./references#CD010631-fig-0060" title="">Analysis 3.9</a>). </p> </section> </section> <section id="CD010631-sec-0402"> <h5 class="title">3.10 Mental state: 1e. Average score decreased rate of BPRS/PANSS (%) ‐ short term (up to 6 months) </h5> <section id="CD010631-sec-0403"> <h6 class="title">3.10.1 BPRS</h6> <p>In this subgroup we only found one relevant trial (N = 197) (<a href="./references#CD010631-bbs2-0015" title="CaiDM . Clinical comparative study of quetiapine and chlorpromazine in the treatment of schizophrenia. Medical Journal of Chinese People's Health2006;18(4):281‐2. ">vs QTP ‐ Cai 2006</a>). There was no significant difference between chlorpromazine and quetiapine (MD −0.80, 95% CI −4.86 to 3.26; <a href="./references#CD010631-fig-0061" title="">Analysis 3.10</a>). </p> </section> <section id="CD010631-sec-0404"> <h6 class="title">3.10.2 PANSS</h6> <p>In this subgroup we found six relevant trials (N = 782). There was no significant difference between chlorpromazine and quetiapine (MD −1.96, 95% CI −7.20 to 3.28; <a href="./references#CD010631-fig-0061" title="">Analysis 3.10</a>). This subgroup had important levels of heterogeneity (Chi² test = 18.14; df = 5; P = 0.003; I² statistic = 72%). </p> </section> </section> <section id="CD010631-sec-0405"> <h5 class="title">3.11 Functioning: 1. Average endpoint score (various scales, high = better) ‐ short term (up to 6 months) </h5> <section id="CD010631-sec-0406"> <h6 class="title">3.11.1 WCST‐IQ</h6> <p>In this subgroup we only found one relevant trial (N = 120) (<a href="./references#CD010631-bbs2-0040" title="NaiX , HuX , QiuS . Effect of quetiapine on cognition function of patients with first episode schizophrenia. Journal of Medical Forum2007;28(2):38‐9. ">vs QTP ‐ Nai 2007</a>). There was a statistically significant difference in favour of quetiapine (MD −11.30, 95% CI −17.62 to −4.98; P = 0.0005; <a href="./references#CD010631-fig-0062" title="">Analysis 3.11</a>). </p> </section> <section id="CD010631-sec-0407"> <h6 class="title">3.11.2 WCST‐MQ</h6> <p>In this subgroup we only found one relevant trial (N = 120) (<a href="./references#CD010631-bbs2-0040" title="NaiX , HuX , QiuS . Effect of quetiapine on cognition function of patients with first episode schizophrenia. Journal of Medical Forum2007;28(2):38‐9. ">vs QTP ‐ Nai 2007</a>). There was a statistically significant difference in favour of quetiapine (MD −19.6, 95% CI −27.37 to −11.83; P &lt; 0.00001; <a href="./references#CD010631-fig-0062" title="">Analysis 3.11</a>). </p> </section> </section> <section id="CD010631-sec-0408"> <h5 class="title">3.12 Cognitive function: 1. Average endpoint scores (various scales, high = better) short term (up to 6 months) </h5> <section id="CD010631-sec-0409"> <h6 class="title">3.12.1 WCST</h6> <p>In this subgroup we found two relevant trials (N = 123). There was a statistically significant difference in favour of quetiapine (MD 8.92, 95% CI 0.40 to 17.43; P = 0.04; <a href="./references#CD010631-fig-0063" title="">Analysis 3.12</a>). </p> </section> <section id="CD010631-sec-0410"> <h6 class="title">3.12.2 WMS‐RC</h6> <p>In this subgroup we only found one relevant trial (N = 71) (<a href="./references#CD010631-bbs2-0044" title="SunXD , ZhouSB , LiZM , HanZF . Effect of cognitive function in first‐episode schizophrenia treated with quetiapine. Journal of Clinical Psychiatry2006;16(2):94‐5. ">vs QTP ‐ Sun 2006</a>). There was a statistically significant difference in favour of chlorpromazine (MD −9.34, 95% CI −17.53 to −1.15; P = 0.03; <a href="./references#CD010631-fig-0063" title="">Analysis 3.12</a>). </p> </section> </section> <section id="CD010631-sec-0411"> <h5 class="title">3.13 Adverse effects: 1. Anticholinergic ‐ short term (up to 6 months)</h5> <section id="CD010631-sec-0412"> <h6 class="title">3.13.1 blurred vision</h6> <p>In this subgroup we found 18 relevant trials (N = 1780). There was a statistically significant difference in favour of quetiapine (RR 5.00, 95% CI 3.46 to 7.22; P &lt; 0.00001; <a href="./references#CD010631-fig-0064" title="">Analysis 3.13</a>). </p> </section> <section id="CD010631-sec-0413"> <h6 class="title">3.13.2 dry mouth</h6> <p>In this subgroup we found 18 relevant trials (N = 1682). There was a statistically significant difference (P &lt; 0.0001) in favour of quetiapine (RR 2.34, 95% CI 1.54 to 3.54; <a href="./references#CD010631-fig-0064" title="">Analysis 3.13</a>). This subgroup had moderate levels of heterogeneity (Chi² test = 32.99; df = 17; P = 0.011; I² statistic = 48%). </p> </section> <section id="CD010631-sec-0414"> <h6 class="title">3.13.2 excessive sweating</h6> <p>In this subgroup we found three relevant trials (N = 162). There was no significant difference between chlorpromazine and quetiapine (RR 3.91, 95% CI 0.84 to 18.19; <a href="./references#CD010631-fig-0064" title="">Analysis 3.13</a>). </p> </section> <section id="CD010631-sec-0415"> <h6 class="title">3.13.3 hypersalivation</h6> <p>We found 11 relevant trials in this subgroup (N = 1135). There was a statistically significant difference in favour of quetiapine (RR 3.85, 95% CI 2.36 to 6.28; P &lt; 0.0001; <a href="./references#CD010631-fig-0064" title="">Analysis 3.13</a>). </p> </section> <section id="CD010631-sec-0416"> <h6 class="title">3.13.4 stuffy nose</h6> <p>In this subgroup we found eight relevant trials (N = 972). There was no significant difference between chlorpromazine and quetiapine (RR 0.69, 95% CI 0.45 to 1.06; <a href="./references#CD010631-fig-0064" title="">Analysis 3.13</a>). </p> </section> </section> <section id="CD010631-sec-0417"> <h5 class="title">3.14 Adverse effects: 2. Cardiovascular ‐ short term (up to 6 months)</h5> <section id="CD010631-sec-0418"> <h6 class="title">3.14.1 abnormal ECG</h6> <p>In this subgroup we found seven relevant trials (N = 708). There was a statistically significant difference in favour of quetiapine (RR 1.82, 95% CI 1.11 to 2.98; P = 0.02; <a href="./references#CD010631-fig-0065" title="">Analysis 3.14</a>). </p> </section> <section id="CD010631-sec-0419"> <h6 class="title">3.14.2 blood pressure drop</h6> <p>In this subgroup we found eight relevant trials (N = 690). There was no significant difference between chlorpromazine and quetiapine (RR 0.97, 95% CI 0.53 to 1.79; <a href="./references#CD010631-fig-0065" title="">Analysis 3.14</a>). This subgroup had moderate levels of heterogeneity (Chi² test = 13.18; df = 7; P = 0.068; I² statistic = 47%). </p> </section> <section id="CD010631-sec-0420"> <h6 class="title">3.14.3 orthostatic hypotension</h6> <p>In this subgroup we found seven relevant trials (N = 605). There was a statistically significant difference in favour of quetiapine (RR 2.64, 95% CI 1.14 to 6.12; P = 0.02; <a href="./references#CD010631-fig-0065" title="">Analysis 3.14</a>). </p> </section> <section id="CD010631-sec-0421"> <h6 class="title">3.14.4 tachycardia</h6> <p>In this subgroup we found 17 relevant trials (N = 1752). There was a statistically significant difference in favour of quetiapine (RR 1.70, 95% CI 1.33 to 2.18; P &lt; 0.0001; <a href="./references#CD010631-fig-0065" title="">Analysis 3.14</a>). </p> </section> </section> <section id="CD010631-sec-0422"> <h5 class="title">3.15 Adverse effects: 3. Central nervous system ‐ short term (up to 6 months)</h5> <section id="CD010631-sec-0423"> <h6 class="title">3.15.1 dizziness</h6> <p>In this subgroup we found 12 relevant trials (N = 1206). There was no significant difference between chlorpromazine and quetiapine (RR 1.40, 95% CI 0.83 to 2.35; <a href="./references#CD010631-fig-0066" title="">Analysis 3.15</a>). This subgroup had moderate levels of heterogeneity (Chi² test = 16.88; df = 11; P = 0.111; I² statistic = 35%). </p> </section> <section id="CD010631-sec-0424"> <h6 class="title">3.15.2 drowsiness</h6> <p>In this subgroup we found 17 relevant trials (N = 1677). There was a statistically significant difference in favour of quetiapine (RR 2.28, 95% CI 1.51 to 3.45; P &lt; 0.0001; <a href="./references#CD010631-fig-0066" title="">Analysis 3.15</a>). This subgroup had moderate levels of heterogeneity (Chi² test = 31.15; df = 16; P = 0.013; I² statistic = 49%). </p> </section> <section id="CD010631-sec-0425"> <h6 class="title">3.15.3 headache</h6> <p>In this subgroup we found three relevant trials (N = 192). There was no significant difference between chlorpromazine and quetiapine (RR 0.74, 95% CI 0.13 to 4.18; <a href="./references#CD010631-fig-0066" title="">Analysis 3.15</a>). </p> </section> <section id="CD010631-sec-0426"> <h6 class="title">3.15.4 insomnia</h6> <p>In this subgroup we found nine relevant trials (N = 867). There was no significant difference between chlorpromazine and quetiapine (RR 0.92, 95% CI 0.55 to 1.54; <a href="./references#CD010631-fig-0066" title="">Analysis 3.15</a>). </p> </section> <section id="CD010631-sec-0427"> <h6 class="title">3.15.5 reduced activity</h6> <p>In this subgroup we found eight relevant trials (N = 788). There was a statistically significant difference in favour of quetiapine (RR 7.80, 95% CI 3.05 to 19.92; P &lt; 0.0001; <a href="./references#CD010631-fig-0066" title="">Analysis 3.15</a>). </p> </section> <section id="CD010631-sec-0428"> <h6 class="title">3.15.6 sedation</h6> <p>In this subgroup we only found one relevant trial (N = 40) (<a href="./references#CD010631-bbs2-0029" title="HeYD , ZhaoCM , ShaoAL , ChenYN . A comparative study of quetiapine and chlorpromazine in the treatment of patients with schizophrenia. Herald of Medicine2003;22(10):680‐2. ">vs QTP ‐ He 2003</a>). There was no significant difference between chlorpromazine and quetiapine (RR 0.33, 95% CI 0.01 to 7.72; <a href="./references#CD010631-fig-0066" title="">Analysis 3.15</a>). </p> </section> </section> <section id="CD010631-sec-0429"> <h5 class="title">3.16 Adverse effects: 4. Gastrointestinal ‐ short term (up to 6 months)</h5> <section id="CD010631-sec-0430"> <h6 class="title">3.16.1 constipation</h6> <p>In this subgroup we found 22 relevant trials (N = 2048). There was a statistically significant difference in favour of quetiapine (RR 2.55, 95% CI 2.04 to 3.20; P &lt; 0.00001; <a href="./references#CD010631-fig-0067" title="">Analysis 3.16</a>). </p> </section> <section id="CD010631-sec-0431"> <h6 class="title">3.16.2 diarrhoea</h6> <p>In this subgroup we only found one relevant trial (N = 62) (<a href="./references#CD010631-bbs2-0019" title="ChenF , ChenY , ZhouB , ChengF , LiuY , ZhoXW , et al. Quetiapine treatment in schizophrenia curative effect and quality of life. Journal of Clinical Psychiatry [Linchuang Jingshen Yixue Zazhi]2007;17(5):319‐20. ">vs QTP ‐ Chen 2007</a>). There was no significant difference between chlorpromazine and quetiapine (RR 5.32, 95% CI 0.27 to 106.54; <a href="./references#CD010631-fig-0067" title="">Analysis 3.16</a>). </p> </section> <section id="CD010631-sec-0432"> <h6 class="title">3.16.3 loss of appetite</h6> <p>In this subgroup we found five relevant trials (N = 472). There was no significant difference between chlorpromazine and quetiapine (RR 2.52, 95% CI 0.82 to 7.72; <a href="./references#CD010631-fig-0067" title="">Analysis 3.16</a>). This subgroup had moderate levels of heterogeneity (Chi² test = 7.06; df = 4; P = 0.133; I² statistic = 43%). </p> </section> <section id="CD010631-sec-0433"> <h6 class="title">3.16.4 nausea/vomiting</h6> <p>In this subgroup we found nine relevant trials (N = 819). There was no significant difference between chlorpromazine and quetiapine (RR 1.23, 95% CI 0.58 to 2.63; <a href="./references#CD010631-fig-0067" title="">Analysis 3.16</a>). </p> </section> </section> <section id="CD010631-sec-0434"> <h5 class="title">3.17 Adverse effects: 5a. Endocrine ‐ various ‐ short term (up to 6 months)</h5> <section id="CD010631-sec-0435"> <h6 class="title">3.17.2 gynaecomastia, galactorrhoea</h6> <p>In this subgroup we only found one relevant trial (N = 83) (<a href="./references#CD010631-bbs2-0028" title="GuoZ , LiuJ , YangJ . Efficacy quetiapine in the treatment of schizophrenic patients and effect on the quality of life. Chinese Journal of Health Psychology2008;16(5):544‐6. ">vs QTP ‐ Guo 2008</a>). There was no significant difference between chlorpromazine and quetiapine (RR 5.37, 95% CI 0.27 to 108.47; <a href="./references#CD010631-fig-0068" title="">Analysis 3.17</a>). </p> </section> <section id="CD010631-sec-0436"> <h6 class="title">3.17.2 hyperprolactinemia</h6> <p>In this subgroup we found two relevant trials (N = 277). There was a statistically significant difference in favour of quetiapine (RR 5.69, 95% CI 2.74 to 11.79; P &lt; 0.00001; <a href="./references#CD010631-fig-0068" title="">Analysis 3.17</a>). </p> </section> <section id="CD010631-sec-0437"> <h6 class="title">3.17.3 menstrual irregularities</h6> <p>In this subgroup we only found one relevant trial (N = 52) (<a href="./references#CD010631-bbs2-0027" title="GuoJ , CaoC , WuD . Effect of quetiapine and chlorpromazine on cognitive function in first‐episode schizophrenic. Chinese Journal of Health Psychology2007;15(7):583‐4. ">vs QTP ‐ Guo 2007</a>). There was no significant difference between chlorpromazine and quetiapine (RR 5.00, 95% CI 0.25 to 99.34; <a href="./references#CD010631-fig-0068" title="">Analysis 3.17</a>). </p> </section> </section> <section id="CD010631-sec-0438"> <h5 class="title">3.18 Adverse effects: 5b. Endocrine ‐ average endpoint ‐ short term (up to 6 months)</h5> <section id="CD010631-sec-0439"> <h6 class="title">3.1.18 prolactin level (ng/mL)</h6> <p>In this subgroup we only found one relevant trial (n = 30) (<a href="./references#CD010631-bbs2-0035" title="KongDL , ZhangSQ , ShuMQ . Effects of quetiapine and chlorpromazine on serum prolactin of schizophrenics. Journal of Clinical Psychosomatic Diseases2003;9(4):200‐1. ">vs QTP ‐ Kong 2003</a>). There was a statistically significant difference in favour of quetiapine (MD 24.62, 95% CI 17.76 to 31.48; P &lt; 0.00001; <a href="./references#CD010631-fig-0069" title="">Analysis 3.18</a>). </p> </section> </section> <section id="CD010631-sec-0440"> <h5 class="title">3.19 Adverse effect: 5c. Endocrine ‐ skewed data ‐ short term (up to 6 months)</h5> <section id="CD010631-sec-0441"> <h6 class="title">3.19.1 average prolactin level (ng/mL)</h6> <p>Data for this outcome are skewed and are best inspected by viewing <a href="./references#CD010631-fig-0070" title="">Analysis 3.19</a>. </p> </section> </section> <section id="CD010631-sec-0442"> <h5 class="title">3.20 Adverse effects: 6a. Haematology ‐ short term (up to 6 months)</h5> <section id="CD010631-sec-0443"> <h6 class="title">3.20.1 elevated ALT</h6> <p>In this subgroup we found eight relevant trials (N = 775). There was no significant difference between chlorpromazine and quetiapine (RR 1.62, 95% CI 0.92 to 2.87; <a href="./references#CD010631-fig-0071" title="">Analysis 3.20</a>). </p> </section> <section id="CD010631-sec-0444"> <h6 class="title">3.20.2 decreased white blood cell count</h6> <p>In this subgroup we found four relevant trials (N = 427). There was no significant difference between chlorpromazine and quetiapine (RR 1.02, 95% CI 0.43 to 2.42; <a href="./references#CD010631-fig-0071" title="">Analysis 3.20</a>). </p> </section> <section id="CD010631-sec-0445"> <h6 class="title">3.20.3 increased white blood cell count</h6> <p>We only found one relevant trial in this subgroup (N = 79) (<a href="./references#CD010631-bbs2-0056" title="ZhouSB , SunXD , LiYM . A comparative study on quetiapine and chlorpromazine in the treatment of schizophrenia. Medical Journal of Chinese People's Health2004;16(11):657‐9. ">vs QTP ‐ Zhou 2004</a>). There was no significant difference between chlorpromazine and quetiapine (RR 2.05, 95% CI 0.40 to 10.56; <a href="./references#CD010631-fig-0071" title="">Analysis 3.20</a>). </p> </section> </section> <section id="CD010631-sec-0446"> <h5 class="title">3.21 Adverse effects: 6b. Haematology ‐ average endpoint ‐ short term (up to 6 months)</h5> <section id="CD010631-sec-0447"> <h6 class="title">3.21.1 blood glucose</h6> <p>In this subgroup we only found one relevant trial (N = 130) (<a href="./references#CD010631-bbs2-0026" title="GuoXF , ZhaoJP , ChenJD , ZhangZC . The effect of chlorpromazine and quetiapine on serum lipid and glucose. Journal of Clinical Psychiatry2006;16(5):257‐9. ">vs QTP ‐ Guo 2006</a>). There was no significant difference between chlorpromazine and quetiapine (MD 0.10, 95% CI −0.18 to 0.38; <a href="./references#CD010631-fig-0072" title="">Analysis 3.21</a>). </p> </section> <section id="CD010631-sec-0448"> <h6 class="title">3.21.2 blood TG</h6> <p>In this subgroup we only found one relevant trial (N = 130) (<a href="./references#CD010631-bbs2-0026" title="GuoXF , ZhaoJP , ChenJD , ZhangZC . The effect of chlorpromazine and quetiapine on serum lipid and glucose. Journal of Clinical Psychiatry2006;16(5):257‐9. ">vs QTP ‐ Guo 2006</a>). There was no significant difference between chlorpromazine and quetiapine (MD 0.00, 95% CI −0.28 to 0.28; <a href="./references#CD010631-fig-0072" title="">Analysis 3.21</a>). </p> </section> <section id="CD010631-sec-0449"> <h6 class="title">3.21.3 blood TC</h6> <p>We only found one relevant trial (N = 130) in this subgroup (<a href="./references#CD010631-bbs2-0026" title="GuoXF , ZhaoJP , ChenJD , ZhangZC . The effect of chlorpromazine and quetiapine on serum lipid and glucose. Journal of Clinical Psychiatry2006;16(5):257‐9. ">vs QTP ‐ Guo 2006</a>). There was no significant difference between chlorpromazine and quetiapine (MD 0.20, 95% CI −0.11 to 0.51; <a href="./references#CD010631-fig-0072" title="">Analysis 3.21</a>). </p> </section> </section> <section id="CD010631-sec-0450"> <h5 class="title">3.22 Adverse effects: 7. Hepatitic ‐ short term (up to 6 months)</h5> <section id="CD010631-sec-0451"> <h6 class="title">3.22.1 abnormal liver function</h6> <p>In this subgroup we found five relevant trials (N = 561). There was a statistically significant difference in favour of quetiapine (RR 2.10, 95% CI 1.32 to 3.33; P = 0.002; <a href="./references#CD010631-fig-0073" title="">Analysis 3.22</a>). </p> </section> </section> <section id="CD010631-sec-0452"> <h5 class="title">3.23 Adverse effects: 8. Movement disorders ‐ short term (up to 6 months)</h5> <section id="CD010631-sec-0453"> <h6 class="title">3.23.1 agitation</h6> <p>We found five relevant trials in this subgroup (N = 313). There was a statistically significant difference in favour of chlorpromazine (RR 0.36, 95% CI 0.14 to 0.95; P = 0.04; <a href="./references#CD010631-fig-0074" title="">Analysis 3.23</a>). </p> </section> <section id="CD010631-sec-0454"> <h6 class="title">3.23.2 akathisia</h6> <p>In this subgroup we found 17 relevant trials (N = 1757). There was a statistically significant difference in favour of quetiapine (RR 3.73, 95% CI 2.55 to 5.47; P &lt; 0.00001; <a href="./references#CD010631-fig-0074" title="">Analysis 3.23</a>). </p> </section> <section id="CD010631-sec-0455"> <h6 class="title">3.23.3 any EPS symptoms</h6> <p>In this subgroup we found eight relevant trials (N = 644). There was a statistically significant difference in favour of quetiapine (RR 8.03, 95% CI 4.78 to 13.51; P &lt; 0.00001; <a href="./references#CD010631-fig-0074" title="">Analysis 3.23</a>). </p> </section> <section id="CD010631-sec-0456"> <h6 class="title">3.23.4 dystonia</h6> <p>In this subgroup we only found one relevant trial (N = 201) (<a href="./references#CD010631-bbs2-0043" title="PeuskensJ , LinkCGG . A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatrica Scandinavica1997;96(4):265‐73. ">vs QTP ‐ Peuskens 1997</a>). There was no significant difference between chlorpromazine and quetiapine (RR 0.33, 95% CI 0.01 to 8.01; <a href="./references#CD010631-fig-0074" title="">Analysis 3.23</a>). </p> </section> <section id="CD010631-sec-0457"> <h6 class="title">3.23.5 myotonia</h6> <p>In this subgroup we found 12 relevant trials (N = 1257). There was a statistically significant difference in favour of quetiapine (RR 4.59, 95% CI 3.18 to 6.64; P &lt; 0.00001; <a href="./references#CD010631-fig-0074" title="">Analysis 3.23</a>). </p> </section> <section id="CD010631-sec-0458"> <h6 class="title">3.23.6 need additional medication for EPS symptoms</h6> <p>We only found one relevant trial in this subgroup (N = 202) (<a href="./references#CD010631-bbs2-0043" title="PeuskensJ , LinkCGG . A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatrica Scandinavica1997;96(4):265‐73. ">vs QTP ‐ Peuskens 1997</a>). There was no significant difference between chlorpromazine and quetiapine (RR 1.50, 95% CI 0.71 to 3.18; <a href="./references#CD010631-fig-0074" title="">Analysis 3.23</a>). </p> </section> <section id="CD010631-sec-0459"> <h6 class="title">3.23.7 torsion movement</h6> <p>In this subgroup we found nine relevant trials (N = 1063). There was a statistically significant difference in favour of quetiapine (RR 5.81, 95% CI 2.76 to 12.23; P &lt; 0.00001; <a href="./references#CD010631-fig-0074" title="">Analysis 3.23</a>). </p> </section> <section id="CD010631-sec-0460"> <h6 class="title">3.23.8 tremor</h6> <p>In this subgroup we found 13 relevant trials (N = 1343). There was a statistically significant difference in favour of quetiapine (RR 2.90, 95% CI 1.89 to 4.45; P &lt; 0.00001; <a href="./references#CD010631-fig-0074" title="">Analysis 3.23</a>). </p> </section> </section> <section id="CD010631-sec-0461"> <h5 class="title">3.24 Adverse effects: 9a. Metabolic ‐ weight gain</h5> <section id="CD010631-sec-0462"> <h6 class="title">3.24.1 short term (up to six months)</h6> <p>In this subgroup we found 15 relevant trials (N = 1259). There was a statistically significant difference in favour of quetiapine (RR 1.67, 95% CI 1.17 to 2.39; P = 0.005; <a href="./references#CD010631-fig-0075" title="">Analysis 3.24</a>). </p> </section> </section> <section id="CD010631-sec-0463"> <h5 class="title">3.25 Adverse effects: 9b. Metabolic ‐ continuous ‐ short term (up to 6 months)</h5> <section id="CD010631-sec-0464"> <h6 class="title">3.25.1 average BMI</h6> <p>In this subgroup we only found one relevant trial (N = 105) (<a href="./references#CD010631-bbs2-0049" title="WangH , PengD , BaiY . Efficacy of quetiapine in the treatment of female patients with schizophrenia. Shanghai Archives of Psychiatry2005;17(2):83‐6. ">vs QTP ‐ Wang 2005</a>). There was no significant difference between chlorpromazine and quetiapine (MD 0.50, 95% CI −0.67 to 1.67; <a href="./references#CD010631-fig-0076" title="">Analysis 3.25</a>). </p> </section> <section id="CD010631-sec-0465"> <h6 class="title">3.25.2 average weight (KG)</h6> <p>In this subgroup we only found one relevant trial (N = 130) (<a href="./references#CD010631-bbs2-0026" title="GuoXF , ZhaoJP , ChenJD , ZhangZC . The effect of chlorpromazine and quetiapine on serum lipid and glucose. Journal of Clinical Psychiatry2006;16(5):257‐9. ">vs QTP ‐ Guo 2006</a>). There was no significant difference between chlorpromazine and quetiapine (MD −1.00, 95% CI −4.68 to 2.68; <a href="./references#CD010631-fig-0076" title="">Analysis 3.25</a>). </p> </section> </section> <section id="CD010631-sec-0466"> <h5 class="title">3.26 Adverse effects: 10. Various other ‐ short term (up to 6 months)</h5> <section id="CD010631-sec-0467"> <h6 class="title">3.26.1 unspecified adverse effects</h6> <p>In this subgroup we found four relevant trials (N = 560). There was a statistically significant difference (P = 0.004) in favour of quetiapine (RR 1.73, 95% CI 1.20 to 2.51; <a href="./references#CD010631-fig-0077" title="">Analysis 3.26</a>). This subgroup had important levels of heterogeneity (Chi² test = 10.42; df = 3; P = 0.015; I² statistic = 71%). </p> </section> </section> <section id="CD010631-sec-0468"> <h5 class="title">3.27 Adverse effects: 11. Average endpoint score (TESS, high = poor) ‐ skewed data</h5> <p>Data for this outcome are skewed and are best inspected by viewing <a href="./references#CD010631-fig-0078" title="">Analysis 3.27</a>. </p> </section> <section id="CD010631-sec-0469"> <h5 class="title">3.28 Quality of life: 1. General ‐ average endpoint score (GQOL1 ‐ 74, high = better)</h5> <section id="CD010631-sec-0470"> <h6 class="title">3.28.1 short term (up to 6 months)</h6> <p>In this subgroup we only found one relevant trial (N = 59) (<a href="./references#CD010631-bbs2-0031" title="JiJ , OuW . Comparative study between the quality of life and its curative effect in schizophrenic patients treated with quetiapine or chlorpromazine. Sichuan Mental Health2004;17(2):73‐5. ">vs QTP ‐ Ji 2004</a>). There was a statistically significant difference in favour of quetiapine (MD −6.49, 95% CI −11.3 to −1.68; P = 0.008; <a href="./references#CD010631-fig-0079" title="">Analysis 3.28</a>). </p> </section> </section> <section id="CD010631-sec-0471"> <h5 class="title">3.29 Leaving the study early: 1a. Short term (up to six months)</h5> <section id="CD010631-sec-0472"> <h6 class="title">3.29.1 due to adverse effect</h6> <p>In this subgroup we found ten relevant trials (N = 1680). There was a statistically significant difference in favour of quetiapine (RR 1.43, 95% CI 1.04 to 1.98; P = 0.03; <a href="./references#CD010631-fig-0080" title="">Analysis 3.29</a>). </p> </section> <section id="CD010631-sec-0473"> <h6 class="title">3.29.2 due to inefficacy</h6> <p>In this subgroup we found three relevant trials (N = 695). There was no significant difference between chlorpromazine and quetiapine (RR 1.42, 95% CI 0.68 to 2.96; <a href="./references#CD010631-fig-0080" title="">Analysis 3.29</a>). </p> </section> <section id="CD010631-sec-0474"> <h6 class="title">3.29.3 due to any other reason</h6> <p>We found 12 relevant trials in this subgroup (N = 1223). There was no significant difference between chlorpromazine and quetiapine (RR 1.04, 95% CI 0.77 to 1.41; <a href="./references#CD010631-fig-0080" title="">Analysis 3.29</a>). </p> </section> <section id="CD010631-sec-0475"> <h6 class="title">3.29.4 due to lost to follow‐up</h6> <p>In this subgroup we found two relevant trials (N = 400). There was no significant difference between chlorpromazine and quetiapine (RR 0.56, 95% CI 0.23 to 1.37; <a href="./references#CD010631-fig-0080" title="">Analysis 3.29</a>). </p> </section> </section> <section id="CD010631-sec-0476"> <h5 class="title">3.30 Leaving the study early: 1b. Medium term (seven to 12 months)</h5> <p>For this outcome we only found one relevant trial (N = 103) (<a href="./references#CD010631-bbs2-0036" title="LiM , HuF , WangS . A study of quetiapine and chlorpromazine on the effects and quality of life in the treatment of schizophrenia. Shandong Archives of Psychiatry2003;16(3):135‐7. ">vs QTP ‐ Li 2003</a>). There was no significant difference between chlorpromazine and quetiapine (RR 1.19, 95% CI 0.61 to 2.32; <a href="./references#CD010631-fig-0081" title="">Analysis 3.30</a>). </p> </section> </section> <section id="CD010631-sec-0477"> <h4 class="title">4. Sensitivity analysis</h4> <section id="CD010631-sec-0478"> <h5 class="title">1. Implication of randomisation</h5> <section id="CD010631-sec-0479"> <h6 class="title">1.1 Chlorpromazine versus olanzapine ‐ clinical response: no significant clinical response </h6> <p>After removing studies that did not adequately explain randomisation methods, there was no substantial difference in the estimate of the effect, with results statistically significant in favour of olanzapine (1 RCT, N = 58; RR 2.49, 95% CI 1.10 to 5.64). </p> </section> <section id="CD010631-sec-0480"> <h6 class="title">1.2 Chlorpromazine versus risperidone ‐ clinical response: no significant clinical response </h6> <p>After removing studies that did not adequately explain randomisation methods, there were no data left in the short term outcome to compare, since all included studies did not provide explanation. </p> </section> <section id="CD010631-sec-0481"> <h6 class="title">1.3 Chlorpromazine versus quetiapine ‐ clinical response: no significant clinical response </h6> <p>After removing studies that did not adequately explain randomisation methods, there was no substantial difference in the estimate of the effect. </p> </section> </section> <section id="CD010631-sec-0482"> <h5 class="title">2. Assumptions for lost binary data</h5> <p>We did not assume any binary data from the included studies.</p> </section> <section id="CD010631-sec-0483"> <h5 class="title">3. Risk of bias</h5> <section id="CD010631-sec-0484"> <h6 class="title">3.1 Chlorpromazine versus olanzapine ‐ clinical response: no significant clinical response </h6> <p>After we removed studies that were rated as 'high' across one or more of the 'Risk of bias' domains, there were no data left in the short‐term outcome to compare, since all included studies were rated as 'high' (<a href="./references#CD010631-bbs2-0004" title="ChangFW , WangCH , ZhaoZ . Clinical effects of olanzapine vs chlorpromazine in treating positive symptoms of schizophrenia. Chinese Journal of New Drugs and Clinical Remedies2003;22(6):357‐9. ">vs OLZ ‐ Chang 2003</a>; <a href="./references#CD010631-bbs2-0005" title="ChenF . Olanzapine and chlorpromazine in the treatment of schizophrenia. Journal of Clinical Psychiatric Medicine2006;16:303‐4. ">vs OLZ ‐ Chen 2006</a>; <a href="./references#CD010631-bbs2-0009" title="WangCH , ZhaoZ , LiY , PanM , LiuX . Evaluation of proximal therapeutic effect and distal social function restoration of olanzapine on schizophrenia patients. Zhongguo lin chuang kang fu [Chinese Journal of Clinical Rehabilitation]2002;6(17):2664‐5. ">vs OLZ ‐ Wang 2002</a>). However, there was no difference in long‐term outcome. </p> </section> <section id="CD010631-sec-0485"> <h6 class="title">3.2 Chlorpromazine versus risperidone ‐ clinical response: no significant clinical response </h6> <p>After we removed studies that we had rated as 'high' across one or more of the 'Risk of bias' domains, there was no substantial difference in the estimate of the effect. </p> </section> <section id="CD010631-sec-0486"> <h6 class="title">3.3 Chlorpromazine versus quetiapine ‐ clinical response: no significant clinical response </h6> <p>After removing studies that rated as 'high' across one or more of the 'Risk of bias' domains, there was no substantial difference in the estimate of the effect. </p> </section> </section> <section id="CD010631-sec-0487"> <h5 class="title">4. Imputed values</h5> <p>We had also planned to undertake a sensitivity analysis to assess the effects of including data from trials where we used imputed values for ICC in calculating the design effect in cluster‐RCTs. However, we did not impute any values in this Cochrane review. </p> </section> <section id="CD010631-sec-0488"> <h5 class="title">5. Fixed‐effect and random‐effects</h5> <section id="CD010631-sec-0489"> <h6 class="title">5.1 Chlorpromazine versus olanzapine ‐ clinical response: no significant clinical response </h6> <p>There was no difference in the estimate of effect if a fixed‐effect model was used in place of the random‐effects model. </p> </section> <section id="CD010631-sec-0490"> <h6 class="title">5.2 Chlorpromazine versus risperidone ‐ clinical response: no significant clinical response </h6> <p>There was no difference in the estimate of effect if a fixed‐effect model was used in place of the random‐effects model. </p> </section> <section id="CD010631-sec-0491"> <h6 class="title">5.3 Chlorpromazine versus quetiapine ‐ clinical response: no significant clinical response </h6> <p>There was no difference in the estimate of effect if a fixed‐effect model was used in place of the random‐effects model. </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD010631-sec-0492" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD010631-sec-0492"></div> <section id="CD010631-sec-0493"> <h3 class="title" id="CD010631-sec-0493">Summary of main results</h3> <section id="CD010631-sec-0494"> <h4 class="title">1. Chlorpromazine versus olanzapine</h4> <section id="CD010631-sec-0495"> <h5 class="title">1.1 Clinical response</h5> <p>Data from included studies indicate that olanzapine is more effective than chlorpromazine when it comes to 'clinical response' outcomes, at least in the short term, since long‐term data are equivocal. Notably, each study providing data defined 'clinical response' differently; one study classified response as a decrease in BPRS score, while another measured the number of people who became stabilised on their study medication. The remaining studies did not explain how clinical response was measured. However, regarding average endpoint scores using the CGI, scores were significantly lower in the olanzapine groups. Disappointingly, only one small study (N = 70) provided data for relapse, which demonstrated no significant difference between groups; a result that will need to be confirmed by future large, high‐quality RCTs. </p> </section> <section id="CD010631-sec-0496"> <h5 class="title">1.2 Mental state</h5> <p>These outcomes were difficult to interpret, with most included studies using a different scale of measurement to rate mental state in participants. Clearly there was no significant difference between the two compounds regarding total mean BPRS scores. However there was a significant level of heterogeneity in the studies. The source of this heterogeneity was <a href="./references#CD010631-bbs2-0005" title="ChenF . Olanzapine and chlorpromazine in the treatment of schizophrenia. Journal of Clinical Psychiatric Medicine2006;16:303‐4. ">vs OLZ ‐ Chen 2006</a> and removal of this study demonstrated a statistically significant difference between groups, in favour of olanzapine. The reasons for this heterogeneity have not been confirmed, since all studies shared a similar setting and used differing dose ranges of chlorpromazine (either 25 to 600 mg/day or 200 to 800 mg/day) and its olanzapine comparator. These findings need clarifying in future studies, as only a small sample provided data (N = 245). Changes in PANSS score were significant, with a greater decrease seen in people receiving olanzapine (N = 351). </p> </section> <section id="CD010631-sec-0497"> <h5 class="title">1.3 Service involvement</h5> <p>Unfortunately, data for service usage/involvement was seriously lacking; the only study that provided data for re‐hospitalisation rates (N = 70) demonstrated an equivocal result between groups. </p> </section> <section id="CD010631-sec-0498"> <h5 class="title">1.4 Functioning</h5> <p>Data from one study (N = 53) suggest that olanzapine is significantly better at improving functioning, using the WCST. A naturalistic study has suggested that people who received atypicals showed a better cognitive pattern in terms of WCST performance than those on typical antipsychotics (<a href="./references#CD010631-bbs2-0177" title="RossiA , DaneluzzoE , TomassiniA , StrugliaF , CavallaroF , SmeraldiE , et al. The effect of verbalization strategy on wisconsin card sorting test performance in schizophrenic patients receiving classical or atypical antipsychotics. BMC Psychiatry2006;6:3. ">Rossi 2006</a>). However, although this is a test that is generally accepted in schizophrenia research, it has not been widely used in the included studies, making it difficult to confirm this result. </p> </section> <section id="CD010631-sec-0499"> <h5 class="title">1.5 Adverse effects</h5> <p>Extrapyramidal adverse effects were largely equivocal; only data for 'any observed EPS' event were significant, with more events in people receiving chlorpromazine; however, this finding is based on only two studies (N = 298). There is a strong dataset indicating that chlorpromazine causes significantly greater instances of drowsiness and constipation. Other significant findings, particularly associated with cardiovascular outcomes (palpitation, tachycardia and blood pressure decrease) are only based on the findings of two small RCTs. </p> </section> <section id="CD010631-sec-0500"> <h5 class="title">1.6 Quality of life</h5> <p>Two different rating scales were used in the two studies that provided data, neither of which were meta‐analysed, with skewed data only available using the QoL scale. GQOLI scores show that ratings on specific areas of quality of life (including physical health, psychological health and social functioning) were significantly better in people receiving olanzapine. Again, this is a result that will need to be confirmed with future studies reporting data using these validated scales. </p> </section> <section id="CD010631-sec-0501"> <h5 class="title">1.7 Leaving the study early</h5> <p>There was no difference between groups for people leaving the studies early for any reason. </p> </section> </section> <section id="CD010631-sec-0502"> <h4 class="title">2. Chlorpromazine versus risperidone</h4> <section id="CD010631-sec-0503"> <h5 class="title">2.1 Clinical response</h5> <p>Data from the seven included RCTs (N = 475) indicate there is no significant difference between compounds in 'clinical response' (as defined in the different studies). Other global state outcomes are equivocal, with skewed data only available using the CGI, and data equivocal for amounts of participants requiring additional antiparkinsonian medication. </p> </section> <section id="CD010631-sec-0504"> <h5 class="title">2.2 Mental state</h5> <p>Most included studies measured mental state outcomes using one of the widely‐accepted rating scales (BPRS, PANSS or SANS), with data for each subscale demonstrating no significant difference between groups. </p> </section> <section id="CD010631-sec-0505"> <h5 class="title">2.3 Functioning</h5> <p>Data show significantly better scores for improvement in functioning using the WCST when receiving risperidone. Again, as only one small study reported data for two subscales of the WCST, it is impossible to make a generalisation with this result. </p> </section> <section id="CD010631-sec-0506"> <h5 class="title">2.4 Adverse effects</h5> <p>Extrapyramidal adverse effects were largely equivocal; however, akathisia was significantly more prominent in people receiving chlorpromazine (31% versus 13%), as was tremor (32% versus 14%). <a href="./references#CD010631-bbs2-0067" title="WangQ , JiaC . Controlled study of risperidone and chlorpromazine in the treatment of schizophrenia. Health Psychology Journal2002;10:226‐8. ">vs RPD ‐ Wang 2002</a> was the source of heterogeneity in the two aforementioned significant findings, and this was the only study to use a fixed dose of chlorpromazine (400 mg/day) and two further treatment arms of risperidone (4 mg/day or 6 mg/day). Chlorpromazine was also associated significantly with more events of constipation (N = 868), loss of appetite (N = 180), tachycardia (N = 557), hypersalivation (N = 373), blurred vision (N = 387), drop of blood pressure (N = 250) and orthostatic hypotension (N = 546), drowsiness (N = 307) and dizziness (N = 299). However, significantly more people receiving risperidone experienced insomnia (N = 342). </p> </section> <section id="CD010631-sec-0507"> <h5 class="title">2.5 Quality of life</h5> <p>With only one study providing data using the QoL scale demonstrating significantly greater improvement in people receiving risperidone (N = 100), it is difficult to generalise this finding to a real‐world setting. </p> </section> <section id="CD010631-sec-0508"> <h5 class="title">2.6 Leaving the study early</h5> <p>There was no difference between groups for people leaving the studies early for any reason with roughly equal numbers of participants leaving their groups. </p> </section> </section> <section id="CD010631-sec-0509"> <h4 class="title">3. Chlorpromazine versus quetiapine</h4> <section id="CD010631-sec-0510"> <h5 class="title">3.1 Clinical response</h5> <p>Data from the 28 included RCTs (N = 3241) indicate there is no significant difference in 'clinical response' (as defined in the different studies) between compounds; however, significantly more people receiving chlorpromazine required additional benzodiazepines or antiparkinsonian drugs. Furthermore, global state outcomes using the CGI are largely equivocal, making it difficult to weigh up any further benefits of either drug taking into account the fact that there was no difference in clinical response. </p> </section> <section id="CD010631-sec-0511"> <h5 class="title">3.2 Mental state</h5> <p>Mental state outcomes using either the BPRS or PANSS were largely equivocal again, with no significant difference between groups. There were some results that suggested quetiapine was significantly more effective at reducing negative symptoms (using PANSS). However, there was a significant degree of heterogeneity in these results. </p> </section> <section id="CD010631-sec-0512"> <h5 class="title">3.3 Functioning</h5> <p>Data showed significantly better scores for improvement in functioning using the WCST when receiving quetiapine. Again, with only one small study reporting data for two subscales of the WCST, it is impossible to make a generalisation with this result. </p> </section> <section id="CD010631-sec-0513"> <h5 class="title">3.4 Adverse effects</h5> <p>Extrapryamidal symptoms were significantly more prominent in people receiving chlorpromazine, particularly with akathisia (N = 1757), 'any' EPS symptom (N = 644), myotonia (N = 1257), torsion movement (N = 1063) and tremor (N = 1343). However, levels of agitation tended to be higher in people receiving quetiapine. Other specific adverse effects, including drowsiness, reduced activity, weight gain, constipation, orthostatic hypotension, tachycardia, hypersalivation, blurred vision and dry mouth, were significantly greater in people receiving chlorpromazine. </p> </section> <section id="CD010631-sec-0514"> <h5 class="title">3.5 Quality of life</h5> <p>GQOLI scores show that ratings on QoL were significantly better in people receiving quetiapine. Again, this needs to be confirmed with future studies reporting data using this validated scale. </p> </section> <section id="CD010631-sec-0515"> <h5 class="title">3.6 Leaving the study early</h5> <p>More people left their study early due to adverse effects if they were receiving chlorpromazine; a finding that reflects the expected tolerability of this drug based on the adverse events recorded above. Leaving the studies early for other reasons were not significantly different between groups in the short or medium term. </p> </section> </section> </section> <section id="CD010631-sec-0516"> <h3 class="title" id="CD010631-sec-0516">Overall completeness and applicability of evidence</h3> <p>None of the included studies provided measured outcomes for economic consideration, nor behaviour or satisfaction with treatment or care. These outcomes are important for managers and policy makers' consideration, as well as for carers. Cearly data for 'satisfaction of treatment or care' would provide a basis for evidence of patient acceptability of either compound. No study reported the outcome of death. Reported outcomes were largely clinician oriented, and outcomes including service involvement was under‐reported, and future studies would need to address this patient important, policy important outcome. The majority of included studies provided data at the short term only (less than six months), making it impossible to assess any medium or long‐term effect either compound has on patients. Several studies were excluded because they did not provide any useable data. </p> <p>Most included studies included inpatients from hospitals in China. Therefore the results of this Cochrane review are more applicable to the Chinese population and are not particularly suitable to apply to community‐treated patients. The dose range employed in most studies was as high as 1000 mg/day, which is far beyond the maximum BNF recommended dosage (<a href="http://www.medicinescomplete.com/mc/bnf/current/PHP2217-chlorpromazine-non-proprietary.htm?q=chlorpromazine%26t=search%26ss=text%26p=1#PHP2217-chlorpromazine-non-proprietary" target="_blank">BNF 2014</a>). As most studies provided a range as opposed to a mean dosage, it is not possible to generalise these findings to other populations. </p> </section> <section id="CD010631-sec-0517"> <h3 class="title" id="CD010631-sec-0517">Quality of the evidence</h3> <p>Unfortunately, the overall quality of the evidence was poor (see <a href="#CD010631-fig-0002">Figure 2</a>; <a href="#CD010631-fig-0003">Figure 3</a> for a graphical overview and summary). No included studies provided details as to randomisation methods and selective reporting was relatively prominent in most included studies. Furthermore, as most studies were undertaken in China (concerns have previously been raised about the quality of reporting in Chinese studies; <a href="./references#CD010631-bbs2-0121" title="Anon . Scientific fraud: action needed in China. Lancet2010;375(9709):94. ">Anon 2010</a>; <a href="./references#CD010631-bbs2-0190" title="WuT , LiY , LiuG , BianZ , LiJ , ZhangJ , et al. Investigation of authenticity of 'claimed' randomized controlled trials (RCTs) and quality assessment of RCT reports published in China. Proceedings of the 14th Cochrane Colloquium; 2006 October 23‐26; Dublin. Dublin, 2006. ">Wu 2006</a>), this data requires interpreting with caution as biases may have inflated the estimate of effect in statistically significant outcomes. We identified duplicated data in two studies (<a href="./references#CD010631-bbs2-0011" title="WuY , LuWH , YiZH , WangJ , SongBF , ShiDQ , et al. Controlled study of olanzapine versus chlorpromazine for the quality of life of patients with schizophrenia. Sichuan Mental Health Journal2008;21(1):8‐11. ">vs OLZ ‐ Wu 2008</a>; <a href="./references#CD010631-bbs2-0070" title="WuY , LuW , YiZ . A comparative study of risperidone and chlorpromazine on quality of life in patients with schizophrenia. Shandong Archive of Psychiatry2004;17:137‐40. ">vs RPD ‐ Wu 2004</a>) where these two studies compared chlorpromazine to olanzapine and risperidone, respectively. <a href="./references#CD010631-bbs2-0011" title="WuY , LuWH , YiZH , WangJ , SongBF , ShiDQ , et al. Controlled study of olanzapine versus chlorpromazine for the quality of life of patients with schizophrenia. Sichuan Mental Health Journal2008;21(1):8‐11. ">vs OLZ ‐ Wu 2008</a> measured quality of life using the SF‐36 scale, and <a href="./references#CD010631-bbs2-0070" title="WuY , LuW , YiZ . A comparative study of risperidone and chlorpromazine on quality of life in patients with schizophrenia. Shandong Archive of Psychiatry2004;17:137‐40. ">vs RPD ‐ Wu 2004</a> measured QoL using the GQOLI scale; however the data for these are identical in both studies. The mean scores, SDs and sample size in each group were identical; and we therefore strongly suspect reporting biases, but need to clarify this with the trial authors. In the meantime, we have included the QoL data from <a href="./references#CD010631-bbs2-0070" title="WuY , LuW , YiZ . A comparative study of risperidone and chlorpromazine on quality of life in patients with schizophrenia. Shandong Archive of Psychiatry2004;17:137‐40. ">vs RPD ‐ Wu 2004</a>, and cross‐checked all other data between studies and found no further duplication. </p> </section> <section id="CD010631-sec-0518"> <h3 class="title" id="CD010631-sec-0518">Potential biases in the review process</h3> <p>Chlorpromazine is an old antipsychotic drug that has been extensively compared with other compounds. There exists the possibility that there are unpublished, unidentified studies that we have not included in this review. We strictly adhered to our protocol regarding data extraction and data management. However, we have presented comparisons with chlorpromazine with the specific name of the comparator drug, instead of the planned, generic 'chlorpromazine versus atypical antipsychotics'. We have only included data for three of the drug comparisons and plan in future updated of this Cochrane review to include all other comparator atypical antipsychotics. We also note that due to the size of the 2012 search results, the search date for this review is out‐of‐date. We intend to re‐run a search this year and republish as soon as possible. </p> </section> <section id="CD010631-sec-0519"> <h3 class="title" id="CD010631-sec-0519">Agreements and disagreements with other studies or reviews</h3> <p>This Cochrane review clarifies the evidence relating to the effects of chlorpromazine versus three comparator atypical antipsychotics, namely olanzapine, risperidone and quetiapine. It provides the evidence base for the disputed adverse effect profile, which has been claimed to be more severe in the older, atypical antipsychotics as compared to the newer compounds. However, 96% of the studies from which this data have been derived were undertaken in Chinese hospitals making it difficult to generalise the finding. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD010631-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/urn:x-wiley:14651858:media:CD010631:CD010631-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_t/tCD010631-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD010631-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/full#CD010631-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010631-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/urn:x-wiley:14651858:media:CD010631:CD010631-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_t/tCD010631-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study." data-id="CD010631-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/full#CD010631-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010631-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/urn:x-wiley:14651858:media:CD010631:CD010631-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_t/tCD010631-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies." data-id="CD010631-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/full#CD010631-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010631-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/urn:x-wiley:14651858:media:CD010631:CD010631-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_t/tCD010631-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 3 Chlorpromazine vs Quetiapine, outcome: 3.1 Clinical response: no significant clinical response." data-id="CD010631-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Funnel plot of comparison: 3 Chlorpromazine vs Quetiapine, outcome: 3.1 Clinical response: no significant clinical response. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/full#CD010631-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010631-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/urn:x-wiley:14651858:media:CD010631:CD010631-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_t/tCD010631-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 1 Clinical response: 1. No significant clinical response." data-id="CD010631-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 1 Clinical response: 1. No significant clinical response. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010631-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/urn:x-wiley:14651858:media:CD010631:CD010631-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_t/tCD010631-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 2 Clinical response: 2. Average endpoint score (CGI, high = poor) ‐ short term (up to 6 months)." data-id="CD010631-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 2 Clinical response: 2. Average endpoint score (CGI, high = poor) ‐ short term (up to 6 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010631-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/urn:x-wiley:14651858:media:CD010631:CD010631-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_t/tCD010631-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 3 Clinical response: 3. Relapse ‐ long term (over 12 months)." data-id="CD010631-fig-0007" src="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 3 Clinical response: 3. Relapse ‐ long term (over 12 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010631-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/urn:x-wiley:14651858:media:CD010631:CD010631-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_t/tCD010631-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 4 Mental state: 1. Average endpoint score (various scales, high = poor) ‐ short term (up to 6 months)." data-id="CD010631-fig-0008" src="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 4 Mental state: 1. Average endpoint score (various scales, high = poor) ‐ short term (up to 6 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010631-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/urn:x-wiley:14651858:media:CD010631:CD010631-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_t/tCD010631-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 5 Mental state: 2. Average endpoint score (BPRS, high = poor) ‐ medium term (7 to 12 months)." data-id="CD010631-fig-0009" src="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 5 Mental state: 2. Average endpoint score (BPRS, high = poor) ‐ medium term (7 to 12 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010631-fig-0010"> <p> <div class="table" id="CD010631-tblf-0001"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>BPRS total</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HGCQ (Turkey) 2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HGCQ (Turkey) 2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Olanzapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HGDV (Morocco) 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HGDV (Morocco) 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Olanzapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs OLZ ‐ Wang 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30.16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>108</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs OLZ ‐ Wang 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Olanzapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27.34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>105</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>HAMA (anxiety)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HGDV (Morocco) 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HGDV (Morocco) 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Olanzapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>MADRS (depression)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HGDV (Morocco) 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HGDV (Morocco) 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Olanzapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>PANSS negative symptom subscale</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs OLZ ‐ Wu 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs OLZ ‐ Wu 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Olanzapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>PANSS positive symptom subscale</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs OLZ ‐ He 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs OLZ ‐ He 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Olanzapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 6 Mental state: 3. Average endpoint score (various scales, high = poor) ‐ skewed data. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0010">Navigate to figure in review</a></div> </div> <div class="figure" id="CD010631-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/urn:x-wiley:14651858:media:CD010631:CD010631-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_t/tCD010631-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 7 Service involvement: 1. Re‐hospitalisation." data-id="CD010631-fig-0011" src="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 7 Service involvement: 1. Re‐hospitalisation.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010631-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/urn:x-wiley:14651858:media:CD010631:CD010631-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_t/tCD010631-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 8 Functioning: 1. Executive function ‐ average endpoint score (WCST, high = poor)." data-id="CD010631-fig-0012" src="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 8 Functioning: 1. Executive function ‐ average endpoint score (WCST, high = poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010631-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/urn:x-wiley:14651858:media:CD010631:CD010631-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_t/tCD010631-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 9 Adverse effects: 1. Anticholinergic ‐ short term (up to 6 months)." data-id="CD010631-fig-0013" src="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 9 Adverse effects: 1. Anticholinergic ‐ short term (up to 6 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010631-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/urn:x-wiley:14651858:media:CD010631:CD010631-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_t/tCD010631-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 10 Adverse effects: 2. Cardiovascular ‐ short term (up to 6 months)." data-id="CD010631-fig-0014" src="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 10 Adverse effects: 2. Cardiovascular ‐ short term (up to 6 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010631-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/urn:x-wiley:14651858:media:CD010631:CD010631-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_t/tCD010631-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 11 Adverse effects: 3. Central nervous system ‐ short term (up to 6 months)." data-id="CD010631-fig-0015" src="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 11 Adverse effects: 3. Central nervous system ‐ short term (up to 6 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010631-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/urn:x-wiley:14651858:media:CD010631:CD010631-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_t/tCD010631-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 12 Adverse effects: 4. Gastrointestinal ‐ short term (up to 6 months)." data-id="CD010631-fig-0016" src="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 12 Adverse effects: 4. Gastrointestinal ‐ short term (up to 6 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010631-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/urn:x-wiley:14651858:media:CD010631:CD010631-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_t/tCD010631-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 13 Adverse effects: 5. Haematology ‐ short term (up to 6 months)." data-id="CD010631-fig-0017" src="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 13 Adverse effects: 5. Haematology ‐ short term (up to 6 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010631-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/urn:x-wiley:14651858:media:CD010631:CD010631-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_t/tCD010631-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 14 Adverse effects: 6. Hepatitic ‐ short term (up to 6 months)." data-id="CD010631-fig-0018" src="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 14 Adverse effects: 6. Hepatitic ‐ short term (up to 6 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010631-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/urn:x-wiley:14651858:media:CD010631:CD010631-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_t/tCD010631-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 15 Adverse effects: 7a. Metabolic ‐ weight gain ‐ short term (up to 6 months)." data-id="CD010631-fig-0019" src="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 15 Adverse effects: 7a. Metabolic ‐ weight gain ‐ short term (up to 6 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010631-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/urn:x-wiley:14651858:media:CD010631:CD010631-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_t/tCD010631-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 16 Adverse effects: 7b. Metabolic ‐ weight gain ‐ continuous measures." data-id="CD010631-fig-0020" src="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 16 Adverse effects: 7b. Metabolic ‐ weight gain ‐ continuous measures. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010631-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/urn:x-wiley:14651858:media:CD010631:CD010631-CMP-001-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_t/tCD010631-CMP-001-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 17 Adverse effects: 7c. Metabolic ‐ other ‐ continuous measures." data-id="CD010631-fig-0021" src="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-001-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 17 Adverse effects: 7c. Metabolic ‐ other ‐ continuous measures. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-001-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010631-fig-0022"> <p> <div class="table" id="CD010631-tblf-0002"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>cholesterol (TC) ‐ medium term (7 to 12 months)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs OLZ ‐ Luo 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs OLZ ‐ Luo 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Olanzapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>high‐density lipoprotein (HDL) ‐ short term (up to 6 months)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs OLZ ‐ Luo 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs OLZ ‐ Luo 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Olanzapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>triglyceride (TG) ‐ short term (up to 6 months)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs OLZ ‐ Luo 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.07</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs OLZ ‐ Luo 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Olanzapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.07</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>triglyceride (TG) ‐ medium term (7 to 12 months)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs OLZ ‐ Luo 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.04</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs OLZ ‐ Luo 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Olanzapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 18 Adverse effects: 7d. Metabolic ‐ other ‐ average endpoint scores ‐ skewed data. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0022">Navigate to figure in review</a></div> </div> <div class="figure" id="CD010631-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/urn:x-wiley:14651858:media:CD010631:CD010631-CMP-001-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_t/tCD010631-CMP-001-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 19 Adverse effects: 8a. Movement disorders ‐ extrapyramidal symptoms ‐ short term (up to 6 months)." data-id="CD010631-fig-0023" src="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-001-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 19 Adverse effects: 8a. Movement disorders ‐ extrapyramidal symptoms ‐ short term (up to 6 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-001-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010631-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/urn:x-wiley:14651858:media:CD010631:CD010631-CMP-001-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_t/tCD010631-CMP-001-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 20 Adverse effects: 8b. Movement disorders ‐ extrapyramidal symptoms ‐ average endpoint score (ESRS, high = poor)." data-id="CD010631-fig-0024" src="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-001-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 20 Adverse effects: 8b. Movement disorders ‐ extrapyramidal symptoms ‐ average endpoint score (ESRS, high = poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-001-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010631-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/urn:x-wiley:14651858:media:CD010631:CD010631-CMP-001-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_t/tCD010631-CMP-001-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 21 Adverse effects: 9a. Various other ‐ sleep ‐ average endpoint score (LSEQ, high = better) ‐ short term (up to 6 months)." data-id="CD010631-fig-0025" src="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-001-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.21</div> <div class="figure-caption"> <p>Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 21 Adverse effects: 9a. Various other ‐ sleep ‐ average endpoint score (LSEQ, high = better) ‐ short term (up to 6 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-001-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010631-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/urn:x-wiley:14651858:media:CD010631:CD010631-CMP-001-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_t/tCD010631-CMP-001-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 22 Adverse effects: 9b. Various other ‐ sleep ‐ average length of sleep (hour/day)." data-id="CD010631-fig-0026" src="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-001-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.22</div> <div class="figure-caption"> <p>Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 22 Adverse effects: 9b. Various other ‐ sleep ‐ average length of sleep (hour/day). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-001-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010631-fig-0027"> <p> <div class="table" id="CD010631-tblf-0003"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>short term (up to 6 months)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HGCQ (Turkey) 2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HGCQ (Turkey) 2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Olanzapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.23</div> <div class="figure-caption"> <p>Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 23 Adverse effects: 9c. Various other ‐ sleep ‐ behaviour following waking (LSEQ) ‐ skewed data. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0027">Navigate to figure in review</a></div> </div> <div class="figure" id="CD010631-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/urn:x-wiley:14651858:media:CD010631:CD010631-CMP-001-24" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_t/tCD010631-CMP-001-24.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 24 Adverse effects: 9b. Various other ‐ rash." data-id="CD010631-fig-0028" src="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-001-24.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.24</div> <div class="figure-caption"> <p>Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 24 Adverse effects: 9b. Various other ‐ rash. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-001-24.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010631-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/urn:x-wiley:14651858:media:CD010631:CD010631-CMP-001-25" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_t/tCD010631-CMP-001-25.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 25 Quality of life: 1a. Average endpoint scores (various scales, high = better) ‐ short term (up to 6 months)." data-id="CD010631-fig-0029" src="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-001-25.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.25</div> <div class="figure-caption"> <p>Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 25 Quality of life: 1a. Average endpoint scores (various scales, high = better) ‐ short term (up to 6 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-001-25.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010631-fig-0030"> <p> <div class="table" id="CD010631-tblf-0004"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>short term (up to 6 months)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs OLZ ‐ Loza 1999 (HGDT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs OLZ ‐ Loza 1999 (HGDT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Olanzapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.26</div> <div class="figure-caption"> <p>Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 26 Quality of life: 1b. Average endpoint score (QoL, high = better) ‐ skewed data. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0030">Navigate to figure in review</a></div> </div> <div class="figure" id="CD010631-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/urn:x-wiley:14651858:media:CD010631:CD010631-CMP-001-27" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_t/tCD010631-CMP-001-27.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 27 Leaving the study early ‐ short term (up to 6 months)." data-id="CD010631-fig-0031" src="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-001-27.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.27</div> <div class="figure-caption"> <p>Comparison 1 CHLORPROMAZINE versus OLANZAPINE, Outcome 27 Leaving the study early ‐ short term (up to 6 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-001-27.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010631-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/urn:x-wiley:14651858:media:CD010631:CD010631-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_t/tCD010631-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 CHLORPROMAZINE versus RISPERIDONE, Outcome 1 Clinical response: 1. No significant clinical response." data-id="CD010631-fig-0032" src="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 CHLORPROMAZINE versus RISPERIDONE, Outcome 1 Clinical response: 1. No significant clinical response. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010631-fig-0033"> <p> <div class="table" id="CD010631-tblf-0005"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>short term (up to 6 months)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs RPD ‐ Ma 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs RPD ‐ Ma 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 CHLORPROMAZINE versus RISPERIDONE, Outcome 2 Global state: 1. Average endpoint score (CGI‐CI, high = poor) ‐ skewed data. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0033">Navigate to figure in review</a></div> </div> <div class="figure" id="CD010631-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/urn:x-wiley:14651858:media:CD010631:CD010631-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_t/tCD010631-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 CHLORPROMAZINE versus RISPERIDONE, Outcome 3 Global state: 2. Need of additional benzhexol." data-id="CD010631-fig-0034" src="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 CHLORPROMAZINE versus RISPERIDONE, Outcome 3 Global state: 2. Need of additional benzhexol. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010631-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/urn:x-wiley:14651858:media:CD010631:CD010631-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_t/tCD010631-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 CHLORPROMAZINE versus RISPERIDONE, Outcome 4 Mental state: 1a. Average endpoint score (various scales, high = poor) ‐ short term (up to 6 months)." data-id="CD010631-fig-0035" src="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 CHLORPROMAZINE versus RISPERIDONE, Outcome 4 Mental state: 1a. Average endpoint score (various scales, high = poor) ‐ short term (up to 6 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010631-fig-0036"> <p> <div class="table" id="CD010631-tblf-0006"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>BPRS thinking disorder subscale</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs RPD ‐ Wu 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs RPD ‐ Wu 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>BPRS withdraw‐retardation subscale</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs RPD ‐ Cui 2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs RPD ‐ Cui 2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs RPD ‐ Wu 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs RPD ‐ Wu 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.02</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>PANSS general pathology subscale</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs RPD ‐ Cui 2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21.17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs RPD ‐ Cui 2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24.47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>PANSS negative symptom subscale</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs RPD ‐ Cui 2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs RPD ‐ Cui 2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs RPD ‐ Luo 2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs RPD ‐ Luo 2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>PANSS positive symptom subscale</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs RPD ‐ Cui 2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs RPD ‐ Cui 2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>SAPS total</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs RPD ‐ He 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs RPD ‐ He 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 CHLORPROMAZINE versus RISPERIDONE, Outcome 5 Mental state: 1b. Average endpoint score (various scales, high = poor) ‐ skewed data ‐ short term (up to 6 months). </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0036">Navigate to figure in review</a></div> </div> <div class="figure" id="CD010631-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/urn:x-wiley:14651858:media:CD010631:CD010631-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_t/tCD010631-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 CHLORPROMAZINE versus RISPERIDONE, Outcome 6 Mental state: 2. Average change score ‐ decreased rate (various scales, high = poor) ‐ short term (up to 6 months)." data-id="CD010631-fig-0037" src="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 CHLORPROMAZINE versus RISPERIDONE, Outcome 6 Mental state: 2. Average change score ‐ decreased rate (various scales, high = poor) ‐ short term (up to 6 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010631-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/urn:x-wiley:14651858:media:CD010631:CD010631-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_t/tCD010631-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 CHLORPROMAZINE versus RISPERIDONE, Outcome 7 Functioning: 1. Average endpoint score (WCST subscales, high = good) ‐ short term (up to 6 months)." data-id="CD010631-fig-0038" src="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 CHLORPROMAZINE versus RISPERIDONE, Outcome 7 Functioning: 1. Average endpoint score (WCST subscales, high = good) ‐ short term (up to 6 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010631-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/urn:x-wiley:14651858:media:CD010631:CD010631-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_t/tCD010631-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 CHLORPROMAZINE versus RISPERIDONE, Outcome 8 Adverse effects: 1. Anticholinergic ‐ short term (up to 6 months)." data-id="CD010631-fig-0039" src="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 CHLORPROMAZINE versus RISPERIDONE, Outcome 8 Adverse effects: 1. Anticholinergic ‐ short term (up to 6 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010631-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/urn:x-wiley:14651858:media:CD010631:CD010631-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_t/tCD010631-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 CHLORPROMAZINE versus RISPERIDONE, Outcome 9 Adverse effects: 2a. Cardiovascular ‐ short term (up to 6 months)." data-id="CD010631-fig-0040" src="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 CHLORPROMAZINE versus RISPERIDONE, Outcome 9 Adverse effects: 2a. Cardiovascular ‐ short term (up to 6 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010631-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/urn:x-wiley:14651858:media:CD010631:CD010631-CMP-002-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_t/tCD010631-CMP-002-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 CHLORPROMAZINE versus RISPERIDONE, Outcome 10 Adverse effects: 2b. Cardiovascular ‐ continuous measures ‐ short term (up to 6 months)." data-id="CD010631-fig-0041" src="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-002-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2 CHLORPROMAZINE versus RISPERIDONE, Outcome 10 Adverse effects: 2b. Cardiovascular ‐ continuous measures ‐ short term (up to 6 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-002-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010631-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/urn:x-wiley:14651858:media:CD010631:CD010631-CMP-002-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_t/tCD010631-CMP-002-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 CHLORPROMAZINE versus RISPERIDONE, Outcome 11 Adverse effects: 3. Central nervous system ‐ short term (up to 6 months)." data-id="CD010631-fig-0042" src="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-002-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2 CHLORPROMAZINE versus RISPERIDONE, Outcome 11 Adverse effects: 3. Central nervous system ‐ short term (up to 6 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-002-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010631-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/urn:x-wiley:14651858:media:CD010631:CD010631-CMP-002-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_t/tCD010631-CMP-002-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 CHLORPROMAZINE versus RISPERIDONE, Outcome 12 Adverse effects: 4. Gastrointestinal ‐ short term (up to 6 months)." data-id="CD010631-fig-0043" src="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-002-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2 CHLORPROMAZINE versus RISPERIDONE, Outcome 12 Adverse effects: 4. Gastrointestinal ‐ short term (up to 6 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-002-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010631-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/urn:x-wiley:14651858:media:CD010631:CD010631-CMP-002-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_t/tCD010631-CMP-002-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 CHLORPROMAZINE versus RISPERIDONE, Outcome 13 Adverse effects: 5. Haematology ‐ short term (up to 6 months)." data-id="CD010631-fig-0044" src="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-002-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2 CHLORPROMAZINE versus RISPERIDONE, Outcome 13 Adverse effects: 5. Haematology ‐ short term (up to 6 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-002-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010631-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/urn:x-wiley:14651858:media:CD010631:CD010631-CMP-002-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_t/tCD010631-CMP-002-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 CHLORPROMAZINE versus RISPERIDONE, Outcome 14 Adverse effects: 6. Hepatitic ‐ short term (up to 6 months)." data-id="CD010631-fig-0045" src="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-002-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.14</div> <div class="figure-caption"> <p>Comparison 2 CHLORPROMAZINE versus RISPERIDONE, Outcome 14 Adverse effects: 6. Hepatitic ‐ short term (up to 6 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-002-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010631-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/urn:x-wiley:14651858:media:CD010631:CD010631-CMP-002-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_t/tCD010631-CMP-002-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 CHLORPROMAZINE versus RISPERIDONE, Outcome 15 Adverse effects: 7. Metabolic ‐ weight gain." data-id="CD010631-fig-0046" src="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-002-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.15</div> <div class="figure-caption"> <p>Comparison 2 CHLORPROMAZINE versus RISPERIDONE, Outcome 15 Adverse effects: 7. Metabolic ‐ weight gain. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-002-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010631-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/urn:x-wiley:14651858:media:CD010631:CD010631-CMP-002-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_t/tCD010631-CMP-002-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 CHLORPROMAZINE versus RISPERIDONE, Outcome 16 Adverse effects: 8. Movement disorders ‐ short term (up to 6 months)." data-id="CD010631-fig-0047" src="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-002-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.16</div> <div class="figure-caption"> <p>Comparison 2 CHLORPROMAZINE versus RISPERIDONE, Outcome 16 Adverse effects: 8. Movement disorders ‐ short term (up to 6 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-002-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010631-fig-0048"> <p> <div class="table" id="CD010631-tblf-0007"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>short term (up to 6 months)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs RPD ‐ Cui 2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs RPD ‐ Cui 2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs RPD ‐ He 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs RPD ‐ He 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs RPD ‐ Liu 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs RPD ‐ Liu 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.17</div> <div class="figure-caption"> <p>Comparison 2 CHLORPROMAZINE versus RISPERIDONE, Outcome 17 Adverse events: 9. Average endpoint score (TESS) ‐ skewed data. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0048">Navigate to figure in review</a></div> </div> <div class="figure" id="CD010631-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/urn:x-wiley:14651858:media:CD010631:CD010631-CMP-002-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_t/tCD010631-CMP-002-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 CHLORPROMAZINE versus RISPERIDONE, Outcome 18 Adverse effects: 10. Various other ‐ short term (up to 6 months)." data-id="CD010631-fig-0049" src="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-002-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.18</div> <div class="figure-caption"> <p>Comparison 2 CHLORPROMAZINE versus RISPERIDONE, Outcome 18 Adverse effects: 10. Various other ‐ short term (up to 6 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-002-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010631-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/urn:x-wiley:14651858:media:CD010631:CD010631-CMP-002-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_t/tCD010631-CMP-002-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 CHLORPROMAZINE versus RISPERIDONE, Outcome 19 Quality of life: 1. Average endpoint score (QOL, high = good)." data-id="CD010631-fig-0050" src="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-002-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.19</div> <div class="figure-caption"> <p>Comparison 2 CHLORPROMAZINE versus RISPERIDONE, Outcome 19 Quality of life: 1. Average endpoint score (QOL, high = good). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-002-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010631-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/urn:x-wiley:14651858:media:CD010631:CD010631-CMP-002-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_t/tCD010631-CMP-002-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 CHLORPROMAZINE versus RISPERIDONE, Outcome 20 Leaving the study early ‐ short term (up to 6 months)." data-id="CD010631-fig-0051" src="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-002-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.20</div> <div class="figure-caption"> <p>Comparison 2 CHLORPROMAZINE versus RISPERIDONE, Outcome 20 Leaving the study early ‐ short term (up to 6 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-002-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010631-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/urn:x-wiley:14651858:media:CD010631:CD010631-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_t/tCD010631-CMP-003-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 1 Clinical response: 1. No significant clinical response." data-id="CD010631-fig-0052" src="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 1 Clinical response: 1. No significant clinical response. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010631-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/urn:x-wiley:14651858:media:CD010631:CD010631-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_t/tCD010631-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 2 Global state: 1. Need of additional benzodiazepines/benzhexol." data-id="CD010631-fig-0053" src="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 2 Global state: 1. Need of additional benzodiazepines/benzhexol. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010631-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/urn:x-wiley:14651858:media:CD010631:CD010631-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_t/tCD010631-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 3 Global state: 2a. Average endpoint scores (various scales, high = poor) ‐ short term (up to 6 months)." data-id="CD010631-fig-0054" src="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 3 Global state: 2a. Average endpoint scores (various scales, high = poor) ‐ short term (up to 6 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010631-fig-0055"> <p> <div class="table" id="CD010631-tblf-0008"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>short term (up to 6 months)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs QTP ‐ Guo 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs QTP ‐ Guo 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quetiapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 4 Global state: 2b. Average endpoint score (CGI‐SI, high = poor) ‐ skewed data). </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0055">Navigate to figure in review</a></div> </div> <div class="figure" id="CD010631-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/urn:x-wiley:14651858:media:CD010631:CD010631-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_t/tCD010631-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 5 Global state: 3. Average change scores (CGI‐SI, high = poor)." data-id="CD010631-fig-0056" src="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 5 Global state: 3. Average change scores (CGI‐SI, high = poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010631-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/urn:x-wiley:14651858:media:CD010631:CD010631-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_t/tCD010631-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 6 Mental state: 1a. Average endpoint scores (various scales, high = poor) ‐ short term (up to 6 months)." data-id="CD010631-fig-0057" src="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 6 Mental state: 1a. Average endpoint scores (various scales, high = poor) ‐ short term (up to 6 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010631-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/urn:x-wiley:14651858:media:CD010631:CD010631-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_t/tCD010631-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 7 Mental state: 1b. Average endpoint scores (various scales, high = poor) ‐ medium term (6 to 12 months)." data-id="CD010631-fig-0058" src="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 7 Mental state: 1b. Average endpoint scores (various scales, high = poor) ‐ medium term (6 to 12 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010631-fig-0059"> <p> <div class="table" id="CD010631-tblf-0009"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>PANSS total ‐ short term (up to 6 months)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs QTP ‐ Zhang 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28.39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs QTP ‐ Zhang 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quetiapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>PANSS positive symptoms ‐ short term (up to 6 months)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs QTP ‐ Guo 2003a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs QTP ‐ Guo 2003a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quetiapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs QTP ‐ Guo 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs QTP ‐ Guo 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quetiapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs QTP ‐ Mei 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs QTP ‐ Mei 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quetiapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs QTP ‐ Sun 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs QTP ‐ Sun 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quetiapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs QTP ‐ Wan 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs QTP ‐ Wan 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quetiapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs QTP ‐ Wang 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs QTP ‐ Wang 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quetiapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs QTP ‐ Wang 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.09</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs QTP ‐ Wang 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quetiapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs QTP ‐ Zhang 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs QTP ‐ Zhang 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quetiapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs QTP ‐ Zhou 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs QTP ‐ Zhou 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quetiapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs QTP ‐ Zou 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs QTP ‐ Zou 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quetiapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.09</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>PANSS negative symptoms ‐ short term (up to 6 months)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs QTP ‐ Guo 2003a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs QTP ‐ Guo 2003a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quetiapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs QTP ‐ Mei 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs QTP ‐ Mei 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quetiapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs QTP ‐ Wang 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs QTP ‐ Wang 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quetiapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs QTP ‐ Zhang 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs QTP ‐ Zhang 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quetiapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>PANSS general pathology ‐ short term (up to 6 months</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs QTP ‐ Guo 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs QTP ‐ Guo 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quetiapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 8 Mental state: 1c. Average endpoint scores (various scales, high = poor) ‐skewed data. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0059">Navigate to figure in review</a></div> </div> <div class="figure" id="CD010631-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/urn:x-wiley:14651858:media:CD010631:CD010631-CMP-003-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_t/tCD010631-CMP-003-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 9 Mental state: 1d. Average change score (various scales, high = poor) ‐ short term (up to 6 months)." data-id="CD010631-fig-0060" src="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-003-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 9 Mental state: 1d. Average change score (various scales, high = poor) ‐ short term (up to 6 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-003-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010631-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/urn:x-wiley:14651858:media:CD010631:CD010631-CMP-003-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_t/tCD010631-CMP-003-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 10 Mental state: 1e. Average score decreased rate of BPRS/PANSS (%) ‐ short term (up to 6 months)." data-id="CD010631-fig-0061" src="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-003-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 10 Mental state: 1e. Average score decreased rate of BPRS/PANSS (%) ‐ short term (up to 6 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-003-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010631-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/urn:x-wiley:14651858:media:CD010631:CD010631-CMP-003-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_t/tCD010631-CMP-003-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 11 Functioning: 1. Average endpoint score (various scales, high = better) ‐ short term (up to 6 months)." data-id="CD010631-fig-0062" src="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-003-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.11</div> <div class="figure-caption"> <p>Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 11 Functioning: 1. Average endpoint score (various scales, high = better) ‐ short term (up to 6 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-003-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010631-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/urn:x-wiley:14651858:media:CD010631:CD010631-CMP-003-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_t/tCD010631-CMP-003-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 12 Cognitive function: 1. Average endpoint score (various scales, high = better) ‐ short term (up to 6 months)." data-id="CD010631-fig-0063" src="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-003-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.12</div> <div class="figure-caption"> <p>Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 12 Cognitive function: 1. Average endpoint score (various scales, high = better) ‐ short term (up to 6 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-003-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010631-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/urn:x-wiley:14651858:media:CD010631:CD010631-CMP-003-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_t/tCD010631-CMP-003-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 13 Adverse effects: 1. Anticholinergic ‐ short term (up to 6 months)." data-id="CD010631-fig-0064" src="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-003-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.13</div> <div class="figure-caption"> <p>Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 13 Adverse effects: 1. Anticholinergic ‐ short term (up to 6 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-003-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010631-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/urn:x-wiley:14651858:media:CD010631:CD010631-CMP-003-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_t/tCD010631-CMP-003-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 14 Adverse effects: 2. Cardiovascular ‐ short term (up to 6 months)." data-id="CD010631-fig-0065" src="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-003-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.14</div> <div class="figure-caption"> <p>Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 14 Adverse effects: 2. Cardiovascular ‐ short term (up to 6 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-003-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010631-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/urn:x-wiley:14651858:media:CD010631:CD010631-CMP-003-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_t/tCD010631-CMP-003-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 15 Adverse effects: 3. Central nervous system ‐ short term (up to 6 months)." data-id="CD010631-fig-0066" src="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-003-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.15</div> <div class="figure-caption"> <p>Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 15 Adverse effects: 3. Central nervous system ‐ short term (up to 6 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-003-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010631-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/urn:x-wiley:14651858:media:CD010631:CD010631-CMP-003-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_t/tCD010631-CMP-003-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 16 Adverse effects: 4. Gastrointestinal ‐ short term (up to 6 months)." data-id="CD010631-fig-0067" src="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-003-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.16</div> <div class="figure-caption"> <p>Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 16 Adverse effects: 4. Gastrointestinal ‐ short term (up to 6 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-003-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010631-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/urn:x-wiley:14651858:media:CD010631:CD010631-CMP-003-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_t/tCD010631-CMP-003-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 17 Adverse effects: 5a. Endocrine ‐ various ‐ short term (up to 6 months)." data-id="CD010631-fig-0068" src="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-003-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.17</div> <div class="figure-caption"> <p>Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 17 Adverse effects: 5a. Endocrine ‐ various ‐ short term (up to 6 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-003-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010631-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/urn:x-wiley:14651858:media:CD010631:CD010631-CMP-003-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_t/tCD010631-CMP-003-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 18 Adverse effects: 5b. Endocrine ‐ average endpoint ‐ short term (up to 6 months)." data-id="CD010631-fig-0069" src="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-003-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.18</div> <div class="figure-caption"> <p>Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 18 Adverse effects: 5b. Endocrine ‐ average endpoint ‐ short term (up to 6 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-003-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010631-fig-0070"> <p> <div class="table" id="CD010631-tblf-0010"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>average prolactin level (ng/mL)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs QTP ‐ Jiang 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>680.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>688.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>97</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs QTP ‐ Jiang 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quetiapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>123.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>132.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs QTP ‐ Wang 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>697.21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80.26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs QTP ‐ Wang 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quetiapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>112.85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>92.37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.19</div> <div class="figure-caption"> <p>Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 19 Adverse effects: 5c. Endocrine ‐ skewed data ‐ short term (up to 6 months). </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0070">Navigate to figure in review</a></div> </div> <div class="figure" id="CD010631-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/urn:x-wiley:14651858:media:CD010631:CD010631-CMP-003-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_t/tCD010631-CMP-003-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 20 Adverse effects: 6a. Haematology ‐ short term (up to 6 months)." data-id="CD010631-fig-0071" src="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-003-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.20</div> <div class="figure-caption"> <p>Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 20 Adverse effects: 6a. Haematology ‐ short term (up to 6 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-003-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010631-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/urn:x-wiley:14651858:media:CD010631:CD010631-CMP-003-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_t/tCD010631-CMP-003-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 21 Adverse effects: 6b. Haematology ‐ average endpoint ‐ short term (up to 6 months)." data-id="CD010631-fig-0072" src="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-003-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.21</div> <div class="figure-caption"> <p>Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 21 Adverse effects: 6b. Haematology ‐ average endpoint ‐ short term (up to 6 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-003-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010631-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/urn:x-wiley:14651858:media:CD010631:CD010631-CMP-003-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_t/tCD010631-CMP-003-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 22 Adverse effects: 7. Hepatitic ‐ short term (up to 6 months)." data-id="CD010631-fig-0073" src="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-003-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.22</div> <div class="figure-caption"> <p>Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 22 Adverse effects: 7. Hepatitic ‐ short term (up to 6 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-003-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010631-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/urn:x-wiley:14651858:media:CD010631:CD010631-CMP-003-23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_t/tCD010631-CMP-003-23.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 23 Adverse effects: 8. Movement disorders ‐ short term (up to 6 months)." data-id="CD010631-fig-0074" src="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-003-23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.23</div> <div class="figure-caption"> <p>Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 23 Adverse effects: 8. Movement disorders ‐ short term (up to 6 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-003-23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010631-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/urn:x-wiley:14651858:media:CD010631:CD010631-CMP-003-24" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_t/tCD010631-CMP-003-24.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 24 Adverse effects: 9a. Metabolic ‐ weight gain." data-id="CD010631-fig-0075" src="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-003-24.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.24</div> <div class="figure-caption"> <p>Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 24 Adverse effects: 9a. Metabolic ‐ weight gain. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-003-24.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010631-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/urn:x-wiley:14651858:media:CD010631:CD010631-CMP-003-25" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_t/tCD010631-CMP-003-25.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 25 Adverse effects: 9b. Metabolic ‐ short term (up to 6 months)." data-id="CD010631-fig-0076" src="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-003-25.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.25</div> <div class="figure-caption"> <p>Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 25 Adverse effects: 9b. Metabolic ‐ short term (up to 6 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-003-25.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010631-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/urn:x-wiley:14651858:media:CD010631:CD010631-CMP-003-26" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_t/tCD010631-CMP-003-26.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 26 Adverse effects: 10. Various other ‐ short term (up to 6 months)." data-id="CD010631-fig-0077" src="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-003-26.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.26</div> <div class="figure-caption"> <p>Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 26 Adverse effects: 10. Various other ‐ short term (up to 6 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-003-26.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010631-fig-0078"> <p> <div class="table" id="CD010631-tblf-0011"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>short term (up to 6 months)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs QTP ‐ Cai 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs QTP ‐ Cai 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quetiapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs QTP ‐ Guo 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs QTP ‐ Guo 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quetiapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs QTP ‐ Guo 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs QTP ‐ Guo 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quetiapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs QTP ‐ Hu 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs QTP ‐ Hu 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quetiapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs QTP ‐ Li 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs QTP ‐ Li 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quetiapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs QTP ‐ Zhang 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs QTP ‐ Zhang 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quetiapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.07</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.04</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs QTP ‐ Zhang 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs QTP ‐ Zhang 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quetiapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>medium term (7 to 12 months)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs QTP ‐ Li 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs QTP ‐ Li 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quetiapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.27</div> <div class="figure-caption"> <p>Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 27 Adverse effects: 11. Average endpoint score (TESS, high = poor) ‐ skewed data. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0078">Navigate to figure in review</a></div> </div> <div class="figure" id="CD010631-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/urn:x-wiley:14651858:media:CD010631:CD010631-CMP-003-28" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_t/tCD010631-CMP-003-28.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 28 Quality of life: 1. General ‐ average endpoint score (GQOL1 ‐ 74, high = better)." data-id="CD010631-fig-0079" src="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-003-28.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.28</div> <div class="figure-caption"> <p>Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 28 Quality of life: 1. General ‐ average endpoint score (GQOL1 ‐ 74, high = better). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-003-28.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010631-fig-0080"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/urn:x-wiley:14651858:media:CD010631:CD010631-CMP-003-29" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_t/tCD010631-CMP-003-29.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 29 Leaving the study early: 1a. Short term (up to 6 months)." data-id="CD010631-fig-0080" src="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-003-29.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.29</div> <div class="figure-caption"> <p>Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 29 Leaving the study early: 1a. Short term (up to 6 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0080">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-003-29.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010631-fig-0081"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/urn:x-wiley:14651858:media:CD010631:CD010631-CMP-003-30" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_t/tCD010631-CMP-003-30.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 30 Leaving the study early: 1b. Medium term (7 to 12 months)." data-id="CD010631-fig-0081" src="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-003-30.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.30</div> <div class="figure-caption"> <p>Comparison 3 CHLORPROMAZINE versus QUETIAPINE, Outcome 30 Leaving the study early: 1b. Medium term (7 to 12 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-fig-0081">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/media/CDSR/CD010631/image_n/nCD010631-CMP-003-30.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD010631-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">CHLORPROMAZINE versus OLANZAPINE for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Chlorpromazine versus olanzapine for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with schizophrenia<br/> <b>Settings:</b> inpatient and outpatient<br/> <b>Intervention:</b> chlorpromazine<br/> <b>Comparison:</b> olanzapine </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Olanzapine</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Chlorpromazine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>No significant clinical response: short term (up to 6 months)</b> <br/> Follow‐up: 6 to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low<sup>1</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 2.34</b> <br/> (1.37 to 3.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>204<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>700 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1000 per 1000</b> <br/> (959 to 1000) </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>190 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>445 per 1000</b> <br/> (260 to 758) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Relapse: long term (over 12 months)</b> <br/> Follow‐up: mean 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.5</b> <br/> (0.46 to 4.86) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>70<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>114 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>171 per 1000</b> <br/> (53 to 555) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>114 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>171 per 1000</b> <br/> (52 to 554) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: short term (up to 6 months)</b> <br/> BRPS average endpoint score (high = poor)<br/> Follow‐up: 6 to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state: short term (up to 6 months) in the intervention groups was<br/> <b>3.21 higher</b> <br/> (0.62 lower to 7.05 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>245<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,5,6,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months)</b> <br/> Follow‐up: mean 8 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 34.47</b> <br/> (4.79 to 248.3) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>298<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>10 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>345 per 1000</b> <br/> (48 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1000 per 1000</b> <br/> (479 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>250 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1000 per 1000</b> <br/> (1000 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life: short term (up to 6 months)</b> <br/> GQOLI‐physical health subscale score (high = good)<br/> Follow‐up: mean 8 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean quality of life: short term (up to 6 months) in the intervention groups was<br/> <b>10.10 lower</b> <br/> (13.93 to 6.27 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,7,9,10</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Leaving the study early due to any reason: short term (up to 6 months)</b> <br/> Follow‐up: mean 6 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population<sup>11</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.69</b> <br/> (0.45 to 6.4) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>139<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>3,12,13</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>159 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>268 per 1000</b> <br/> (71 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate<sup>11</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>229 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>387 per 1000</b> <br/> (103 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Control risk: the control risks are representative of the control group risks of the study population.<br/> <sup>2</sup>Risk of bias: rated serious ‐ most included studies had unclear risk of bias in terms of allocation and blinding, hence selection and detection bias are likely to be present. Two studies also had high risk of reporting bias.<br/> <sup>3</sup>Publication bias: strongly suspected ‐ we identified only small trial(s) from China for this outcome. Publication bias is highly suspected.<br/> <sup>4</sup>Imprecision: serious ‐ only one small trial with unclear risk of selection and detection bias contributed data to this outcome. The result was imprecise with few event and a wide CI.<br/> <sup>5</sup>Inconsistency: serious ‐ unexplained heterogeneity present, suggesting different magnitude of effect.<br/> <sup>6</sup>Indirectness: serious ‐ binary outcome assessing mental state is unavailable. We, therefore, employed BPRS score as an alternative indicator.<br/> <sup>7</sup>Imprecision: serious ‐ a relatively wide CI around the point of estimate of effect. Sample size is smaller than the optimal information size.<br/> <sup>8</sup>Imprecision: serious ‐ although significant difference was observed between groups, the CI was wide (95% CI 4.97 to 248.3).<br/> <sup>9</sup>Indirectness: serious ‐ binary outcome for quality of life is unavailable. We, thus, used outcome from QOL‐ physical health subscale as an alternative indicator.<br/> <sup>10</sup>Imprecision: serious ‐ although significant difference was observed between group, the total sample size is smaller than the optimal information size.<br/> <sup>11</sup>Control risk: the control risks in the study population are very close to the moderate risk observed here. Thus we adopted it to represent the control risk.<br/> <sup>12</sup>Risk of bias: serious ‐ most included studies that contributed data to this outcome had high risk of bias with the selection, detection and reporting of the result.<br/> <sup>13</sup>Imprecision: serious ‐ estimate of effect was not significant and the total sample size is smaller than the desired optimal information size. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">CHLORPROMAZINE versus OLANZAPINE for schizophrenia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/full#CD010631-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010631-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">CHLORPROMAZINE versus RISPERIDONE for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Chlorpromazine versus risperidone for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with schizophrenia<br/> <b>Settings:</b> inpatient and outpatient<br/> <b>Intervention:</b> chlorpromazine<br/> <b>Comparison:</b> risperidone </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Risperidone</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Chlorpromazine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>No significant clinical response ‐ short term (up to 6 months)</b> <br/> Follow‐up: median 8 to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low<sup>1</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 0.84</b> <br/> (0.53 to 1.34) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>475<br/> (7 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>‐</p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>60 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>50 per 1000</b> <br/> (32 to 80) </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>114 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>96 per 1000</b> <br/> (60 to 153) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>240 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>202 per 1000</b> <br/> (127 to 322) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: short term (up to 6 months)</b> <br/> BPRS endpoint scale score (high = poor)<br/> Follow‐up: 6 to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state: short term (up to 6 months) in the intervention groups was<br/> <b>0.9 higher</b> <br/> (3.49 lower to 5.28 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>247<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,4,5,6,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months)</b> <br/> Follow‐up: 8 to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low<sup>1</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.7</b> <br/> (0.85 to 3.4) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>235<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,6,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>130 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>221 per 1000</b> <br/> (111 to 442) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>240 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>408 per 1000</b> <br/> (204 to 816) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life: short term (up to 6 months)</b> <br/> QOL endpoint scale score (high = good)<br/> Follow‐up: mean 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean quality of life: short term (up to 6 months) in the intervention groups was<br/> <b>14.2 lower</b> <br/> (20.5 to 7.9 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>7,8,9,10</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Leaving the study early due to adverse effects ‐ short term (up to 6 months)</b> <br/> Follow‐up: mean 8 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.21</b> <br/> (0.01 to 4.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>41<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>7,10</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>95 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>20 per 1000</b> <br/> (1 to 391) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>95 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>20 per 1000</b> <br/> (1 to 390) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Control risk: the control risks are representative of those observed in the study population.<br/> <sup>2</sup>Risk of bias: serious ‐ most of the included studies had unclear risk of bias in terms of allocation and blinding, hence selection and detection bias are likely to be present. Some of the studies also had high risk of reporting bias.<br/> <sup>3</sup>Publication bias: strongly suspected ‐ only Chinese studies with relatively small sample size were identified. Publication bias is highly likely.<br/> <sup>4</sup>Inconsistency: serious ‐ unexplained heterogeneity present, suggesting different magnitude of effect.<br/> <sup>5</sup>Indirectness: serious ‐ binary outcome assessing mental state is unavailable. We, therefore, employed BPRS score as an alternative indicator.<br/> <sup>6</sup>Imprecision: serious ‐ although the CI around the estimate of effect relatively tight, the result was not significant and sample size was smaller than the optimal information size.<br/> <sup>7</sup>Publication bias: strongly suspected ‐ only one study with unclear risk of selection and detection bias available for this outcome.<br/> <sup>8</sup>Indirectness: serious ‐ binary outcome for quality of life was not available. Therefore, we adopted QOL score as an indicator.<br/> <sup>9</sup>Imprecision: serious ‐ estimate of effect was significant with tight CI, but the study sample size is smaller than the optimal information size.<br/> <sup>10</sup>Imprecision: serious ‐ estimate of effect was not significant and with relatively wide CI. Sample size was smaller than the optimal information size. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">CHLORPROMAZINE versus RISPERIDONE for schizophrenia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/full#CD010631-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010631-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">CHLORPROMAZINE versus QUETIAPINE for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Chlorpromazine versus quetiapine for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with schizophrenia<br/> <b>Settings:</b> inpatient and outpatient<br/> <b>Intervention:</b> chlorpromazine<br/> <b>Comparison:</b> quetiapine </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Quetiapine</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Chlorpromazine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>No significant clinical response: short term (up to 6 months)</b> <br/> Follow‐up: 4 to 16 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 0.93</b> <br/> (0.81 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>3241<br/> (28 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>‐</p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>70 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>65 per 1000</b> <br/> (57 to 74) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b><sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>128 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>119 per 1000</b> <br/> (104 to 136) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>High</b><sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>360 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>335 per 1000</b> <br/> (292 to 382) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: short term (up to 6 months)</b> <br/> BPRS endpoint scale score (high = poor)<br/> Follow‐up: 6 to 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state: short term (up to 6 months) in the intervention groups was<br/> <b>0.18 lower</b> <br/> (1.23 lower to 0.88 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>548<br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life: short term (up to 6 months)</b> <br/> GQOL1‐74 endpoint scale score (high = good)<br/> Follow‐up: mean 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean quality of life: short term (up to 6 months) in the intervention groups was<br/> <b>6.49 lower</b> <br/> (11.3 to 1.68 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>6,7,8,9</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months)</b> <br/> Follow‐up: 6 to 8 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 8.03</b> <br/> (4.78 to 13.51) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>644<br/> (8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>36 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>293 per 1000</b> <br/> (174 to 493) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>High</b> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>80 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>642 per 1000</b> <br/> (382 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Leaving the study early due to any reason short term (up to 6 months)</b> <br/> Follow‐up: 6 to 16 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.04</b> <br/> (0.77 to 1.41) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1223<br/> (12 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>93 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>97 per 1000</b> <br/> (72 to 131) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>High</b><sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>280 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>291 per 1000</b> <br/> (216 to 395) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Control risk: are representative of those observed in the study population.<br/> <sup>2</sup>Risk of bias: serious ‐ most of the included studies had unclear risk of bias in terms of allocation and blinding, hence selection and detection bias are likely to be present. Some of the studies also had high risk of reporting bias.<br/> <sup>3</sup>Indirectness: serious ‐ binary outcome on mental state is not available. Thus we employed BPRS rating as an indicator.<br/> <sup>4</sup>Imprecision: serious ‐ although the estimate of effect was not significant, the CI was relatively tight around the point of estimate. The sample size is also relatively large and exceed the calculated optimal information size.<br/> <sup>5</sup>Publication bias: strongly suspected ‐ only Chinese trials with small sample size were identified for this outcome.<br/> <sup>6</sup>Risk of bias: serious ‐ the only study contributed data to this outcome had unclear risk of selection and detection bias. It also had attrition data that we excluded from the final analysis.<br/> <sup>7</sup>Indirectness: serious ‐ there was no binary measurement available on quality of life. Therefore, we used GQOLI‐74 as an alternative indicator.<br/> <sup>8</sup>Imprecision: serious ‐ sample size was smaller than the optimal information size.<br/> <sup>9</sup>Publication bias: strongly suspected ‐ we only identified a Chinese trial with a small sample size with positive findings for this outcome. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">CHLORPROMAZINE versus QUETIAPINE for schizophrenia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/full#CD010631-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010631-tbl-0004"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Related Cochrane Reviews</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reference</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010631-bbs2-0115" title="AdamsCE , AwadG , RathboneJ , ThornleyB . Chlorpromazine versus placebo for schizophrenia. Cochrane Database of Systematic Reviews2014, Issue 1. [DOI: 10.1002/14651858.CD000284.pub3] ">Adams 2014</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine versus haloperidol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010631-bbs2-0162" title="LeuchtC , KitzmantelM , ChuaL , KaneJ , LeuchtS . Haloperidol versus chlorpromazine for schizophrenia. Cochrane Database of Systematic Reviews2008, Issue 1. [DOI: 10.1002/14651858.CD004278.pub2] ">Leucht 2008</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine doses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010631-bbs2-0164" title="LiuX , DeHaanS . Chlorpromazine dose for people with schizophrenia. Cochrane Database of Systematic Reviews2009, Issue 2. [DOI: 10.1002/14651858.CD007778] ">Liu 2009</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine cessation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010631-bbs2-0117" title="AlmerieMQ , AlkhateebH , EssaliA , MatarHE , RezkE . Cessation of medication for people with schizophrenia already stable on chlorpromazine. Cochrane Database of Systematic Reviews2007, Issue 1. [DOI: 10.1002/14651858.CD006329] ">Almerie 2007</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine for acute aggression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010631-bbs2-0116" title="AhmedU , JonesH , AdamsCE . Chlorpromazine for psychosis induced aggression or agitation. Cochrane Database of Systematic Reviews2010, Issue 4. [DOI: 10.1002/14651858.CD007445.pub2] ">Ahmed 2010</a> </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Related Cochrane Reviews</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/full#CD010631-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010631-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">CHLORPROMAZINE versus OLANZAPINE</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clinical response: 1. No significant clinical response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>274</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.19 [1.39, 3.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 short term ‐ up to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>204</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.34 [1.37, 3.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 long term ‐ over 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.83 [0.76, 4.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Clinical response: 2. Average endpoint score (CGI, high = poor) ‐ short term (up to 6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.36, 1.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Clinical response: 3. Relapse ‐ long term (over 12 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.5 [0.46, 4.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Mental state: 1. Average endpoint score (various scales, high = poor) ‐ short term (up to 6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 BPRS total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>245</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.21 [‐0.62, 7.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 BPRS activation subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>299</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.27, 0.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 BPRS anxiety‐depression subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.57 [1.36, 1.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 BPRS hostile‐suspiciousness subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>299</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.31 [‐1.98, 1.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 BPRS thinking disorder subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>299</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.80 [‐2.66, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6 BPRS withdraw‐retardation subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>299</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.49 [‐2.25, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7 NOSIE total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐18.36 [‐22.39, ‐14.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8 PANSS total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>351</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.46 [4.49, 16.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.9 PANSS general pathology subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [‐0.32, 2.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.10 PANSS negative symptom subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.38 [0.31, 4.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.11 PANSS positive symptom subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [‐0.30, 2.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.12 SAPS total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.10 [‐4.53, 0.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Mental state: 2. Average endpoint score (BPRS, high = poor) ‐ medium term (7 to 12 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 BPRS total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.60 [5.94, 11.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Mental state: 3. Average endpoint score (various scales, high = poor) ‐ skewed data <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 BPRS total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 HAMA (anxiety)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 MADRS (depression)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 PANSS negative symptom subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5 PANSS positive symptom subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Service involvement: 1. Re‐hospitalisation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 long term (over 12 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.5 [0.46, 4.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Functioning: 1. Executive function ‐ average endpoint score (WCST, high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 short term (up to 6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.96 [1.01, 20.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Adverse effects: 1. Anticholinergic ‐ short term (up to 6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 blurred vision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>241</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.59 [0.66, 10.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 dry mouth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>536</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.29, 4.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 excessive sweating</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.62, 14.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4 hypersalivation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.99 [4.14, 29.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.5 stuffy nose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [1.06, 8.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Adverse effects: 2. Cardiovascular ‐ short term (up to 6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 abnormal ECG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.60 [0.60, 21.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 apathism</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.0 [1.15, 21.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 blood pressure (drop)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.82 [1.13, 68.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.4 orthostatic hypotension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>561</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.78 [2.68, 35.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.5 palpitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>237</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>40.66 [2.49, 664.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.6 tachycardia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>241</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.53 [1.66, 7.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Adverse effects: 3. Central nervous system ‐ short term (up to 6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.85 [1.11, 13.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 drowsiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>536</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.46 [1.66, 3.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3 fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.13, 7.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Adverse effects: 4. Gastrointestinal ‐ short term (up to 6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 appetite loss</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.01 [2.82, 42.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 constipation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>622</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.29 [2.61, 7.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3 diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.0 [0.25, 100.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.4 dysphagia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.13, 71.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.5 nausea/vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.49 [0.43, 5.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Adverse effects: 5. Haematology ‐ short term (up to 6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>266</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.46 [1.16, 17.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 abnormal haemogram</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.0 [0.87, 18.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 leukopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.69 [0.36, 125.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Adverse effects: 6. Hepatitic ‐ short term (up to 6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 abnormal liver function</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.00 [0.25, 101.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 abnormal transaminase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.01, 150.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Adverse effects: 7a. Metabolic ‐ weight gain ‐ short term (up to 6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>536</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.25, 1.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Adverse effects: 7b. Metabolic ‐ weight gain ‐ continuous measures <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 short term (up to 6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.11 [‐9.15, ‐1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 medium term (7 to 12 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [‐11.87, 13.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Adverse effects: 7c. Metabolic ‐ other ‐ continuous measures <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 cholesterol (TC) ‐ short term (up to 6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.40 [‐1.02, 0.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2 high‐density lipoprotein (HDL) ‐ short term (up to 6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [‐0.12, 0.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.3 low‐density lipoprotein (LDL) ‐ short term (up to 6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.31, 0.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.4 low‐density lipoprotein (LDL) ‐ medium term (7 to 12 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [‐0.41, 0.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Adverse effects: 7d. Metabolic ‐ other ‐ average endpoint scores ‐ skewed data <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 cholesterol (TC) ‐ medium term (7 to 12 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2 high‐density lipoprotein (HDL) ‐ short term (up to 6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.3 triglyceride (TG) ‐ short term (up to 6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.4 triglyceride (TG) ‐ medium term (7 to 12 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Adverse effects: 8a. Movement disorders ‐ extrapyramidal symptoms ‐ short term (up to 6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1 akathisia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>417</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.86 [0.29, 11.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.2 any EPS symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>298</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>34.47 [4.79, 248.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.3 muscle stiffness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.13 [0.73, 51.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.4 tremor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.78 [0.84, 54.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Adverse effects: 8b. Movement disorders ‐ extrapyramidal symptoms ‐ average endpoint score (ESRS, high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1 short term (up to 6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.14, 1.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Adverse effects: 9a. Various other ‐ sleep ‐ average endpoint score (LSEQ, high = better) ‐ short term (up to 6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1 awaking from sleep</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.30 [‐21.91, 11.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.2 getting to sleep score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.60 [‐19.88, 18.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.3 quality of sleep</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐15.0 [‐33.07, 3.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 Adverse effects: 9b. Various other ‐ sleep ‐ average length of sleep (hour/day) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1 short term (up to 6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.63 [2.08, 5.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.2 medium term (7 to 12 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.41 [2.82, 6.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 Adverse effects: 9c. Various other ‐ sleep ‐ behaviour following waking (LSEQ) ‐ skewed data <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.1 short term (up to 6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24 Adverse effects: 9b. Various other ‐ rash <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [0.14, 28.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.1 short term (up to 6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [0.14, 28.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25 Quality of life: 1a. Average endpoint scores (various scales, high = better) ‐ short term (up to 6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.1 GQOLI ‐ living condition</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.0 [‐4.21, 2.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.2 GQOLI ‐ physical health</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐10.10 [‐13.93, ‐6.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.3 GQOLI ‐ psychological health</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐22.60 [‐25.94, ‐19.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.4 GQOLI ‐ social function</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐18.20 [‐20.51, ‐15.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">26 Quality of life: 1b. Average endpoint score (QoL, high = better) ‐ skewed data <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.1 short term (up to 6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">27 Leaving the study early ‐ short term (up to 6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.1 due to any reason</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.69 [0.45, 6.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.2 due to lack of efficacy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.08, 2.66]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">CHLORPROMAZINE versus OLANZAPINE</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010631-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">CHLORPROMAZINE versus RISPERIDONE</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clinical response: 1. No significant clinical response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>475</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.53, 1.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 short term (up to 6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>475</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.53, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Global state: 1. Average endpoint score (CGI‐CI, high = poor) ‐ skewed data <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 short term (up to 6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Global state: 2. Need of additional benzhexol <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.26, 5.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 short term (up to 6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.26, 5.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Mental state: 1a. Average endpoint score (various scales, high = poor) ‐ short term (up to 6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 BPRS total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>247</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [‐3.49, 5.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 BPRS activation subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [‐0.81, 1.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 BPRS anxiety‐depression subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [‐1.56, 1.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 BPRS hostile‐suspiciousness subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [‐1.41, 3.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 NORS total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.80 [‐2.53, 6.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6 PANSS total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>397</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.95 [‐5.58, 1.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7 PANSS positive symptom subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>337</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐1.67, 1.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8 PANSS negative symptom subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>230</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.16 [‐1.57, 7.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.9 PANSS general pathology subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>267</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.85 [‐2.15, 0.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.10 SANS total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.89 [‐4.49, 26.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Mental state: 1b. Average endpoint score (various scales, high = poor) ‐ skewed data ‐ short term (up to 6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 BPRS thinking disorder subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 BPRS withdraw‐retardation subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 PANSS general pathology subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 PANSS negative symptom subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5 PANSS positive symptom subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6 SAPS total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Mental state: 2. Average change score ‐ decreased rate (various scales, high = poor) ‐ short term (up to 6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 PANSS total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.11 [‐0.23, 0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 PANSS negative subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.21 [‐0.44, 0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 PANSS positive subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.07 [‐0.36, 0.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Functioning: 1. Average endpoint score (WCST subscales, high = good) ‐ short term (up to 6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 WCST‐IQ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐11.30 [‐18.34, ‐4.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 WCST‐MQ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐19.60 [‐28.83, ‐10.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Adverse effects: 1. Anticholinergic ‐ short term (up to 6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 blurred vision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>387</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.44 [1.32, 4.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 dry mouth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>852</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.00 [0.88, 4.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 excessive sweating</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.62, 14.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4 hypersalivation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>373</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.67 [3.80, 19.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.5 stuffy nose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [1.06, 8.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Adverse effects: 2a. Cardiovascular ‐ short term (up to 6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 abnormal ECG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>229</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.41 [0.96, 6.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 apathism</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.25 [2.35, 16.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 blood pressure drop</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.25 [2.61, 26.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4 bradycardia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.5 [0.05, 5.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.5 orthostatic hypotension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>546</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.74 [2.28, 14.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.6 palpitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>237</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>40.66 [2.49, 664.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.7 sinus tachycardia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.12 [0.35, 28.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.8 tachycardia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>557</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.64 [1.64, 4.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Adverse effects: 2b. Cardiovascular ‐ continuous measures ‐ short term (up to 6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 cardiac rate (upright position)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.90 [‐1.57, 9.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 cardiac rate (horizontal position)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.42 [3.47, 11.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 contractive blood pressure (upright position)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.06 [‐2.20, 0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.4 contractive blood pressure (horizontal position)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.38 [0.61, 2.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.5 diastolic blood pressure (upright position)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.53 [‐1.29, 0.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.6 diastolic blood pressure (horizontal position)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [‐0.18, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Adverse effects: 3. Central nervous system ‐ short term (up to 6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1191</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.96 [0.92, 4.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 agitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.01, 7.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>299</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.57 [1.75, 7.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3 drowsiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>307</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.93 [1.49, 16.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.4 fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>13.05 [4.82, 35.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.5 insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>342</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.10, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.6 reduced activity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.05 [0.18, 23.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Adverse effects: 4. Gastrointestinal ‐ short term (up to 6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 constipation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>868</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [2.05, 4.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.0 [0.25, 100.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3 dysphagia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.67 [1.09, 12.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.4 loss of appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.01 [2.82, 42.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.5 nausea/vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>350</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.37, 1.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Adverse effects: 5. Haematology ‐ short term (up to 6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>266</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.46 [1.16, 17.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 abnormal haemogram</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.0 [0.87, 18.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 leukopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.69 [0.36, 125.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Adverse effects: 6. Hepatitic ‐ short term (up to 6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>307</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [0.17, 10.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 abnormal liver function</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.0 [0.25, 100.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 abnormal transaminase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>229</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.07, 11.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Adverse effects: 7. Metabolic ‐ weight gain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>302</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [0.52, 3.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 short term (up to 6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>302</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [0.52, 3.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Adverse effects: 8. Movement disorders ‐ short term (up to 6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 akathisia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>435</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.37 [1.46, 3.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 any EPS symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>235</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.70 [0.85, 3.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.3 dystonia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.61 [0.97, 2.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.4 muscle stiffness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>335</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.96 [0.92, 9.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.5 torsion movements</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.00 [0.50, 161.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.6 tremor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>435</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.15 [1.47, 3.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Adverse events: 9. Average endpoint score (TESS) ‐ skewed data <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 short term (up to 6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Adverse effects: 10. Various other ‐ short term (up to 6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 concentration (poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.95 [1.35, 2.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2 memory deterioration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.95 [1.35, 2.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.3 sexual dysfunction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.55 [1.43, 4.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.4 unspecified</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.38 [0.97, 1.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Quality of life: 1. Average endpoint score (QOL, high = good) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1 short term (up to 6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐14.20 [‐20.50, ‐7.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Leaving the study early ‐ short term (up to 6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1 due to adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.01, 4.11]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">CHLORPROMAZINE versus RISPERIDONE</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010631-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">CHLORPROMAZINE versus QUETIAPINE</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clinical response: 1. No significant clinical response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 short term (up to 6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3241</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.81, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Global state: 1. Need of additional benzodiazepines/benzhexol <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 short term (up to 6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [1.10, 1.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Global state: 2a. Average endpoint scores (various scales, high = poor) ‐ short term (up to 6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 CGI‐SI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>177</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.82, 0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 CGI‐GI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>229</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.11 [‐0.33, 0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Global state: 2b. Average endpoint score (CGI‐SI, high = poor) ‐ skewed data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 short term (up to 6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Global state: 3. Average change scores (CGI‐SI, high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 short term (up to 6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>384</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.30 [‐0.32, ‐0.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Mental state: 1a. Average endpoint scores (various scales, high = poor) ‐ short term (up to 6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 BPRS total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>548</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.18 [‐1.23, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 BPRS anxiety‐depression subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.27 [‐1.16, 0.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 BPRS activation subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.22 [‐0.26, 0.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 BPRS hostile‐suspiciousness subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.09 [‐1.15, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5 BPRS thinking disorder subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.15 [‐1.39, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6 BPRS withdraw‐retardation subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.76, 0.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.7 PANSS total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2049</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.05 [‐2.30, 2.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.8 PANSS positive symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [‐0.11, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.9 PANSS negative symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1361</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.13, 1.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.10 PANSS general pathology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1530</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.11 [‐3.06, 0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.11 HAMD total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.4 [5.13, 9.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Mental state: 1b. Average endpoint scores (various scales, high = poor) ‐ medium term (6 to 12 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 PANSS total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.90 [1.74, 8.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 PANSS general pathology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐4.34, 3.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 PANSS negative symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.70 [0.44, 4.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Mental state: 1c. Average endpoint scores (various scales, high = poor) ‐skewed data <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 PANSS total ‐ short term (up to 6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 PANSS positive symptoms ‐ short term (up to 6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 PANSS negative symptoms ‐ short term (up to 6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4 PANSS general pathology ‐ short term (up to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Mental state: 1d. Average change score (various scales, high = poor) ‐ short term (up to 6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 PANSS total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>426</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.50 [‐2.82, ‐2.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 PANSS positive symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>384</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [1.10, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 PANSS negative symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>384</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.70, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4 PANSS general pathology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>384</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.85, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Mental state: 1e. Average score decreased rate of BPRS/PANSS (%) ‐ short term (up to 6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 BPRS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>197</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.80 [‐4.86, 3.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 PANSS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>782</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.96 [‐7.20, 3.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Functioning: 1. Average endpoint score (various scales, high = better) ‐ short term (up to 6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 WCST‐IQ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐11.30 [‐17.62, ‐4.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 WCST‐MQ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐19.60 [‐27.37, ‐11.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Cognitive function: 1. Average endpoint score (various scales, high = better) ‐ short term (up to 6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 WCST</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.92 [0.40, 17.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 WMS‐RC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐9.34 [‐17.53, ‐1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Adverse effects: 1. Anticholinergic ‐ short term (up to 6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 blurred vision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1780</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.00 [3.46, 7.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 dry mouth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1682</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.34 [1.54, 3.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.3 excessive sweating</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.91 [0.84, 18.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.4 hypersalivation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.85 [2.36, 6.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.5 stuffy nose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>972</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.45, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Adverse effects: 2. Cardiovascular ‐ short term (up to 6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 abnormal ECG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>708</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.82 [1.11, 2.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 blood pressure drop</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>690</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.53, 1.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3 orthostatic hypotension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>605</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.64 [1.14, 6.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.4 tachycardia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1752</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.70 [1.33, 2.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Adverse effects: 3. Central nervous system ‐ short term (up to 6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [0.83, 2.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 drowsiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1677</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.28 [1.51, 3.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.3 headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>192</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.13, 4.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.4 insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>867</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.55, 1.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.5 reduced activity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>788</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.80 [3.05, 19.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.6 sedation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Adverse effects: 4. Gastrointestinal ‐ short term (up to 6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 constipation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2048</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.55 [2.04, 3.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.32 [0.27, 106.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.3 loss of appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>472</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.52 [0.82, 7.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.4 nausea/vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>819</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.58, 2.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Adverse effects: 5a. Endocrine ‐ various ‐ short term (up to 6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 gynaecomastia, galactorrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.37 [0.27, 108.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2 hyperprolactinemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.69 [2.74, 11.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.3 menstrual irregularities</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.0 [0.25, 99.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Adverse effects: 5b. Endocrine ‐ average endpoint ‐ short term (up to 6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>24.62 [17.76, 31.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 prolactin level (ng/mL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>24.62 [17.76, 31.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Adverse effects: 5c. Endocrine ‐ skewed data ‐ short term (up to 6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1 average prolactin level (ng/mL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Adverse effects: 6a. Haematology ‐ short term (up to 6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1 elevated ALT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>775</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.62 [0.92, 2.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.2 decreased white blood cell count</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>427</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.43, 2.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.3 increased white blood cell count</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.05 [0.40, 10.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Adverse effects: 6b. Haematology ‐ average endpoint ‐ short term (up to 6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1 blood glucose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.18, 0.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.2 blood TG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.28, 0.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.3 blood TC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [‐0.11, 0.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 Adverse effects: 7. Hepatitic ‐ short term (up to 6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1 abnormal liver function</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>561</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.10 [1.32, 3.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 Adverse effects: 8. Movement disorders ‐ short term (up to 6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.1 agitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>313</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.14, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.2 akathisia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1757</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.73 [2.55, 5.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.3 any EPS symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>644</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.03 [4.78, 13.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.4 dystonia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 8.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.5 myotonia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1257</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.59 [3.18, 6.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.6 need additional medication for EPS symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>202</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.5 [0.71, 3.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.7 torsion movement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1063</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.81 [2.76, 12.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.8 tremor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1343</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.90 [1.89, 4.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24 Adverse effects: 9a. Metabolic ‐ weight gain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1259</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [1.17, 2.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.1 weight gain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1259</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [1.17, 2.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25 Adverse effects: 9b. Metabolic ‐ short term (up to 6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.1 average BMI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.5 [‐0.67, 1.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.2 average weight (KG)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.0 [‐4.68, 2.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">26 Adverse effects: 10. Various other ‐ short term (up to 6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>560</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.73 [1.19, 2.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.1 unspecified adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>560</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.73 [1.19, 2.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">27 Adverse effects: 11. Average endpoint score (TESS, high = poor) ‐ skewed data <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.1 short term (up to 6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.2 medium term (7 to 12 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">28 Quality of life: 1. General ‐ average endpoint score (GQOL1 ‐ 74, high = better) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.1 short term (up to 6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.49 [‐11.30, ‐1.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">29 Leaving the study early: 1a. Short term (up to 6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.1 due to adverse effect</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1680</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [1.04, 1.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.2 due to inefficacy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>695</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [0.68, 2.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.3 due to any other reason</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1223</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.77, 1.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.4 due to loss to follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.23, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">30 Leaving the study early: 1b. Medium term (7 to 12 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.61, 2.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">CHLORPROMAZINE versus QUETIAPINE</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010631.pub2/references#CD010631-tbl-0007">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD010631.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD010631-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD010631-note-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD010631-note-0002">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ru#CD010631-note-0001">Русский</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010631\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010631\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010631\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010631\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010631\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010631\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010631\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010631\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010631\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010631\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010631\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010631\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010631\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010631\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010631\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010631\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010631\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010631\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=7LavyS58&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010631.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010631.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD010631.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD010631.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010631.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740719943761"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010631.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740719943765"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010631.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918df5163fe89368',t:'MTc0MDcxOTk0NC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 